

The University of Alabama at Birmingham

**Report on Federal Awards in Accordance with the
OMB Uniform Guidance**

For the Year Ended September 30, 2020

EIN: 63-6005396

The University of Alabama at Birmingham
Index
For the Year Ended September 30, 2020

	Page(s)
Part I Federal Award Programs	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	1–2
Report of Independent Auditors on Compliance with Requirements that Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance.....	3–5
Schedule of Expenditures of Federal Awards.....	6–33
Notes to Schedule of Expenditures of Federal Awards	34–35
Part II Schedule of Findings and Questioned Costs	
Schedule of Findings and Questioned Costs.....	36
Part III Summary Schedule of Prior Audit Findings	
Summary Schedule of Prior Audit Findings	37
Part IV 2020 Financial Report	

Part I
Federal Award Programs



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Trustees of The University of Alabama:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham (“UAB”), a campus of the University of Alabama System, which is a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2020, and the related statements of revenues, expenses, and changes in net position and of cash flows (where applicable) for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated January 21, 2021. Our report includes an emphasis of matter regarding the presentation of the financial statements as discussed in Note 1 to the financial statements. Our report includes a reference to other auditors who audited the financial statements of Southern Research Institute, as described in our report on UAB’s financial statements. This report does not include the results of the other auditors’ testing of internal control over financial reporting or compliance and other matters that are reported on separately by those auditors. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation and UAB Research Foundation were not audited in accordance with *Government Auditing Standards* and accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with these component units.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered UAB’s internal control over financial reporting (“internal control”) as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the UAB’s internal control. Accordingly, we do not express an opinion on the effectiveness of the UAB’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether UAB's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Birmingham, Alabama
January 21, 2021



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over
Compliance in Accordance with the Uniform Guidance**

To the Board of Trustees of The University of Alabama:

Report on Compliance for Each Major Federal Program

We have audited The University of Alabama at Birmingham's ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of UAB's major federal programs for the year ended September 30, 2020. UAB's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

UAB's basic financial statements include the operations of Southern Research Institute ("SRI"), UAB's discretely presented component unit, which expended \$47,548,107 in federal awards during its year ended December 28, 2018 which is not included in UAB's schedule of expenditures of federal awards for the year ended September 30, 2019. Our audit, described below, did not include the operations of SRI because SRI engaged other auditors to perform an audit in accordance with the Uniform Guidance.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of UAB's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about UAB's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of UAB's compliance.

Opinion on Each Major Federal Program

In our opinion, the University of Alabama at Birmingham complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2020.



Report on Internal Control Over Compliance

Management of UAB is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered UAB's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of UAB 's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and the discretely presented component unit of UAB as of and for the year ended September 30, 2020, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements. We issued our report thereon dated January 21, 2021, which contained unmodified opinions on those financial statements. Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in



accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic financial statements as a whole.

PricewaterhouseCoopers LLP

June 25, 2021, except for our report on the Schedule of Expenditures of Federal Awards, as to which the date is January 21, 2021

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
RESEARCH AND DEVELOPMENT CLUSTER							
Department of Agriculture							
Agriculture and Food Research Initiative (AFRI)	10.310	\$ 72,618	\$ -			\$ 72,618	\$ 9,119
CFDA 10.310 Total		72,618	-			72,618	9,119
Solid Waste Management Grants	10.762	-	1,319	ROWAN UNIVERSITY	CPAP000000598654	1,319	-
CFDA 10.762 Total		-	1,319			1,319	-
Total Department of Agriculture		72,618	1,319			73,937	9,119
Department of Commerce							
Cluster Grants	11.020	92,581	-			92,581	-
CFDA 11.020 Total		92,581	-			92,581	-
Unallied Science Program	11.472	-	19,746	AUBURN UNIVERSITY	ACQ-210-039-2019-AU	19,746	-
CFDA 11.472 Total		-	19,746			19,746	-
Measurement and Engineering Research and Standards	11.609	-	10,507	TROY STATE UNIVERSITY	70NANB18H289	10,507	-
CFDA 11.609 Total		-	10,507			10,507	-
Total Department of Commerce		92,581	30,253			122,834	-
Department of Defense							
Basic and Applied Scientific Research	12.300	-	565,236	WRIGHT STATE UNIVERSITY	N00014-16-1-3159	565,236	-
Basic and Applied Scientific Research	12.300	87,235	-			87,235	-
CFDA 12.300 Total		87,235	565,236			652,471	-
Military Medical Research and Development	12.420	8,632,724	-			8,632,724	2,512,320
Military Medical Research and Development	12.420	-	544,844	OCEAN STATE RESEARCH INSTITUTE	W81XWH-17-0619	544,844	-
Military Medical Research and Development	12.420	-	206,521	NOVAN INC	W81XWI-1910850	206,521	-
Military Medical Research and Development	12.420	-	160,141	EMORY UNIVERSITY	W81XWH1810373	160,141	-
Military Medical Research and Development	12.420	-	68,637	UNIVERSITY OF UTAH	W81XWH-16-1-0655	68,637	-
Military Medical Research and Development	12.420	-	67,023	THE MIND RESEARCH NETWORK	W81XWH-17-2-0052	67,023	-
Military Medical Research and Development	12.420	-	33,311	REGENTS OF THE UNIVERSITY OF COLORADO	W81XWH-17-0597	33,311	-
Military Medical Research and Development	12.420	-	6,326	JOHNS HOPKINS UNIVERSITY	W81XWH-14-2-0189	6,326	-
Military Medical Research and Development	12.420	-	2,448	DUKE UNIVERSITY	W81XWH-17-1-0473	2,448	-
Military Medical Research and Development	12.420	-	676	UNIVERSITY OF SOUTHERN CALIFORNIA	W81XWH-13-MRPRA-MRFA	676	-
Military Medical Research and Development	12.420	-	16	REGENTS OF THE UNIVERSITY OF COLORADO	W81XWH-17-1-0597	16	-
Military Medical Research and Development	12.420	-	(15,229)	JOHNS HOPKINS UNIVERSITY	W81XW4-10-2-0133	(15,229)	-
CFDA 12.420 Total		8,632,724	1,074,714			9,707,438	2,512,320
Basic Scientific Research	12.431	-	69,126	THE UNIVERSITY OF MONTANA	W911NF-15-2-0020	69,126	-
Basic Scientific Research	12.431	-	(520)	UNIVERSITY OF TENNESSEE(KNOXVILLE)	W911NF-15-1-0614	(520)	-
CFDA 12.431 Total		-	68,606			68,606	-
Basic, Applied, and Advanced Research in Science and Engineering	12.630	57,694	-			57,694	-
CFDA 12.630 Total		57,694	-			57,694	-
Uniformed Services University Medical Research Projects	12.750	-	102,426	THE GENEVA FOUNDATION	HU00011920043 N19-A09	102,426	-
Uniformed Services University Medical Research Projects	12.750	-	16,926	HENRY M JACKSON FOUNDATION	HU0001-17-2-0023	16,926	-
CFDA 12.750 Total		-	119,352			119,352	-
Air Force Defense Research Sciences Program	12.800	118,981	-			118,981	-
CFDA 12.800 Total		118,981	-			118,981	-
Research and Technology Development	12.910	-	82,327	UNIVERSITY OF MICHIGAN	W56HZV1920001	82,327	-
CFDA 12.910 Total		-	82,327			82,327	-

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Contract #W911QY-15-C-0134	12.RD	2,798,403	-			2,798,403	2,277,523
Contract #FA9101-18-D-0004	12.RD	857,571	-			857,571	
Contract	12.RD	-	261,532	STEEL FOUNDER'S SOCIETY OF AMERICA	SP4701-17-D-1161	261,532	
Contract	12.RD	-	230,360	FLORIDA INSTITUTE FOR HUMAN & MACHINE COGNITION, I	HR001119S0021	230,360	
Contract	12.RD	-	86,465	ADVANCED TECHNOLOGY INTERNATIONAL	SP4701-17-D-1134	86,465	
Contract	12.RD	-	76,500	THE GENEVA FOUNDATION	HU000117ZTS04 (N17-A06)	76,500	
Contract	12.RD	-	71,747	ADVANCED TECHNOLOGY INTERNATIONAL	SP4701-15-C7003	71,747	
Contract #FA4417-16-P-R026	12.RD	65,171	-			65,171	
Contract	12.RD	-	64,702	ADVANCED TECHNOLOGY INTERNATIONAL	2016-517	64,702	
Contract #FA441716PR26P0008	12.RD	49,905	-			49,905	
Contract	12.RD	-	28,247	TDA	W81XWH-17-C-0141	28,247	
Contract	12.RD	-	20,231	CHILDREN'S HOSPITAL BOSTON	W81XWH-17-1-0532	20,231	
Contract	12.RD	-	18,430	ADVANCED TECHNOLOGY INTERNATIONAL	2017-523	18,430	
Contract	12.RD	-	801	ALION SCIENCE AND TECHNOLOGY CORPORATION	FA8075-14-D-0014	801	
Contract	12.RD	-	512	JOHNS HOPKINS UNIVERSITY	W81XWH1810810	512	
Contract	12.RD	-	(58)	EMORY UNIVERSITY	HDTRA1-15-C-0075	(58)	
CFDA 12.RD Total		<u>3,771,050</u>	<u>859,469</u>			<u>4,630,519</u>	<u>2,277,523</u>
Total Department of Defense		<u>12,667,684</u>	<u>2,769,704</u>			<u>15,437,388</u>	<u>4,789,843</u>
Department of Interior							
Marine Turtle Conservation Fund	15.645	9,092	-			9,092	
CFDA 15.645 Total		<u>9,092</u>	<u>-</u>			<u>9,092</u>	<u>-</u>
Total Department of Interior		<u>9,092</u>	<u>-</u>			<u>9,092</u>	<u>-</u>
Department of Justice							
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	88,451	-			88,451	
CFDA 16.560 Total		<u>88,451</u>	<u>-</u>			<u>88,451</u>	<u>-</u>
Total Department of Justice		<u>88,451</u>	<u>-</u>			<u>88,451</u>	<u>-</u>
Department of Transportation							
Highway Research and Development Program	20.200	-	(10,996)	NATL ACADEMY OF SCIENCES	DTFH61-13-H-00024	(10,996)	
CFDA 20.200 Total		<u>-</u>	<u>(10,996)</u>			<u>(10,996)</u>	<u>-</u>
Highway Training and Education	20.215	14,466	-			14,466	
CFDA 20.215 Total		<u>14,466</u>	<u>-</u>			<u>14,466</u>	<u>-</u>
University Transportation Centers Program	20.701	-	180,455	UNIVERSITY OF FLORIDA	69A3551747104	180,455	
University Transportation Centers Program	20.701	-	18,973	ROWAN UNIVERSITY	69A3551847102	18,973	
CFDA 20.701 Total		<u>-</u>	<u>199,428</u>			<u>199,428</u>	<u>-</u>
Contract #DTNH2217D00066 Opt 2	20.RD	297,385	-			297,385	
Contract #DTNH2217D00066 Opt 1	20.RD	38,341	-			38,341	
Contract	20.RD	-	131	UNIVERSITY OF FLORIDA	69A3551747104	131	
CFDA 20.RD Total		<u>335,726</u>	<u>131</u>			<u>335,857</u>	<u>-</u>
Total Department of Transportation		<u>350,192</u>	<u>188,563</u>			<u>538,755</u>	<u>-</u>
National Aeronautics and Space Administration							
Space Operations	43.007	90,705	-			90,705	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Education	43.008	-	25,574	UNIVERSITY OF ALABAMA IN HUNTSVILLE	NNX15AJ18H	25,574	
Education	43.008	-	17,667	UNIVERSITY OF ALABAMA IN HUNTSVILLE	80NSSC19M0051	17,667	
Education	43.008	-	6,211	UNIVERSITY OF ALABAMA IN HUNTSVILLE	80NSSC20M0134	6,211	
CFDA 43.008 Total		-	49,452			49,452	-
Contract #NNJ15HA80B	43.RD	7,409,282	-			7,409,282	
Contract	43.RD	-	39,960	GEOCENT, LLC	NASA SBIR H7.01-9532-PHASE II	39,960	
Contract	43.RD	-	24,266	GEOCENT, LLC	80NSSC18C0169	24,266	
CFDA 43.RD Total		7,409,282	64,226			7,473,508	-
Total National Aeronautics and Space Administration		7,499,987	113,678			7,613,665	-
National Science Foundation							
Engineering Grants	47.041	533,222	-			533,222	35,000
Engineering Grants	47.041	-	65,120	GEORGIA INSTITUTE OF TECHNOLOGY	1643289	65,120	
Engineering Grants	47.041	-	19,400	BOSTON UNIVERSITY MEDICAL CAMPUS	4500003100	19,400	
Engineering Grants	47.041	-	1,739	ROWAN UNIVERSITY	ECCS-1903466	1,739	
CFDA 47.041 Total		533,222	86,259			619,481	35,000
Mathematical and Physical Sciences	47.049	801,392	-			801,392	
CFDA 47.049 Total		801,392	-			801,392	-
Geosciences	47.050	390,200	-			390,200	15,810
CFDA 47.050 Total		390,200	-			390,200	15,810
Computer and Information Science and Engineering	47.070	553,379	-			553,379	
CFDA 47.070 Total		553,379	-			553,379	-
Biological Sciences	47.074	1,097,046	-			1,097,046	
Biological Sciences	47.074	-	3,511	BROWN UNIVERSITY	IOS-1923445	3,511	
CFDA 47.074 Total		1,097,046	3,511			1,100,557	-
Social, Behavioral, and Economic Sciences	47.075	65,399	-			65,399	
CFDA 47.075 Total		65,399	-			65,399	-
Education and Human Resources	47.076	1,630,038	-			1,630,038	141,527
Education and Human Resources	47.076	-	111,270	UNIVERSITY OF ALABAMA IN TUSCALOOSA	HRD1619659	111,270	
Education and Human Resources	47.076	-	1,043	UNIVERSITY OF ALABAMA IN TUSCALOOSA	DGE-1723250	1,043	
CFDA 47.076 Total		1,630,038	112,313			1,742,351	141,527
International Science and Engineering (OISE)	47.079	52,079	-			52,079	
CFDA 47.079 Total		52,079	-			52,079	-
Office of Integrative Activities	47.083	-	603,350	UNIVERSITY OF ALABAMA IN HUNTSVILLE	OIA-1655280	603,350	
Office of Integrative Activities	47.083	-	287,655	CLEMSON UNIVERSITY	OIA-1632881	287,655	
Office of Integrative Activities	47.083	-	225,363	LOUISIANA STATE UNIVERSITY	OIA-1632891	225,363	
Office of Integrative Activities	47.083	129,490	-			129,490	
Office of Integrative Activities	47.083	-	60,012	UNIVERSITY OF SOUTHERN MISSISSIPPI	OIA-1632825	60,012	
Office of Integrative Activities	47.083	-	(3,692)	MEDICAL UNIVERSITY OF SOUTH CAROLINA	OIA-1539034	(3,692)	
CFDA 47.083 Total		129,490	1,172,688			1,302,178	-
Total National Science Foundation		5,252,245	1,374,771			6,627,016	192,337
Department of Veterans Affairs							
Contract - Intergovernmental Personnel Agreements	64.RD	3,244,922	-			3,244,922	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Contract #36C24719P1270	64.RD	92,161	-			92,161	
Contract #MARKLAND-ASHLEY GILM	64.RD	29,067	-			29,067	
Contract #SLAY, LAURIE	64.RD	23,106	-			23,106	
Contract #36C24718C0003 OPTION 1	64.RD	3,167	-			3,167	
CFDA 64.RD Total		<u>3,639,007</u>	<u>-</u>			<u>3,639,007</u>	<u>-</u>
Total Department of Veterans Affairs		<u>3,639,007</u>	<u>-</u>			<u>3,639,007</u>	<u>-</u>
Department of Energy							
Office of Science Financial Assistance Program	81.049	743,757	-			743,757	266,374
CFDA 81.049 Total		<u>743,757</u>	<u>-</u>			<u>743,757</u>	<u>266,374</u>
Fossil Energy Research and Development	81.089	15,145	-			15,145	
Fossil Energy Research and Development	81.089	-	1,803	SOUTHERN STATES ENERGY BOARD	DE-FE0029465	1,803	
CFDA 81.089 Total		<u>15,145</u>	<u>1,803</u>			<u>16,948</u>	<u>-</u>
Stewardship Science Grant Program	81.112	129,364	-			129,364	
CFDA 81.112 Total		<u>129,364</u>	<u>-</u>			<u>129,364</u>	<u>-</u>
Contract	81.RD	-	45,211	UNIVERSITY OF CALIFORNIA LAWREN LIVERMORE NATL LAB	DE-AC52-07NA27644	45,211	
Contract	81.RD	-	29,711	UT-BATTELLE, LLC	DE-AC05-00OR22725	29,711	
CFDA 81.RD Total		<u>-</u>	<u>74,922</u>			<u>74,922</u>	<u>-</u>
Total Department of Energy		<u>888,266</u>	<u>76,725</u>			<u>964,991</u>	<u>266,374</u>
Department of Education							
Education Research, Development and Dissemination	84.305	242,668	-			242,668	
CFDA 84.305 Total		<u>242,668</u>	<u>-</u>			<u>242,668</u>	<u>-</u>
Total Department of Education		<u>242,668</u>	<u>-</u>			<u>242,668</u>	<u>-</u>
Department of Health and Human Services							
Global AIDS	93.067	-	74,553	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	1NU2GGH001920-01-S01	74,553	
CFDA 93.067 Total		<u>-</u>	<u>74,553</u>			<u>74,553</u>	<u>-</u>
Chronic Diseases: Research, Control, and Prevention	93.068	652,263	-			652,263	46,266
CFDA 93.068 Total		<u>652,263</u>	<u>-</u>			<u>652,263</u>	<u>46,266</u>
Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.073	-	(25)	ALABAMA DEPT OF PUBLIC HEALTH	C90116057-6NU50DD000002	(25)	
CFDA 93.073 Total		<u>-</u>	<u>(25)</u>			<u>(25)</u>	<u>-</u>
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	137,949	-			137,949	5,524
CFDA 93.077 Total		<u>137,949</u>	<u>-</u>			<u>137,949</u>	<u>5,524</u>
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	56,862	-			56,862	
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	-	37,900	HEMOPHILIA OF GEORGIA INC	5NU27DD001155-05-00	37,900	
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	-	310	HEMOPHILIA OF GEORGIA INC	6NU27DD001155-04-02	310	
CFDA 93.080 Total		<u>56,862</u>	<u>38,210</u>			<u>95,072</u>	<u>-</u>
Food and Drug Administration_Research	93.103	191,019	-			191,019	59,522
Food and Drug Administration_Research	93.103	-	23,102	NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC	5U01FD005478-04	23,102	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
CFDA 93.103 Total		<u>191,019</u>	<u>15,590</u>			<u>206,609</u>	<u>59,522</u>
Environmental Health	93.113	7,551,733	-			7,551,733	1,227,632
Environmental Health	93.113	-	(1,819)	VIRGINIA TECH	7R01ES023029-02	(1,819)	
CFDA 93.113 Total		<u>7,551,733</u>	<u>(1,819)</u>			<u>7,549,914</u>	<u>1,227,632</u>
Oral Diseases and Disorders Research	93.121	7,613,444	-			7,613,444	2,967,228
Oral Diseases and Disorders Research	93.121	-	21,303	KAISER FOUNDATION RESEARCH INSTITUTE	1U01DE028727-01	21,303	
Oral Diseases and Disorders Research	93.121	-	9,192	LOUISIANA STATE UNIVERSITY	5R01DE019452-09	9,192	
Oral Diseases and Disorders Research	93.121	-	(169)	UNIVERSITY OF CONNECTICUT HEALTH CENTER	1R34DE027410-01	(169)	
Oral Diseases and Disorders Research	93.121	-	(651)	LOUISIANA STATE UNIVERSITY	5R01DE019452-08	(651)	
CFDA 93.121 Total		<u>7,613,444</u>	<u>29,675</u>			<u>7,643,119</u>	<u>2,967,228</u>
Community Programs to Improve Minority Health Grant Program	93.137	204,082	-			204,082	30,006
CFDA 93.137 Total		<u>204,082</u>	<u>-</u>			<u>204,082</u>	<u>30,006</u>
NIEHS Hazardous Waste Worker Health and Safety Training	93.142	-	186,095	ALABAMA FIRE COLLEGE	3U45ES006155-29S1	186,095	
NIEHS Hazardous Waste Worker Health and Safety Training	93.142	40,846	-			40,846	
CFDA 93.142 Total		<u>40,846</u>	<u>186,095</u>			<u>226,941</u>	<u>-</u>
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	346,233	-			346,233	
CFDA 93.143 Total		<u>346,233</u>	<u>-</u>			<u>346,233</u>	<u>-</u>
AIDS Education and Training Centers	93.145	-	100,500	VANDERBILT UNIVERSITY MEDICAL CENTER	2U1OH30535-04-00	100,500	
AIDS Education and Training Centers	93.145	-	23,614	VANDERBILT UNIVERSITY MEDICAL CENTER	5 U1OHA30535-05-00	23,614	
CFDA 93.145 Total		<u>-</u>	<u>124,114</u>			<u>124,114</u>	<u>-</u>
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	1,732	-			1,732	
CFDA 93.153 Total		<u>1,732</u>	<u>-</u>			<u>1,732</u>	<u>-</u>
Human Genome Research	93.172	652,148	-			652,148	
Human Genome Research	93.172	-	444,796	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	5U01HG007301-06	444,796	
Human Genome Research	93.172	-	195,037	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	5U01HG007301-07	195,037	
Human Genome Research	93.172	-	160,900	HARVARD MEDICAL - SCHEPENS EYE RESEARCH	2U01HG007530-05	160,900	
CFDA 93.172 Total		<u>652,148</u>	<u>800,733</u>			<u>1,452,881</u>	<u>-</u>
Research Related to Deafness and Communication Disorders	93.173	858,601	-			858,601	173,721
Research Related to Deafness and Communication Disorders	93.173	-	67,067	UNIVERSITY OF ALABAMA IN TUSCALOOSA	R01DC016303	67,067	
Research Related to Deafness and Communication Disorders	93.173	-	50,514	BAEBIES INC	R44DC016576	50,514	
Research Related to Deafness and Communication Disorders	93.173	-	7,865	UNIVERSITY OF MINNESOTA	1R01DC017613-01A1	7,865	
CFDA 93.173 Total		<u>858,601</u>	<u>125,446</u>			<u>984,047</u>	<u>173,721</u>
Research and Training in Complementary and Alternative Medicine	93.213	666,115	-			666,115	7,175
CFDA 93.213 Total		<u>666,115</u>	<u>-</u>			<u>666,115</u>	<u>7,175</u>
Family Planning_Services	93.217	-	67,392	ALABAMA DEPT OF PUBLIC HEALTH	C00119055B-FPHPA006461	67,392	
CFDA 93.217 Total		<u>-</u>	<u>67,392</u>			<u>67,392</u>	<u>-</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Research on Healthcare Costs, Quality and Outcomes	93.226	518,428	-			518,428	
Research on Healthcare Costs, Quality and Outcomes	93.226	-	23,696	UNIVERSITY OF ARKANSAS FOR MEDICAL STUDIES	1R01HS025703-01A1	23,696	
Research on Healthcare Costs, Quality and Outcomes	93.226	-	21,175	UNIVERSITY OF ALABAMA IN TUSCALOOSA	1R21HS026571-01	21,175	
Research on Healthcare Costs, Quality and Outcomes	93.226	-	15,053	INDIANA UNIVERSITY	5R01HS025411-03	15,053	
CFDA 93.226 Total		<u>518,428</u>	<u>59,924</u>			<u>578,352</u>	<u>-</u>
National Center on Sleep Disorders Research	93.233	847,320	-			847,320	309,521
CFDA 93.233 Total		<u>847,320</u>	<u>-</u>			<u>847,320</u>	<u>309,521</u>
Mental Health Research Grants	93.242	9,432,242	-			9,432,242	1,813,789
Mental Health Research Grants	93.242	-	236,503	UNIVERSITY OF PITTSBURGH	1R01MH115754-01A1	236,503	
Mental Health Research Grants	93.242	-	156,218	BROWN UNIVERSITY	1R01MH112386-01A1	156,218	
Mental Health Research Grants	93.242	-	87,676	MERIDIAN BIOTECH, LLC	1R41MH119793-01A1	87,676	
Mental Health Research Grants	93.242	-	86,506	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01MH113438-03	86,506	
Mental Health Research Grants	93.242	-	47,430	UNIVERSITY OF CALIFORNIA IN SAN DIEGO	1RF1MH117155-01	47,430	
Mental Health Research Grants	93.242	-	29,922	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925-04	29,922	
Mental Health Research Grants	93.242	-	26,126	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925	26,126	
Mental Health Research Grants	93.242	-	24,877	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R34MH119962-01A1	24,877	
Mental Health Research Grants	93.242	-	21,418	MASSACHUSETTS GENERAL HOSPITAL	5R01MH112385-01	21,418	
Mental Health Research Grants	93.242	-	15,746	SOUTHERN RESEARCH INSTITUTE	7R01MH110681-04	15,746	
Mental Health Research Grants	93.242	-	12,178	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5U01MH115495-03	12,178	
Mental Health Research Grants	93.242	-	9,491	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5U01MH115495-02	9,491	
Mental Health Research Grants	93.242	-	6,911	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925-03S1	6,911	
Mental Health Research Grants	93.242	-	6,404	JOHNS HOPKINS UNIVERSITY	5R25MH080661-13	6,404	
CFDA 93.242 Total		<u>9,432,242</u>	<u>767,406</u>			<u>10,199,648</u>	<u>1,813,789</u>
Occupational Safety and Health Program	93.262	1,079,743	-			1,079,743	441,051
Occupational Safety and Health Program	93.262	-	18,377	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	2T42OH008673-14	18,377	
Occupational Safety and Health Program	93.262	-	7,328	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	2T42OH010278-08-00	7,328	
CFDA 93.262 Total		<u>1,079,743</u>	<u>25,705</u>			<u>1,105,448</u>	<u>441,051</u>
Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief	93.266	-	400	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5001GH000526-02	400	
CFDA 93.266 Total		<u>-</u>	<u>400</u>			<u>400</u>	<u>-</u>
Alcohol Research Programs	93.273	904,237	-			904,237	214,957
Alcohol Research Programs	93.273	-	17,639	UNIVERSITY OF WASHINGTON	5U01AA020793-08	17,639	
CFDA 93.273 Total		<u>904,237</u>	<u>17,639</u>			<u>921,876</u>	<u>214,957</u>
Drug Abuse and Addiction Research Programs	93.279	2,802,694	-			2,802,694	318,545
Drug Abuse and Addiction Research Programs	93.279	-	138,158	YALE UNIVERSITY	1UG3DA047003	138,158	
Drug Abuse and Addiction Research Programs	93.279	-	45,230	ALABAMA STATE UNIVERSITY	1R15DA045564-01	45,230	
Drug Abuse and Addiction Research Programs	93.279	-	3,345	MEDICAL UNIVERSITY OF SOUTH CAROLINA	2UG1DA013727-21	3,345	
Drug Abuse and Addiction Research Programs	93.279	-	2,447	UNIVERSITY OF WASHINGTON	5R01DA047045-02	2,447	
Drug Abuse and Addiction Research Programs	93.279	-	1,132	YALE UNIVERSITY	5P30DA018343-14	1,132	
Drug Abuse and Addiction Research Programs	93.279	-	1,115	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5UG1DA013727-20	1,115	
CFDA 93.279 Total		<u>2,802,694</u>	<u>191,427</u>			<u>2,994,121</u>	<u>318,545</u>
The Affordable Care Act: Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	523,591	-			523,591	
CFDA 93.283 Total		<u>523,591</u>	<u>-</u>			<u>523,591</u>	<u>-</u>
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	493,831	-			493,831	70,623
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	690	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	R01EB020125	690	
CFDA 93.286 Total		<u>493,831</u>	<u>690</u>			<u>494,521</u>	<u>70,623</u>
Minority Health and Health Disparities Research	93.307	4,357,522	-			4,357,522	548,349
Minority Health and Health Disparities Research	93.307	-	59,683	BAYOU LA BATRE CLINIC	1U54MD008602	59,683	
Minority Health and Health Disparities Research	93.307	-	39,842	DREXEL UNIVERSITY	7R01MD013558-03	39,842	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Minority Health and Health Disparities Research	93.307	-	16,635	UNIVERSITY OF PENNSYLVANIA	5R01MD013558-04	16,635	
Minority Health and Health Disparities Research	93.307	-	15,369	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01MD011609-03	15,369	
Minority Health and Health Disparities Research	93.307	-	13,531	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5U01MD011279-05	13,531	
Minority Health and Health Disparities Research	93.307	-	3,068	UNIVERSITY OF PITTSBURGH	5R01MD009118-02	3,068	
Minority Health and Health Disparities Research	93.307	-	2,855	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01MD011609-04	2,855	
Minority Health and Health Disparities Research	93.307	-	(14)	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	5R01MD009055-04	(14)	
CFDA 93.307 Total		<u>4,357,522</u>	<u>150,969</u>			<u>4,508,491</u>	<u>548,349</u>
Trans-NIH Research Support	93.310	1,673,523	-			1,673,523	452,958
Trans-NIH Research Support	93.310	-	27,520	REGENTS OF THE UNIVERSITY OF COLORADO	3R01DK111622-02S1	27,520	
Trans-NIH Research Support	93.310	-	16,051	YALE UNIVERSITY	1UG3NS115597-01	16,051	
Trans-NIH Research Support	93.310	-	13,541	EMORY UNIVERSITY	1U01CA242109-01	13,541	
Trans-NIH Research Support	93.310	-	(66)	UNIVERSITY OF IBADAN	1U54HG007479-01	(66)	
Trans-NIH Research Support	93.310	-	(127)	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5UG3OD023316-02	(127)	
Trans-NIH Research Support	93.310	-	(189)	INDIANA UNIVERSITY	7R01AG043972-06	(189)	
Trans-NIH Research Support	93.310	-	(250)	UNIVERSITY OF IBADAN	3U54HG007479-02S1	(250)	
Trans-NIH Research Support	93.310	-	(343)	HARVARD COLLEGE	5U01HG007530-04	(343)	
CFDA 93.310 Total		<u>1,673,523</u>	<u>56,137</u>			<u>1,729,660</u>	<u>452,958</u>
Rare Disorders: Research, Surveillance, Health Promotion, and Education	93.315	84,993	-			84,993	
CFDA 93.315 Total		<u>84,993</u>	<u>-</u>			<u>84,993</u>	<u>-</u>
National Center for Advancing Translational Sciences	93.350	21,560,383	-			21,560,383	6,183,932
National Center for Advancing Translational Sciences	93.350	-	157,126	UNIVERSITY OF MASSACHUSETTS WORCESTER	5U01TR001812-04	157,126	
National Center for Advancing Translational Sciences	93.350	-	128,827	NORTHWESTERN UNIVERSITY	5U01TR001806-03	128,827	
National Center for Advancing Translational Sciences	93.350	-	88,012	OREGON HEALTH & SCIENCES UNIVERSITY	5U24TR002306-03	88,012	
National Center for Advancing Translational Sciences	93.350	-	45,573	UNIVERSITY OF IOWA	3UL1TR002537-02S1	45,573	
National Center for Advancing Translational Sciences	93.350	-	35,993	UNIVERSITY OF MASSACHUSETTS WORCESTER	5U01TR001812-05	35,993	
National Center for Advancing Translational Sciences	93.350	-	28,904	UNIVERSITY OF IOWA	5UL1TR002537-03	28,904	
National Center for Advancing Translational Sciences	93.350	-	26,486	UNIVERSITY OF PITTSBURGH	5UL1TR001857-04	26,486	
National Center for Advancing Translational Sciences	93.350	-	10,867	UNIVERSITY OF PITTSBURGH	5UL1TR001857-05	10,867	
National Center for Advancing Translational Sciences	93.350	-	2,001	MEDSTAR RESEARCH INSTITUTE	UL1TR000101	2,001	
National Center for Advancing Translational Sciences	93.350	-	(20)	UNIVERSITY OF PITTSBURGH	5UL1TR001857-03	(20)	
National Center for Advancing Translational Sciences	93.350	-	(5,839)	BLONDIN BIO SCIENCE LLC	1R43TR001283-01	(5,839)	
CFDA 93.350 Total		<u>21,560,383</u>	<u>517,930</u>			<u>22,078,313</u>	<u>6,183,932</u>
Research Infrastructure Programs	93.351	971,956	-			971,956	
Research Infrastructure Programs	93.351	-	116,594	TRICORDER ARRAY TECHNOLOGIES, LLC	1R41OD026185-01A1	116,594	
Research Infrastructure Programs	93.351	-	9,679	TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC	1R41OD027206-01	9,679	
CFDA 93.351 Total		<u>971,956</u>	<u>126,273</u>			<u>1,098,229</u>	<u>-</u>
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	830,309	-			830,309	331,402
CFDA 93.353 Total		<u>830,309</u>	<u>-</u>			<u>830,309</u>	<u>331,402</u>
Nursing Research	93.361	1,338,391	-			1,338,391	37,335
Nursing Research	93.361	-	168,576	CASE WESTERN UNIVERSITY	1R01NR018391-01	168,576	
Nursing Research	93.361	-	164,507	CASE WESTERN UNIVERSITY	R01NR018391	164,507	
Nursing Research	93.361	-	4,631	DANA-FARBER CANCER INSTITUTE	5R01NR016720-03	4,631	
Nursing Research	93.361	-	2,334	DANA-FARBER CANCER INSTITUTE	5R01NR016720-04	2,334	
CFDA 93.361 Total		<u>1,338,391</u>	<u>340,048</u>			<u>1,678,439</u>	<u>37,335</u>
Cancer Cause and Prevention Research	93.393	7,429,114	-			7,429,114	480,447
Cancer Cause and Prevention Research	93.393	-	229,599	UNIVERSITY OF MASSACHUSETTS WORCESTER	5R01CA218008-02	229,599	
Cancer Cause and Prevention Research	93.393	-	217,562	DARTMOUTH COLLEGE	1R01CA225792-01A1	217,562	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cancer Cause and Prevention Research	93.393	-	139,926	DARTMOUTH COLLEGE	6R01CA229197-02	139,926	
Cancer Cause and Prevention Research	93.393	-	108,692	UNIVERSITY OF KANSAS MEDICAL CENTER	1R01CA226838-03	108,692	
Cancer Cause and Prevention Research	93.393	-	76,152	VANDERBILT UNIVERSITY MEDICAL CENTER	5P01CA02882-33	76,152	
Cancer Cause and Prevention Research	93.393	-	45,351	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01CA190612-06	45,351	
Cancer Cause and Prevention Research	93.393	-	31,688	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	5U01CA235507-02	31,688	
Cancer Cause and Prevention Research	93.393	-	10,131	FRED HUTCHINSON CANCER RESEARCH CENTER	5R01CA211996-03	10,131	
Cancer Cause and Prevention Research	93.393	-	6,278	FRED HUTCHINSON CANCER RESEARCH CENTER	5R01CA211996-04	6,278	
Cancer Cause and Prevention Research	93.393	-	5,478	UNIVERSITY OF TENNESSEE IN MEMPHIS	1R01CA242737-01A1	5,478	
Cancer Cause and Prevention Research	93.393	-	3,999	DUKE UNIVERSITY	7R37CA233777-02	3,999	
Cancer Cause and Prevention Research	93.393	-	950	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	5R01CA199167-03	950	
CFDA 93.393 Total		<u>7,429,114</u>	<u>875,806</u>			<u>8,304,920</u>	<u>480,447</u>
Cancer Detection and Diagnosis Research	93.394	4,067,525	-			4,067,525	316,787
Cancer Detection and Diagnosis Research	93.394	-	376,993	PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDI	5P01CA221775-05	376,993	
Cancer Detection and Diagnosis Research	93.394	-	78,412	UNIVERSITY OF OKLAHOMA	1R01CA193378-01	78,412	
Cancer Detection and Diagnosis Research	93.394	-	65,854	FRED HUTCHINSON CANCER RESEARCH CENTER	U01CA214114	65,854	
Cancer Detection and Diagnosis Research	93.394	-	39,345	UNIVERSITY OF CALIFORNIA - BERKELEY	1R01CA246695-01	39,345	
Cancer Detection and Diagnosis Research	93.394	-	17,273	MEMORIAL SLOAN KETTERING CANCER CENTER	1R01CA235711-01A1	17,273	
Cancer Detection and Diagnosis Research	93.394	-	16,360	UNIVERSITY OF BRITISH COLUMBIA	1R01CA221918-01A1	16,360	
Cancer Detection and Diagnosis Research	93.394	-	14,445	EMORY UNIVERSITY	5R01CA203388-03	14,445	
Cancer Detection and Diagnosis Research	93.394	-	12,579	UNIVERSITY OF MICHIGAN	5U24CA086368-18	12,579	
Cancer Detection and Diagnosis Research	93.394	-	7,999	MASSACHUSETTS GENERAL HOSPITAL	5U01CA152990-09	7,999	
Cancer Detection and Diagnosis Research	93.394	-	4,898	UNIVERSITY OF MARYLAND	1R01CA228399-01A1	4,898	
Cancer Detection and Diagnosis Research	93.394	-	4,519	UNIVERSITY OF MASSACHUSETTS WORCESTER	1R01CA194787-01A1	4,519	
Cancer Detection and Diagnosis Research	93.394	-	3,758	MEMORIAL SLOAN KETTERING CANCER CENTER	5R01CA235711-02	3,758	
Cancer Detection and Diagnosis Research	93.394	-	2,413	NRG ONCOLOGY INC	U24CA196067	2,413	
Cancer Detection and Diagnosis Research	93.394	-	491	CHILDREN'S HOSPITAL OF PHILADELPHIA	R01CA193478-01A1	491	
Cancer Detection and Diagnosis Research	93.394	-	86	NRG ONCOLOGY INC	1U10CA180860-1	86	
CFDA 93.394 Total		<u>4,067,525</u>	<u>645,425</u>			<u>4,712,950</u>	<u>316,787</u>
Cancer Treatment Research	93.395	3,432,276	-			3,432,276	120,079
Cancer Treatment Research	93.395	-	187,288	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886	187,288	
Cancer Treatment Research	93.395	-	128,739	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886-06	128,739	
Cancer Treatment Research	93.395	-	66,460	CHILDREN'S HOSPITAL OF PHILADELPHIA	1U01CA228823-01	66,460	
Cancer Treatment Research	93.395	-	38,829	TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER	7R01CA219187-02	38,829	
Cancer Treatment Research	93.395	-	30,229	JOHNS HOPKINS UNIVERSITY	UM1CA137443	30,229	
Cancer Treatment Research	93.395	-	28,599	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	5R01CA196854-03	28,599	
Cancer Treatment Research	93.395	-	21,654	MAYO CLINIC ROCHESTER	5UG1CA189823-03	21,654	
Cancer Treatment Research	93.395	-	18,896	JOHNS HOPKINS UNIVERSITY	U01CA137443	18,896	
Cancer Treatment Research	93.395	-	11,507	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	5U24CA055727-26	11,507	
Cancer Treatment Research	93.395	-	10,596	SEATTLE CHILDREN'S HOSPITAL	5R01CA175216-04	10,596	
Cancer Treatment Research	93.395	-	8,798	CHILDREN'S HOSPITAL OF PHILADELPHIA	1R01CA196854	8,798	
Cancer Treatment Research	93.395	-	8,731	NRG ONCOLOGY INC	2U10CA180868-06	8,731	
Cancer Treatment Research	93.395	-	7,706	EASTERN COOPERATIVE ONCOLOGY GROUP	U10CA180820-06	7,706	
Cancer Treatment Research	93.395	-	6,705	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	5U24CA055727-24	6,705	
Cancer Treatment Research	93.395	-	6,186	CHILDREN'S HOSPITAL OF PHILADELPHIA	5U10CA180886-07	6,186	
Cancer Treatment Research	93.395	-	4,010	CHILDREN'S HOSPITAL OF PHILADELPHIA	UM1CA097452	4,010	
Cancer Treatment Research	93.395	-	2,559	JOHNS HOPKINS UNIVERSITY	SUM1CA137443	2,559	
Cancer Treatment Research	93.395	-	1,631	CHILDREN'S HOSPITAL OF PHILADELPHIA	1U10CA180886-01	1,631	
Cancer Treatment Research	93.395	-	1,210	CHILDREN'S HOSPITAL OF PHILADELPHIA	UG1CA189955	1,210	
Cancer Treatment Research	93.395	-	703	CHILDREN'S HOSPITAL OF PHILADELPHIA	R01CA212190-01A1	703	
Cancer Treatment Research	93.395	-	496	OREGON HEALTH & SCIENCES UNIVERSITY	5UG1CA189974-05	496	
Cancer Treatment Research	93.395	-	153	CHILDREN'S HOSPITAL OF PHILADELPHIA	U10CA098543	153	
CFDA 93.395 Total		<u>3,432,276</u>	<u>591,685</u>			<u>4,023,961</u>	<u>120,079</u>
Cancer Biology Research	93.396	4,321,108	-			4,321,108	355,255
Cancer Biology Research	93.396	-	182,892	PENNSYLVANIA STATE UNIVERSITY (THE)	1R01CA230628-01A1	182,892	
Cancer Biology Research	93.396	-	54,618	CORNELL UNIVERSITY	5R01CA201402-04	54,618	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cancer Biology Research	93.396	-	6,845	UNIVERSITY OF MICHIGAN	P01CA093900	6,845	
Cancer Biology Research	93.396	-	5,623	CEDARS-SINAI MEDICAL CENTER	5P01CA098912-14	5,623	
CFDA 93.396 Total		4,321,108	249,978			4,571,086	355,255
Cancer Centers Support Grants	93.397	7,383,457	-			7,383,457	230,423
Cancer Centers Support Grants	93.397	-	559,365	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	5P50CA107399-11A1	559,365	67,406
Cancer Centers Support Grants	93.397	-	451,604	JOHNS HOPKINS UNIVERSITY	2P50CA098252-16	451,604	
Cancer Centers Support Grants	93.397	-	82,028	INDIANA UNIVERSITY	5U54CA196519	82,028	
Cancer Centers Support Grants	93.397	-	21,709	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	2P50CA107399-11A1	21,709	19,647
Cancer Centers Support Grants	93.397	-	19,292	INDIANA UNIVERSITY	5U54CA196519-05	19,292	
Cancer Centers Support Grants	93.397	-	8,312	JOHNS HOPKINS UNIVERSITY	5P50CA098252-15	8,312	
Cancer Centers Support Grants	93.397	-	2,483	INDIANA UNIVERSITY	5U54CA196519-04	2,483	
CFDA 93.397 Total		7,383,457	1,144,793			8,528,250	317,476
Cancer Research Manpower	93.398	1,799,339	-			1,799,339	
CFDA 93.398 Total		1,799,339	-			1,799,339	-
Cancer Control	93.399	-	27,325	OREGON HEALTH & SCIENCES UNIVERSITY	2UG1CA189974-06	27,325	
Cancer Control	93.399	-	27,208	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886-06 REVISED	27,208	
Cancer Control	93.399	-	24,507	EASTERN COOPERATIVE ONCOLOGY GROUP	2UG1CA189828-06	24,507	
Cancer Control	93.399	-	20,442	CHILDREN'S HOSPITAL OF PHILADELPHIA	2UG1CA189955-06	20,442	
CFDA 93.399 Total		-	99,482			99,482	-
Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations	93.431	-	10,319	NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO	NU58DP006488	10,319	
Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations	93.431	-	4,803	NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO	NU58DP006488-01-00	4,803	
CFDA 93.431 Total		-	15,122			15,122	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	3,075,414	-			3,075,414	543,434
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	33,231	UNIVERSITY OF CHICAGO	90REG0005-01-00	33,231	
CFDA 93.433 Total		3,075,414	33,231			3,108,645	543,434
Ending the HIV Epidemic: A Plan for America ? Ryan White HIV/AIDS Parts A and B	93.686	-	25,000	ALABAMA DEPT OF PUBLIC HEALTH	C00119147-UT8HA33956	25,000	
CFDA 93.686 Total		-	25,000			25,000	-
Cardiovascular Diseases Research	93.837	28,404,677	-			28,404,677	6,699,103
Cardiovascular Diseases Research	93.837	-	504,890	CORNELL UNIVERSITY	5R01HL080477-13	504,890	
Cardiovascular Diseases Research	93.837	-	288,833	INDIANA UNIVERSITY	5R01HL145528-03	288,833	
Cardiovascular Diseases Research	93.837	-	244,213	BOSTON UNIVERSITY MEDICAL CAMPUS	1U01HL146382-02	244,213	
Cardiovascular Diseases Research	93.837	-	228,216	DUKE UNIVERSITY	1R01HL144773-01	228,216	
Cardiovascular Diseases Research	93.837	-	214,765	BOSTON UNIVERSITY MEDICAL CAMPUS	1U01HL146382-01	214,765	
Cardiovascular Diseases Research	93.837	-	204,282	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	2P01HL051952-21A1	204,282	
Cardiovascular Diseases Research	93.837	-	203,174	CORNELL UNIVERSITY	1R01HL135199-02	203,174	
Cardiovascular Diseases Research	93.837	-	199,218	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	5R01HL146130-03	199,218	
Cardiovascular Diseases Research	93.837	-	181,418	GEORGIA STATE UNIVERSITY	7R01HL142291-02	181,418	
Cardiovascular Diseases Research	93.837	-	119,429	MEDICAL COLLEGE OF WISCONSIN	5R01HL140493-02	119,429	
Cardiovascular Diseases Research	93.837	-	118,495	VANDERBILT UNIVERSITY MEDICAL CENTER	1P01HL128203-01A1	118,495	
Cardiovascular Diseases Research	93.837	-	88,646	BRIGHAM & WOMENS HOSPITAL	5U01HL123336-04	88,646	
Cardiovascular Diseases Research	93.837	-	68,577	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01HL139837-01	68,577	
Cardiovascular Diseases Research	93.837	-	56,930	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HL142825-01A1	56,930	
Cardiovascular Diseases Research	93.837	-	52,890	MEDICAL COLLEGE OF WISCONSIN	5R01HL140493-03	52,890	
Cardiovascular Diseases Research	93.837	-	49,610	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	5R01HL128857-04	49,610	
Cardiovascular Diseases Research	93.837	-	46,683	DUKE UNIVERSITY	7R01HL133618-03	46,683	
Cardiovascular Diseases Research	93.837	-	43,404	VANDERBILT UNIVERSITY MEDICAL CENTER	5P01HL128203-05	43,404	
Cardiovascular Diseases Research	93.837	-	43,283	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	7R01HL091357-06	43,283	
Cardiovascular Diseases Research	93.837	-	39,627	DUKE UNIVERSITY	5R01HL126524-04	39,627	
Cardiovascular Diseases Research	93.837	-	31,036	UNIVERSITY OF MARYLAND	5U24HL134763	31,036	
Cardiovascular Diseases Research	93.837	-	26,710	INDIANA UNIVERSITY	7R25HL124208-05	26,710	
Cardiovascular Diseases Research	93.837	-	18,779	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01HL146636-01A1	18,779	
Cardiovascular Diseases Research	93.837	-	18,547	UNIVERSITY OF WASHINGTON	1R01HL36868-01A1	18,547	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cardiovascular Diseases Research	93.837	-	17,420	MAYO CLINIC ARIZONA	1R01HL142627-01A1	17,420	
Cardiovascular Diseases Research	93.837	-	15,047	EMORY UNIVERSITY	5R01HL129511-03	15,047	
Cardiovascular Diseases Research	93.837	-	14,888	DUKE UNIVERSITY	5U01HL134679-02	14,888	
Cardiovascular Diseases Research	93.837	-	14,731	MASSACHUSETTS GENERAL HOSPITAL	5U01HL123336-06	14,731	
Cardiovascular Diseases Research	93.837	-	13,306	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC	1R01HL125877-01A1	13,306	
Cardiovascular Diseases Research	93.837	-	11,133	UNIVERSITY OF UTAH	1R01HL142603-01A1	11,133	
Cardiovascular Diseases Research	93.837	-	10,802	KAISER FOUNDATION RESEARCH INSTITUTE	1R01HL122658-01A1	10,802	
Cardiovascular Diseases Research	93.837	-	10,334	VANDERBILT UNIVERSITY MEDICAL CENTER	1R01HL148661-01	10,334	
Cardiovascular Diseases Research	93.837	-	9,856	OREGON HEALTH & SCIENCES UNIVERSITY	5R01HL136373-02	9,856	
Cardiovascular Diseases Research	93.837	-	9,703	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HL143885-01A1	9,703	
Cardiovascular Diseases Research	93.837	-	9,672	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01HL143885-02	9,672	
Cardiovascular Diseases Research	93.837	-	9,180	THE GEORGE WASHINGTON UNIVERSITY	U24HL140168	9,180	
Cardiovascular Diseases Research	93.837	-	7,853	HARVARD MEDICAL - SCHEPHENS EYE RESEARCH	1R01HL136685-001	7,853	
Cardiovascular Diseases Research	93.837	-	5,595	UNIVERSITY OF PENNSYLVANIA	5R01HL151292-02	5,595	
Cardiovascular Diseases Research	93.837	-	4,401	NORTHWESTERN UNIVERSITY	2R01HL107577-05A1	4,401	
Cardiovascular Diseases Research	93.837	-	4,209	NEW ENGLAND RESEARCH INSTITUTES INC	U01HL107407	4,209	
Cardiovascular Diseases Research	93.837	-	3,313	EMORY UNIVERSITY	R01HL150887-01	3,313	
Cardiovascular Diseases Research	93.837	-	3,023	THE SOCIETY OF THORACIC SURGEONS	5R01HL130502-03 REVISED	3,023	
Cardiovascular Diseases Research	93.837	-	2,731	THE SOCIETY OF THORACIC SURGEONS	5R01AG047416-02	2,731	
Cardiovascular Diseases Research	93.837	-	1,590	KAISER FOUNDATION RESEARCH INSTITUTE	1R01HL122658	1,590	
Cardiovascular Diseases Research	93.837	-	1,392	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	7R01HL055673-19	1,392	
Cardiovascular Diseases Research	93.837	-	936	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	5R01HL128857-02	936	
Cardiovascular Diseases Research	93.837	-	887	DUKE UNIVERSITY	5R01HL133618-03	887	
Cardiovascular Diseases Research	93.837	-	596	TULANE UNIVERSITY	5R01HL127092-02	596	
Cardiovascular Diseases Research	93.837	-	(37)	BRIGHAM & WOMENS HOSPITAL	5U01HL130163-02	(37)	
Cardiovascular Diseases Research	93.837	-	(118)	MASSACHUSETTS GENERAL HOSPITAL	1U01HL123336-01	(118)	
Cardiovascular Diseases Research	93.837	-	(244)	AUGUSTA UNIVERSITY	5P01HL06999-14	(244)	
Cardiovascular Diseases Research	93.837	-	(1,954)	AUGUSTA UNIVERSITY	5P01HL06999-15	(1,954)	
Cardiovascular Diseases Research	93.837	-	(2,830)	MAYO CLINIC ROCHESTER	5R01HL131535-03	(2,830)	
Cardiovascular Diseases Research	93.837	-	(3,898)	BRIGHAM & WOMENS HOSPITAL	5U01HL101422	(3,898)	
Cardiovascular Diseases Research	93.837	-	(4,957)	LOMA LINDA UNIVERSITY	1R01HL142291-01	(4,957)	
CFDA 93.837 Total		28,404,677	3,260,215			31,664,892	6,699,103
Lung Diseases Research	93.838	11,175,315	-			11,175,315	799,374
Lung Diseases Research	93.838	-	187,400	EMORY UNIVERSITY	5R01HL136414-04	187,400	
Lung Diseases Research	93.838	-	106,369	UNIVERSITY OF SOUTH ALABAMA	1R01HL140182-01A1	106,369	
Lung Diseases Research	93.838	-	96,498	THE GEORGE WASHINGTON UNIVERSITY	R01HL098354	96,498	
Lung Diseases Research	93.838	-	82,698	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01HL137880-03	82,698	
Lung Diseases Research	93.838	-	78,657	NATIONAL JEWISH MEDICAL AND RESEARCH CENTER	2R01HL089897	78,657	
Lung Diseases Research	93.838	-	47,054	YALE UNIVERSITY	1U01HL145567-01	47,054	
Lung Diseases Research	93.838	-	33,856	EMORY UNIVERSITY	5R01HL139876-02	33,856	
Lung Diseases Research	93.838	-	31,468	UNIVERSITY OF PENNSYLVANIA	1U01HL145435	31,468	
Lung Diseases Research	93.838	-	28,548	COPD FOUNDATION	5U01HL128954-05	28,548	
Lung Diseases Research	93.838	-	16,288	UNIVERSITY OF SOUTH ALABAMA	1R01HL141473-01	16,288	
Lung Diseases Research	93.838	-	15,291	THE GEORGE WASHINGTON UNIVERSITY	5R01HL098354	15,291	
Lung Diseases Research	93.838	-	14,395	UNIVERSITY OF PITTSBURGH	5U01HL1289454-04	14,395	
Lung Diseases Research	93.838	-	11,019	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U24HL141762-02	11,019	
Lung Diseases Research	93.838	-	10,724	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01HL137880-04	10,724	
Lung Diseases Research	93.838	-	10,099	UNIVERSITY OF PENNSYLVANIA	5U01HL145435-02	10,099	
Lung Diseases Research	93.838	-	8,820	NORTHWESTERN UNIVERSITY	1U01HL146408-01	8,820	
Lung Diseases Research	93.838	-	6,672	NORTHWESTERN UNIVERSITY	5R01HL122477-06A1	6,672	
Lung Diseases Research	93.838	-	5,497	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	2R01HL093081-09	5,497	
Lung Diseases Research	93.838	-	5,035	SANFORD RESEARCH	1R01HL135112-01A1	5,035	
Lung Diseases Research	93.838	-	2,395	NORTHWESTERN UNIVERSITY	5R01HL122477	2,395	
Lung Diseases Research	93.838	-	30	UNIVERSITY OF MICHIGAN	1R01HL147261-01A1	30	
Lung Diseases Research	93.838	-	(497)	THE GEORGE WASHINGTON UNIVERSITY	2R01HL098354-04	(497)	
CFDA 93.838 Total		11,175,315	798,316			11,973,631	799,374
Blood Diseases and Resources Research	93.839	1,347,127	-			1,347,127	519,090
Blood Diseases and Resources Research	93.839	-	141,910	BETH ISRAEL DEACONESS MEDICAL CENTER	1P01HL131477-01A1	141,910	
Blood Diseases and Resources Research	93.839	-	34,644	MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION	5U01HL133990-04	34,644	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Blood Diseases and Resources Research	93.839	-	18,963	UNIVERSITY OF WASHINGTON	1R01HL126538	18,963	
Blood Diseases and Resources Research	93.839	-	15,520	ALL CHILDREN'S RESEARCH INSTITUTE, INC.	1U01HL130048-01A1	15,520	
Blood Diseases and Resources Research	93.839	-	15,430	UNIVERSITY OF PITTSBURGH	1UGHL143192-01A1	15,430	
Blood Diseases and Resources Research	93.839	-	6,016	MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION	5U01HL133990-05	6,016	
Blood Diseases and Resources Research	93.839	-	728	AUGUSTA UNIVERSITY	5U01HL117684-05	728	
Blood Diseases and Resources Research	93.839	-	15	INDIANA UNIVERSITY	5R24HL123767-04 REVISED	15	
Blood Diseases and Resources Research	93.839	-	(104)	UNIVERSITY OF WASHINGTON	1U01HL116383-01	(104)	
Blood Diseases and Resources Research	93.839	-	(3,008)	MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION	5U01HL133990-03	(3,008)	
CFDA 93.839 Total		<u>1,347,127</u>	<u>230,114</u>			<u>1,577,241</u>	<u>519,090</u>
Translation and Implementation Science Rsrch for Heart, Lung, Blood Diseases, Sleep Disorders	93.840	-	24,332	YALE UNIVERSITY	1R01HL151603-01	24,332	
CFDA 93.840 Total		<u>-</u>	<u>24,332</u>			<u>24,332</u>	<u>-</u>
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	5,833,616	-			5,833,616	1,286,864
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	77,934	HEBREW REHABILITATION CENTER	R01AR075356	77,934	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	69,685	MEDICAL UNIVERSITY OF SOUTH CAROLINA	3P30AR072582-03S1	69,685	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	64,518	THE HOSPITAL FOR SICK CHILDREN	5R21AR074006-02	64,518	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	19,029	NORTHWESTERN UNIVERSITY	UH2AR067681	19,029	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	10,055	WASHINGTON STATE UNIVERSITY	1R01AR072615-01A1	10,055	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	8,693	BRIGHAM & WOMENS HOSPITAL	1U01AR068043-01A1	8,693	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	5,410	EMORY UNIVERSITY	2R01AR048266-16A1	5,410	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	(101,039)	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01AR060852-03	(101,039)	
CFDA 93.846 Total		<u>5,833,616</u>	<u>154,285</u>			<u>5,987,901</u>	<u>1,286,864</u>
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	23,401,811	-			23,401,811	2,690,167
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	387,467	THE GEORGE WASHINGTON UNIVERSITY	5-U01DK098246-07	387,467	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	157,167	ENDOMMETICS, LLC	5R44DK109789-03	157,167	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	146,112	UNIVERSITY OF MIAMI	1R01DK116875-01A1	146,112	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	138,615	SEATTLE CHILDREN'S HOSPITAL	5R01DK103608-03	138,615	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	123,516	OREGON HEALTH & SCIENCES UNIVERSITY	7R01DK104347-03	123,516	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	108,280	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01DK105124-01	108,280	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	74,164	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01DK082753-08	74,164	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	57,200	THE CHILDREN'S MERCY HOSPITAL	5U01DK066143-17	57,200	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	56,475	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7R01DK116603-02	56,475	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	52,721	JOHNS HOPKINS UNIVERSITY	5R01DK111966-03	52,721	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	45,893	TUFTS MEDICAL CENTER INC.	5U01DK102730-04	45,893	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	40,672	THE GEORGE WASHINGTON UNIVERSITY	1R01DK104845-01	40,672	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	35,684	JOHNS HOPKINS UNIVERSITY	5R01DK111966-04	35,684	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	34,080	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	5P50DK096418-08	34,080	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	31,904	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	2U01DK100867-07	31,904	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	29,803	PENNSYLVANIA STATE UNIVERSITY (THE)	1R01DK114888-01	29,803	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	21,527	UNIVERSITY OF KANSAS MEDICAL CENTER	5R01DK113111-03	21,527	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	21,286	INDIANA UNIVERSITY	5R01DK114222-02	21,286	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	20,734	OREGON HEALTH & SCIENCES UNIVERSITY	7R01DK112358-02	20,734	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	20,044	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	2U01DK100866-07	20,044	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	14,793	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5U01DK058369-18	14,793	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	14,572	UNIVERSITY OF MASSACHUSETTS DARTMOUTH	1R56DK114514-01A1	14,572	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	12,963	REGENTS OF THE UNIVERSITY OF COLORADO	5UM1DK072493-14	12,963	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	11,890	DUKE UNIVERSITY	1R01DK121007-01	11,890	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	9,242	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01DK100867-08	9,242	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	8,289	UNIVERSITY OF PENNSYLVANIA	5U24DK060990-19	8,289	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	6,796	UNIVERSITY OF MARYLAND	5P30DK090868-11	6,796	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	6,691	REGENTS OF THE UNIVERSITY OF COLORADO	7UM1DK072493-12	6,691	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	5,069	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	2UM1DK072493-11	5,069	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	4,639	TEXAS A&M UNIVERSITY	1R01DK119497-01A1	4,639	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	4,255	UNIVERSITY OF SOUTH FLORIDA	U01 DK061055	4,255	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,832	THE CHILDREN'S MERCY HOSPITAL	2U01DK066143-16	3,832	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,756	TUFTS MEDICAL CENTER INC.	5U01DK102730-05	3,756	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,190	MEDICAL UNIVERSITY OF SOUTH CAROLINA	1U01DK116743-01	3,190	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	2,743	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5UM1DK100867-06 REVISED	2,743	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,323	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01DK084246-08	1,323	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,139	THE GEORGE WASHINGTON UNIVERSITY	R01DK104845	1,139	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	955	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	5P50DK096418-07	955	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	934	JOHNS HOPKINS UNIVERSITY	5U01DK062431-13	934	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	680	EMORY UNIVERSITY	5R01DK087694-09	680	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	542	KAISER FOUNDATION RESEARCH INSTITUTE	1R01DK106201-01	542	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	367	KAISER FOUNDATION RESEARCH INSTITUTE	1R01DK106201-03	367	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	276	JOHNS HOPKINS UNIVERSITY	U01DK062431	276	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	233	MOUNT SINAI SCHOOL OF MEDICINE	5U54DK083909-09	233	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	146	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	5UM1DK100866	146	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(234)	KAISER FOUNDATION RESEARCH INSTITUTE	R01 DK084997-01A1	(234)	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(434)	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5U01DK058369-17	(434)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(555)	INDIANA UNIVERSITY	1R01DK116603-01A1	(555)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(671)	THE GEORGE WASHINGTON UNIVERSITY	2U01DK298246	(671)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(726)	MOUNT SINAI SCHOOL OF MEDICINE	5U54DK083909	(726)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(13,227)	EMORY UNIVERSITY	1DP3DK108245-01	(13,227)	
CFDA 93.847 Total		<u>23,401,811</u>	<u>1,706,812</u>			<u>25,108,623</u>	<u>2,690,167</u>
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	19,242,374	-			19,242,374	3,140,484
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	273,221	MASSACHUSETTS GENERAL HOSPITAL	5P01NS087997-05	273,221	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	231,393	STANFORD UNIVERSITY	1U01NS110728-01	231,393	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	183,966	BROWN UNIVERSITY	5R01NS100016-03	183,966	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	140,941	UNIVERSITY OF FLORIDA	1R01NS102624-01	140,941	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	95,364	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01NS097876-03	95,364	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	86,912	CORNELL UNIVERSITY	5R01NS097443-04	86,912	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	65,077	SOUTHERN RESEARCH INSTITUTE	5R01NS101958-04	65,077	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	54,361	MAYO CLINIC JACKSONVILLE	5U01NS080168-07	54,361	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	53,278	UNIVERSITY OF MIAMI	3R01NS040807-15S1	53,278	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	45,228	MAYO CLINIC JACKSONVILLE	5U01NS080168-06	45,228	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	39,082	MASSACHUSETTS GENERAL HOSPITAL	1R01NS099209-01	39,082	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	38,541	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01NS097876-04	38,541	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	32,711	CHILDREN'S HOSPITAL BOSTON	2U42NS092090-06	32,711	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	29,856	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA U	1R01NS109023-01A1	29,856	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	29,814	UNIVERSITY OF MICHIGAN	1R01NS092706-01A1	29,814	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	18,157	MAYO CLINIC ROCHESTER	1U54NS115198-01	18,157	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	16,281	STANFORD UNIVERSITY	2U01NS038455-16A1	16,281	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	13,873	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01NS097507	13,873	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	13,364	UNIVERSITY OF MIAMI	1R01NS084288-01A1	13,364	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,954	STANFORD UNIVERSITY	1R01NS103037-01A1	12,954	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,712	MAYO CLINIC JACKSONVILLE	5U01NS080168-02	12,712	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	11,650	UNIVERSITY OF CINCINNATI	1U01NS095869-01A1	11,650	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	10,720	NORTHWESTERN UNIVERSITY	1R01NS093843-01A1	10,720	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	10,090	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01NS099368-03	10,090	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	8,215	UNIVERSITY OF UTAH	1U01NS107486-01A1	8,215	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	7,453	UNIVERSITY OF CINCINNATI	7U01NS102353-02	7,453	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	7,283	AUGUSTA UNIVERSITY	7R01NS090083-04	7,283	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	6,695	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	5R01NS096053-04	6,695	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	6,031	MASSACHUSETTS GENERAL HOSPITAL	1U10NS077420	6,031	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	5,605	UNIVERSITY OF CINCINNATI	1U01NS099043-01A1	5,605	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	5,178	UNIVERSITY OF CINCINNATI	1U01NS100699-01A1	5,178	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	4,993	NORTHWESTERN UNIVERSITY	1U01NS113851-01	4,993	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	4,868	THE METHODIST HOSPITAL RESEARCH INST	1U01NS104326-03	4,868	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,808	THE METHODIST HOSPITAL RESEARCH INST	1U01NS104326-01	3,808	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,661	UNIVERSITY OF IOWA	7U01NS093663-05	3,661	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,222	JOHNS HOPKINS UNIVERSITY	1U01NS080824-01A1	3,222	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,302	CHILDREN'S HOSPITAL BOSTON	5U54NS092090	2,302	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,069	MASSACHUSETTS GENERAL HOSPITAL	1U24NS107155	2,069	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,945	UNIVERSITY OF CINCINNATI	ABTC 1401	1,945	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,581	UNIVERSITY OF CINCINNATI	1U01NS106655-01A1	1,581	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,580	MASSACHUSETTS GENERAL HOSPITAL	1U01NS093663-01A1	1,580	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,433	UNIVERSITY OF SOUTHERN CALIFORNIA	5U54NS092089-03	1,433	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,248	UNIVERSITY OF CINCINNATI	1U01NS106513-01A1	1,248	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	921	CHILDREN'S HOSPITAL BOSTON	3U01NS082320-05S1	921	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	855	MAYO CLINIC JACKSONVILLE	5R01NS097876-02	855	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	768	CHILDREN'S HOSPITAL BOSTON	5U01NS082320-05	768	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(519)	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	U01NS058634-05	(519)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(1,156)	UNIVERSITY OF IOWA	U01NS093663	(1,156)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(1,207)	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	1R01NS096053-01A1	(1,207)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(1,229)	MASSACHUSETTS GENERAL HOSPITAL	5P01NS087997	(1,229)	
CFDA 93.853 Total		<u>19,242,374</u>	<u>1,597,149</u>			<u>20,839,523</u>	<u>3,140,484</u>
Allergy, Immunology and Transplantation Research	93.855	42,175,801	-			42,175,801	14,972,712
Allergy, Immunology and Transplantation Research	93.855	-	384,693	UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1A1106701-06	384,693	
Allergy, Immunology and Transplantation Research	93.855	-	372,988	FAMILY HEALTH INTERNATIONAL	UM1A1068619	372,988	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Allergy, Immunology and Transplantation Research	93.855	-	331,826	EMORY UNIVERSITY	5R01AI064060-12	331,826	
Allergy, Immunology and Transplantation Research	93.855	-	320,326	EMORY UNIVERSITY	1P01AI125180-01	320,326	
Allergy, Immunology and Transplantation Research	93.855	-	294,917	EMORY UNIVERSITY	5R01AI064060-15	294,917	
Allergy, Immunology and Transplantation Research	93.855	-	252,598	UNIVERSITY OF WISCONSIN IN MADISON	1R01AI148379-01	252,598	
Allergy, Immunology and Transplantation Research	93.855	-	220,017	EMORY UNIVERSITY	3UM1AI148684-0AS1	220,017	
Allergy, Immunology and Transplantation Research	93.855	-	181,465	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01AI113362	181,465	
Allergy, Immunology and Transplantation Research	93.855	-	169,857	UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1AI068636-13	169,857	
Allergy, Immunology and Transplantation Research	93.855	-	168,888	OREGON HEALTH & SCIENCES UNIVERSITY	R01AI133712-02	168,888	
Allergy, Immunology and Transplantation Research	93.855	-	141,709	UNIVERSITY OF MARYLAND	1R01AI125561-01	141,709	
Allergy, Immunology and Transplantation Research	93.855	-	140,519	JOHNS HOPKINS UNIVERSITY	UM1AI068632	140,519	
Allergy, Immunology and Transplantation Research	93.855	-	129,918	UNIVERSITY OF KANSAS	1R01AI125093-01	129,918	
Allergy, Immunology and Transplantation Research	93.855	-	108,307	HARVARD COLLEGE	1R01AI145547-02	108,307	
Allergy, Immunology and Transplantation Research	93.855	-	102,795	UNIVERSITY OF TEXAS MEDICAL BRANCH	1R01AI127744	102,795	
Allergy, Immunology and Transplantation Research	93.855	-	101,290	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI106716-08	101,290	
Allergy, Immunology and Transplantation Research	93.855	-	91,419	BIODTECH INC	2R44AI11445-02A1	91,419	
Allergy, Immunology and Transplantation Research	93.855	-	89,033	UNIVERSITY OF SOUTHERN CALIFORNIA	1R01AI135122-01A1	89,033	
Allergy, Immunology and Transplantation Research	93.855	-	82,074	NOVAN INC	4R44AI143022-02	82,074	
Allergy, Immunology and Transplantation Research	93.855	-	74,531	UNIVERSITY OF SOUTHERN CALIFORNIA	1R21AI130927-01A1	74,531	
Allergy, Immunology and Transplantation Research	93.855	-	67,818	FRED HUTCHINSON CANCER RESEARCH CENTER	3UM1AI068614-14S1	67,818	
Allergy, Immunology and Transplantation Research	93.855	-	66,811	UNIVERSITY OF TEXAS HEALTH CENTER AT SAN ANTONIO	5R01AI141877-03	66,811	
Allergy, Immunology and Transplantation Research	93.855	-	64,859	HARVARD COLLEGE	1R01AI145547-01	64,859	
Allergy, Immunology and Transplantation Research	93.855	-	62,908	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01AI118594-05	62,908	
Allergy, Immunology and Transplantation Research	93.855	-	60,445	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-14	60,445	
Allergy, Immunology and Transplantation Research	93.855	-	59,727	UNIVERSITY OF ROCHESTER	5R01AI117787	59,727	
Allergy, Immunology and Transplantation Research	93.855	-	58,646	UNIVERSITY OF VIRGINIA	1R01AI129678-01	58,646	
Allergy, Immunology and Transplantation Research	93.855	-	54,789	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI068636-14	54,789	
Allergy, Immunology and Transplantation Research	93.855	-	50,941	MOUNT SINAI SCHOOL OF MEDICINE	5U01AI063594-16	50,941	
Allergy, Immunology and Transplantation Research	93.855	-	50,696	UNIVERSITY OF MARYLAND	2U19AI110820-06	50,696	
Allergy, Immunology and Transplantation Research	93.855	-	49,733	JOHNS HOPKINS UNIVERSITY	5U01AI069918-14	49,733	
Allergy, Immunology and Transplantation Research	93.855	-	47,114	UNIVERSITY OF KANSAS	5R21AI140701-02	47,114	
Allergy, Immunology and Transplantation Research	93.855	-	46,606	UNIVERSITY OF CALIFORNIA IN DAVIS	1R01AI143554-01	46,606	
Allergy, Immunology and Transplantation Research	93.855	-	45,668	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	UM1AI068633	45,668	
Allergy, Immunology and Transplantation Research	93.855	-	44,117	UNIVERSITY OF ROCHESTER	5R01AI129518-05	44,117	
Allergy, Immunology and Transplantation Research	93.855	-	41,405	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-14	41,405	
Allergy, Immunology and Transplantation Research	93.855	-	38,609	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-13	38,609	
Allergy, Immunology and Transplantation Research	93.855	-	37,289	BENAROYA RESEARCH INSITUTE AT VIRGINIA MASON	5UM1AI109565-07	37,289	
Allergy, Immunology and Transplantation Research	93.855	-	30,938	UNIVERSITY OF KANSAS	1R01AI138970-01	30,938	
Allergy, Immunology and Transplantation Research	93.855	-	29,959	EMORY UNIVERSITY	1UM1AI148684-01	29,959	
Allergy, Immunology and Transplantation Research	93.855	-	27,656	UNIVERSITY OF ROCHESTER	1U01AI131344-01	27,656	
Allergy, Immunology and Transplantation Research	93.855	-	25,775	VANDERBILT UNIVERSITY MEDICAL CENTER	501AI132004-03	25,775	
Allergy, Immunology and Transplantation Research	93.855	-	24,984	EMORY UNIVERSITY	U19AI110483-06	24,984	
Allergy, Immunology and Transplantation Research	93.855	-	24,881	NORTHWESTERN UNIVERSITY	1P01AI131346-01	24,881	
Allergy, Immunology and Transplantation Research	93.855	-	24,825	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	7R01AI134972-03	24,825	
Allergy, Immunology and Transplantation Research	93.855	-	24,457	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01AI120790-01	24,457	
Allergy, Immunology and Transplantation Research	93.855	-	24,445	UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1AI068636-13 REVISED	24,445	
Allergy, Immunology and Transplantation Research	93.855	-	22,475	EMORY UNIVERSITY	1R01AI148471-01	22,475	
Allergy, Immunology and Transplantation Research	93.855	-	19,226	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01AI149339-01	19,226	
Allergy, Immunology and Transplantation Research	93.855	-	18,791	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI068636-14R	18,791	
Allergy, Immunology and Transplantation Research	93.855	-	17,669	FHI 360	UM1AI068619	17,669	
Allergy, Immunology and Transplantation Research	93.855	-	16,882	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01AI137680-01A1	16,882	
Allergy, Immunology and Transplantation Research	93.855	-	14,912	JOHNS HOPKINS UNIVERSITY	1U01AI134591-04	14,912	
Allergy, Immunology and Transplantation Research	93.855	-	14,522	MFLUIDX	2R44AI141044-02	14,522	
Allergy, Immunology and Transplantation Research	93.855	-	14,392	INDIANA UNIVERSITY	1R01AI37116-01A1	14,392	
Allergy, Immunology and Transplantation Research	93.855	-	14,267	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI068636	14,267	
Allergy, Immunology and Transplantation Research	93.855	-	14,040	UNIVERSITY OF MARYLAND	1R01AI125841-01	14,040	
Allergy, Immunology and Transplantation Research	93.855	-	9,941	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1UM1AI110498-02	9,941	
Allergy, Immunology and Transplantation Research	93.855	-	9,293	UNIVERSITY OF CALIFORNIA LOS ANGELES	UM1AI06716	9,293	
Allergy, Immunology and Transplantation Research	93.855	-	9,149	TEXAS A&M UNIVERSITY	1R21AI151914-01	9,149	
Allergy, Immunology and Transplantation Research	93.855	-	8,625	UNIVERSITY OF CALIFORNIA LOS ANGELES	UM1AI068636-13	8,625	
Allergy, Immunology and Transplantation Research	93.855	-	8,461	BENAROYA RESEARCH INSITUTE AT VIRGINIA MASON	5UM1AI109565-02S	8,461	
Allergy, Immunology and Transplantation Research	93.855	-	7,799	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-13	7,799	
Allergy, Immunology and Transplantation Research	93.855	-	7,259	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-13 REVISED	7,259	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Allergy, Immunology and Transplantation Research	93.855	-	5,114	JOHNS HOPKINS UNIVERSITY	1U01AI138897-03	5,114	
Allergy, Immunology and Transplantation Research	93.855	-	4,211	MOUNT SINAI SCHOOL OF MEDICINE	5U01AI063594-17	4,211	
Allergy, Immunology and Transplantation Research	93.855	-	3,828	DUKE UNIVERSITY	5UM1AI104681-06	3,828	
Allergy, Immunology and Transplantation Research	93.855	-	3,653	HARVARD COLLEGE	2P30AI060354-16	3,653	
Allergy, Immunology and Transplantation Research	93.855	-	3,372	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5R01AI128864-02	3,372	
Allergy, Immunology and Transplantation Research	93.855	-	2,642	DUKE UNIVERSITY	5UM1AI104681-08	2,642	
Allergy, Immunology and Transplantation Research	93.855	-	2,613	DUKE UNIVERSITY	5UM1AI104681	2,613	
Allergy, Immunology and Transplantation Research	93.855	-	1,901	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U54AI082973-11	1,901	
Allergy, Immunology and Transplantation Research	93.855	-	591	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-12	591	
Allergy, Immunology and Transplantation Research	93.855	-	568	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U54AI082973-10	568	
Allergy, Immunology and Transplantation Research	93.855	-	463	FHI 360	UM1 AI068619	463	
Allergy, Immunology and Transplantation Research	93.855	-	81	MOUNT SINAI SCHOOL OF MEDICINE	5U01AI063594	81	
Allergy, Immunology and Transplantation Research	93.855	-	(2,909)	BRIGHAM & WOMENS HOSPITAL	5R01AI12001-03	(2,909)	
Allergy, Immunology and Transplantation Research	93.855	-	(6,275)	DUKE CLINICAL RESEARCH INSTITUTE	5UM1AI04681-05	(6,275)	
Allergy, Immunology and Transplantation Research	93.855	-	(6,920)	UNIVERSITY OF WASHINGTON	5U19AI113173-05	(6,920)	
CFDA 93.855 Total		42,175,801	5,185,907			47,361,708	14,972,712
Biomedical Research and Research Training	93.859	6,264,123	-			6,264,123	114,101
Biomedical Research and Research Training	93.859	-	150,907	JOHNS HOPKINS UNIVERSITY	1R01GM121404-01A1	150,907	
Biomedical Research and Research Training	93.859	-	87,085	EMORY UNIVERSITY	1R01GM131099-01	87,085	
Biomedical Research and Research Training	93.859	-	18,329	NORTHERN ILLINOIS UNIVERSITY	R25GM129216	18,329	
Biomedical Research and Research Training	93.859	-	11,012	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	5R01GM118578-04	11,012	
Biomedical Research and Research Training	93.859	-	3,472	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	5R01GM118578-03	3,472	
Biomedical Research and Research Training	93.859	-	(111)	WASHINGTON UNIVERSITY IN ST LOUIS	5R01GM113838-03	(111)	
CFDA 93.859 Total		6,264,123	270,694			6,534,817	114,101
Emerging Infections Sentinel Networks	93.860	-	6,812	OLIVE VIEW-UCLA EDUCATION & RESEARCH INSTITUTE, IN	1U01CK000480-01/5U01CK0000480-05-1	6,812	
CFDA 93.860 Total		-	6,812			6,812	-
Child Health and Human Development Extramural Research	93.865	9,251,344	-			9,251,344	2,512,185
Child Health and Human Development Extramural Research	93.865	-	833,053	THE GEORGE WASHINGTON UNIVERSITY	U10HD036801	833,053	40,138
Child Health and Human Development Extramural Research	93.865	-	531,155	RTI INTERNATIONAL	U10HD34216	531,155	
Child Health and Human Development Extramural Research	93.865	-	447,448	HARVARD COLLEGE	5U01HD052102-15	447,448	
Child Health and Human Development Extramural Research	93.865	-	193,766	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R01HD089918-04	193,766	
Child Health and Human Development Extramural Research	93.865	-	175,669	RTI INTERNATIONAL	2U24HD069031	175,669	
Child Health and Human Development Extramural Research	93.865	-	150,465	SHARP HEALTHCARE FOUNDATION	5R01HD088646-03	150,465	
Child Health and Human Development Extramural Research	93.865	-	118,060	INDIANA UNIVERSITY	5R01HD86007-02	118,060	
Child Health and Human Development Extramural Research	93.865	-	92,004	UNIVERSITY OF MIAMI	1R01HD101352-01 REVISED	92,004	
Child Health and Human Development Extramural Research	93.865	-	89,626	BAEBIES INC	1R44HD095225-03	89,626	
Child Health and Human Development Extramural Research	93.865	-	86,618	UNIVERSITY OF TEXAS AT AUSTIN	7U01HD077384-06	86,618	
Child Health and Human Development Extramural Research	93.865	-	74,062	WASHINGTON UNIVERSITY IN ST LOUIS	1R01HD086323-02	74,062	
Child Health and Human Development Extramural Research	93.865	-	70,269	UNIVERSITY OF CAPE TOWN	5R01HD083026-04	70,269	
Child Health and Human Development Extramural Research	93.865	-	65,779	NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC	3P01HD067244-08S1	65,779	
Child Health and Human Development Extramural Research	93.865	-	26,789	FLORIDA STATE UNIVERSITY	5U19HD089875-05	26,789	
Child Health and Human Development Extramural Research	93.865	-	25,178	THE GEORGE WASHINGTON UNIVERSITY	1U54NS115054-01	25,178	
Child Health and Human Development Extramural Research	93.865	-	24,935	UNIVERSITY OF WISCONSIN MILWAUKEE	1R01HD096085-01A1	24,935	
Child Health and Human Development Extramural Research	93.865	-	21,546	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U19HD089881-04	21,546	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Child Health and Human Development Extramural Research	93.865	-	14,214	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U19HD089881-05	14,214	
Child Health and Human Development Extramural Research	93.865	-	12,047	SHARP HEALTHCARE FOUNDATION	5R01HD088646-04	12,047	
Child Health and Human Development Extramural Research	93.865	-	10,323	UNIVERSITY OF TEXAS MEDICAL BRANCH	5P2CHD065702-10	10,323	
Child Health and Human Development Extramural Research	93.865	-	9,193	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R03HD096188-02	9,193	
Child Health and Human Development Extramural Research	93.865	-	8,807	BAEBIES INC	1R44HD095225-02	8,807	
Child Health and Human Development Extramural Research	93.865	-	7,912	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HD086139-01A1	7,912	
Child Health and Human Development Extramural Research	93.865	-	2,681	FLORIDA STATE UNIVERSITY	5U19HD089875-06	2,681	
Child Health and Human Development Extramural Research	93.865	-	2,042	MISSISSIPPI STATE UNIVERSITY	1R15HD098660-01	2,042	
Child Health and Human Development Extramural Research	93.865	-	1,993	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1R01HD089918-01	1,993	
Child Health and Human Development Extramural Research	93.865	-	540	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01HD092471-01	540	
Child Health and Human Development Extramural Research	93.865	-	(463)	HARVARD COLLEGE	5U01HD052102-14	(463)	
Child Health and Human Development Extramural Research	93.865	-	(718)	REGENTS OF THE UNIVERSITY OF COLORADO	5R01HD080477-05	(718)	
Child Health and Human Development Extramural Research	93.865	-	(2,601)	WASHINGTON UNIVERSITY IN ST LOUIS	1U01HD077384-02	(2,601)	
Child Health and Human Development Extramural Research	93.865	-	(14,052)	UNIVERSITY OF TEXAS MEDICAL BRANCH	5R01HD083003-02	(14,052)	
Child Health and Human Development Extramural Research	93.865	-	(14,164)	DUKE UNIVERSITY	R01HD081044	(14,164)	
CFDA 93.865 Total		9,251,344	3,064,176			12,315,520	2,552,323
Aging Research	93.866	9,933,855	-			9,933,855	1,294,939
Aging Research	93.866	-	463,770	UNIVERSITY OF FLORIDA	5R37AG033906-18	463,770	
Aging Research	93.866	-	253,636	JOHNS HOPKINS UNIVERSITY	1RF1AG050609-01A1	253,636	
Aging Research	93.866	-	151,599	THE JACKSON LAORATORY	1RF1AG063755-01	151,599	
Aging Research	93.866	-	142,337	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1R01AG059009	142,337	
Aging Research	93.866	-	120,336	INDIANA UNIVERSITY	1R01AG057703-01	120,336	
Aging Research	93.866	-	119,423	UNIVERSITY OF WASHINGTON	1R01AG056486-01	119,423	
Aging Research	93.866	-	112,025	UNIVERSITY OF SOUTHERN CALIFORNIA	U19AG02-4904	112,025	
Aging Research	93.866	-	95,872	UNIVERSITY OF SOUTHERN CALIFORNIA	1U24AG057437-01	95,872	
Aging Research	93.866	-	93,377	MOUNT SINAI SCHOOL OF MEDICINE	5R01AG061186-02	93,377	
Aging Research	93.866	-	91,616	MOUNT SINAI SCHOOL OF MEDICINE	1R01AG061186-01	91,616	
Aging Research	93.866	-	83,445	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	7R01AG056360-02	83,445	
Aging Research	93.866	-	61,086	NORTHERN CALIFORNIA INST FOR RESEARCH AND EDU	1R01AG063887-01	61,086	
Aging Research	93.866	-	60,749	UNIVERSITY OF PENNSYLVANIA	5R01AG062819-02	60,749	
Aging Research	93.866	-	51,933	UNIVERSITY OF MICHIGAN	1RF1AG057540-01	51,933	
Aging Research	93.866	-	40,260	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	1R01AG058571-01	40,260	
Aging Research	93.866	-	36,641	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5R01AG047290-03	36,641	
Aging Research	93.866	-	36,102	CALIFORNIA PACIFIC MED. CTR. RES. INST.	1R56AG061085-01	36,102	
Aging Research	93.866	-	30,913	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7RF1AG056111-02	30,913	
Aging Research	93.866	-	28,261	PENNSYLVANIA STATE UNIVERSITY (THE)	1U012AG062370	28,261	
Aging Research	93.866	-	23,640	WASHINGTON UNIVERSITY IN ST LOUIS	5R01AG053267-02	23,640	
Aging Research	93.866	-	19,935	UNIVERSITY OF WISCONSIN IN MADISON	5R01AG040178-07	19,935	
Aging Research	93.866	-	19,623	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	1U19AG062682-01	19,623	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Aging Research	93.866	-	19,596	UNIVERSITY OF CALIFORNIA LOS ANGELES	5R01AG054366-03	19,596	
Aging Research	93.866	-	17,378	EMORY UNIVERSITY	5R34AG058835-02	17,378	
Aging Research	93.866	-	15,583	MAYO CLINIC ROCHESTER	1U19AG063911-01	15,583	
Aging Research	93.866	-	13,273	UNIVERSITY OF SOUTHERN CALIFORNIA	1R01AG063689-01	13,273	
Aging Research	93.866	-	11,552	UNIVERSITY OF SOUTHERN CALIFORNIA	R01AG053798	11,552	
Aging Research	93.866	-	10,847	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01AG057709	10,847	
Aging Research	93.866	-	10,670	UNIVERSITY OF FLORIDA	R37AG033906	10,670	
Aging Research	93.866	-	10,073	UNIVERSITY OF PENNSYLVANIA	1R01AG062819-01A1	10,073	
Aging Research	93.866	-	6,341	THE JACKSON LABORATORY	5R01AG052608-04	6,341	
Aging Research	93.866	-	5,448	REGENTS OF THE UNIVERSITY OF COLORADO	1R01AG054366-01A1	5,448	
Aging Research	93.866	-	3,104	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01AG050819-02	3,104	
Aging Research	93.866	-	2,352	UNIVERSITY OF SOUTHERN CALIFORNIA	5U19AG010483-24	2,352	
Aging Research	93.866	-	1,026	NORTHWESTERN UNIVERSITY	1R01AG047416-01A1	1,026	
Aging Research	93.866	-	445	UNIVERSITY OF WASHINGTON	1R56AG057262-01	445	
Aging Research	93.866	-	(289)	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	1R01AG046920-01A1	(289)	
Aging Research	93.866	-	(1,056)	DREXEL UNIVERSITY	1R01AG049970	(1,056)	
Aging Research	93.866	-	(1,718)	INDIANA UNIVERSITY	1RF1AG056111-01	(1,718)	
Aging Research	93.866	-	(2,828)	MINNEAPOLIS MEDICAL RESEARCH FOUNDATION	U01AG029824-07S2	(2,828)	
Aging Research	93.866	-	(50,999)	UNIVERSITY OF FLORIDA	2R37AG033906-11	(50,999)	
CFDA 93.866 Total		9,933,855	2,207,377			12,141,232	1,294,939
Vision Research	93.867	11,916,019	-			11,916,019	2,215,497
Vision Research	93.867	-	400,668	VANDERBILT UNIVERSITY MEDICAL CENTER	5U24EY029893-02	400,668	
Vision Research	93.867	-	230,057	UNIVERSITY OF FLORIDA	1R01EY028968-01A1	230,057	
Vision Research	93.867	-	125,282	UNIVERSITY OF FLORIDA	5R01EY024280-07	125,282	
Vision Research	93.867	-	123,821	UNIVERSITY OF CALIFORNIA - BERKELEY	2R01EY023591-06	123,821	
Vision Research	93.867	-	103,684	UNIVERSITY OF PENNSYLVANIA	1R01EY030192-02S1	103,684	
Vision Research	93.867	-	90,202	MICHIGAN STATE UNIVERSITY	5R01EY016077-10	90,202	
Vision Research	93.867	-	51,964	UNIVERSITY OF ILLINOIS AT CHICAGO	5R01EY024966-04	51,964	
Vision Research	93.867	-	51,409	OKLAHOMA MEDICAL RESEARCH FOUNDATION	1R01EY024944-01A1	51,409	
Vision Research	93.867	-	43,540	JAEB CENTER FOR HEALTH RESEARCH INC	5U10EY011751-20	43,540	
Vision Research	93.867	-	42,955	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01EY026220-03	42,955	
Vision Research	93.867	-	42,283	OKLAHOMA MEDICAL RESEARCH FOUNDATION	5R01EY024944-03	42,283	
Vision Research	93.867	-	40,585	DOHENY EYE INSTITUTE INC	7R01EY024378-06	40,585	
Vision Research	93.867	-	32,231	JAEB CENTER FOR HEALTH RESEARCH INC	MTS1	32,231	
Vision Research	93.867	-	19,278	UNIVERSITY OF WASHINGTON	1R01EY028282-01A1	19,278	
Vision Research	93.867	-	7,771	UNIVERSITY OF CALIFORNIA - BERKELEY	R01EY023591	7,771	
Vision Research	93.867	-	6,153	NEW YORK UNIVERSITY MEDICAL SCHOOL	1U10EY026869-01	6,153	
Vision Research	93.867	-	3,125	DOHENY EYE INSTITUTE INC	1R01EY030501-01A1	3,125	
Vision Research	93.867	-	1,226	MOUNT SINAI SCHOOL OF MEDICINE	R01EY015220	1,226	
Vision Research	93.867	-	1,112	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	2R01EY014263-09	1,112	
Vision Research	93.867	-	317	UNIVERSITY OF FLORIDA	R01EY024280	317	
Vision Research	93.867	-	103	VANDERBILT UNIVERSITY MEDICAL CENTER	1U24EY029893-01	103	
Vision Research	93.867	-	11	STATE UNIVERSITY OF NEW YORK BUFFALO, SUNY	2R01EY022091-05A1	11	
CFDA 93.867 Total		11,916,019	1,417,777			13,333,796	2,215,497
HIV Emergency Relief Project Grants	93.914	-	216	BOSTON UNIVERSITY MEDICAL CAMPUS	5U69HA30462-02-00	216	
HIV Emergency Relief Project Grants	93.914	-	160	THE FENWAY INSTITUTE, FENWAY HEALTH	U69HA31067	160	
CFDA 93.914 Total		-	376			376	-
CDC Collaboration with Academia to Strengthen Public Health	93.967	-	7,834	ASSOCIATION OF AMERICAN MEDICAL COLLEGES	5NU36OE00007-03-00	7,834	
CFDA 93.967 Total		-	7,834			7,834	-
International Research and Research Training	93.989	-	46,289	UNIVERSIDAD PERUANA CAYETANO HEREDIA	5D43TW009763-05	46,289	
International Research and Research Training	93.989	40,113	-			40,113	20,365
CFDA 93.989 Total		40,113	46,289			86,402	20,365
Contract #HHSN2682018000051 TO 01 Opt 1	93.RD	1,327,258	-			1,327,258	395,777
Contract #HHSN272201600018C	93.RD	1,196,289	-			1,196,289	572,354
Contract #HHSN272201300012I/HHSN27200014	93.RD	698,983	-			698,983	443,915

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Contract #HHSN272201600017C	93.RD	690,413	-			690,413	293,589
Contract #HHSN272201100035C	93.RD	551,461	-			551,461	139,128
Contract #HHSN272201300012I	93.RD	517,098	-			517,098	268,922
Contract #HHSN268201800005I Base	93.RD	431,162	-			431,162	
Contract #75N93019D00016	93.RD	420,332	-			420,332	
Contract #HHSN268201800007I TO 01 Opt 1	93.RD	339,416	-			339,416	
Contract #HHSN272201100038C	93.RD	310,163	-			310,163	66,390
Contract #HHSN261201500036I TO9	93.RD	304,610	-			304,610	295,340
Contract #HHSN272201300012I/TO F00131	93.RD	296,604	-			296,604	117,018
Contract #HHSN272201100037C	93.RD	286,010	-			286,010	20,186
Contract #HHSN261201500036I TO 11	93.RD	282,312	-			282,312	212,328
Contract #HHSN261201500036I TO 10	93.RD	281,113	-			281,113	167,668
Contract #75N91019D00019/75N91019F00131	93.RD	280,310	-			280,310	260,937
Contract #HHSN272201300012I/TO F00132	93.RD	250,376	-			250,376	119,651
Contract #HHSN268201800005I Opt 2	93.RD	241,136	-			241,136	25,625
Contract #75D30118C02929	93.RD	222,036	-			222,036	51,220
Contract #HHSN272201100036C	93.RD	204,092	-			204,092	34,269
Contract #HHSN272201100034C	93.RD	175,098	-			175,098	
Contract #HHSN268200900047C OPT5	93.RD	151,592	-			151,592	
Contract #HHSN261201500036I TO 07	93.RD	133,863	-			133,863	
Contract #HHSN272201300012I/HHSN27200015	93.RD	131,011	-			131,011	111,619
Contract #HHSN268201800007I TO 01	93.RD	113,767	-			113,767	
Contract #HHSN272201300012I/HHSN27200013	93.RD	111,841	-			111,841	87,226
Contract #HHSN261201500036I	93.RD	110,970	-			110,970	89,637
Contract #75N91019D00019/75N91019F00132	93.RD	110,058	-			110,058	93,100
Contract #HHSN261201500036I TO8	93.RD	109,480	-			109,480	
Contract	93.RD	-	107,673	UNIVERSITY OF UTAH	HHSN275201800009I	107,673	
Contract #HHSN272201300012I/HHSN27200011	93.RD	97,322	-			97,322	36,644
Contract	93.RD	-	79,042	LOVELACE BIOMEDICAL RESERACH INSTITUE	HHSNO100201700023I-75A50120F33002	79,042	
Contract #HHSN272201300012I-TO12 Opt 2	93.RD	68,846	-			68,846	61,350
Contract	93.RD	-	61,873	UNIVERSITY OF PUERTO RICO	R01DE028195	61,873	
Contract	93.RD	-	61,866	UNIVERSITY OF ROCHESTER	HHSN27220140000SC	61,866	
Contract	93.RD	-	56,313	UNIVERSITY OF WISCONSIN IN MADISON	HHSN261201200033I	56,313	
Contract	93.RD	-	54,997	EASTERN COOPERATIVE ONCOLOGY GROUP	EA1151	54,997	
Contract	93.RD	-	52,999	ABT ASSOCIATES INC	HHSND20002013M53890B/75D30119F069241	52,999	
Contract #75D30118C02902	93.RD	49,215	-			49,215	9,850
Contract #75N91019D00019/75N91019F00130	93.RD	46,552	-			46,552	
Contract #IPA JILL HYDE - DETECT STUDY	93.RD	45,107	-			45,107	
Contract	93.RD	-	41,280	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	10T3HL147154-01	41,280	
Contract	93.RD	-	39,614	JOHNS HOPKINS UNIVERSITY	5U24TR002306-03	39,614	
Contract #HHSN268201800005I TO 01 BASE	93.RD	38,641	-			38,641	
Contract	93.RD	-	35,929	RAND CORPORATION	HHSM-500-2017-00083G	35,929	
Contract	93.RD	-	33,539	MEDICAL UNIVERSITY OF SOUTH CAROLINA	1UG30D023316-01	33,539	
Contract	93.RD	-	23,155	NORTHWESTERN UNIVERSITY	HHSN261201200035I	23,155	
Contract	93.RD	-	22,812	SUMMIT OXFORD LIMITED	HHSO100201700014C	22,812	
Contract #HHSN272201300012I/Task F00132	93.RD	20,521	-			20,521	12,968
Contract	93.RD	-	20,396	VANDERBILT UNIVERSITY MEDICAL CENTER	HHSN272201300023I	20,396	
Contract #HHSN27201300012I/HHSN27200011	93.RD	20,034	-			20,034	
Contract	93.RD	-	16,607	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5U01MD011279-04	16,607	
Contract	93.RD	-	15,084	AI BIOSCIENCES INC.	75N930019C00018	15,084	
Contract	93.RD	-	13,814	DUKE UNIVERSITY	1R01AG062502-01A1	13,814	
Contract	93.RD	-	12,744	UNIVERSITY OF PENNSYLVANIA	5-UH3-HL-141736-03	12,744	
Contract	93.RD	-	10,484	ABT ASSOCIATES INC	HHSND20002013M53890B	10,484	
Contract	93.RD	-	9,981	NORTHWESTERN UNIVERSITY	5U01DK103225-05	9,981	
Contract	93.RD	-	9,549	WESTAT CORPORATION	HHSN275201800001I	9,549	
Contract	93.RD	-	9,193	CHILDREN'S HOSPITAL BOSTON	75D30119C05584	9,193	
Contract	93.RD	-	8,237	JOHNS HOPKINS UNIVERSITY	U01CA137443	8,237	
Contract	93.RD	-	7,517	JAEB CENTER FOR HEALTH RESEARCH INC	U10EY011751	7,517	
Contract	93.RD	-	7,331	JANSSEN RESEARCH AND DEVELOPMENT, LLC	HHSO100201500014C	7,331	
Contract	93.RD	-	5,337	ATOX BIO, LTD	HHSO1002014000013C	5,337	
Contract	93.RD	-	5,062	CHILDREN'S HOSPITAL LOS ANGELES	1U01AI126612-01A1	5,062	
Contract	93.RD	-	4,173	MAYO CLINIC ROCHESTER	HHSN261201200042I	4,173	
Contract	93.RD	-	3,934	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-13	3,934	
Contract	93.RD	-	3,775	EMMES CORPORATION	HHSN275201800006I	3,775	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Contract	93.RD	-	3,467	JOHNS HOPKINS UNIVERSITY	SUM1CA137443-10	3,467	
Contract	93.RD	-	2,946	ABT ASSOCIATES INC	HHS20002013M538908/75D30119F06241	2,946	
Contract	93.RD	-	2,449	DUKE UNIVERSITY	HHSN2722013000171	2,449	
Contract	93.RD	-	1,302	UNIVERSITY OF ROCHESTER	HHSN272201200005C	1,302	
Contract	93.RD	-	70	UNIVERSITY OF HAWAII	R01CA0208851	70	
Contract #HHSN272201300012/HHSN27200012	93.RD	(17)	-			(17)	
Contract #HHSN272201300012/HHSN27200010	93.RD	(1,119)	-			(1,119)	
Contract	93.RD	-	(1,271)	NORTHWESTERN UNIVERSITY	HHSN272201600016C	(1,271)	
Contract #HHSN2682018000071 TO 01 BASE	93.RD	(1,722)	-			(1,722)	
Contract	93.RD	-	(1,806)	WASHINGTON UNIVERSITY IN ST LOUIS	1K08GM129763-01	(1,806)	
Contract #HHSN275201300014C	93.RD	(5,401)	-			(5,401)	
Contract	93.RD	-	(5,411)	CHILDREN'S HOSPITAL OF PHILADELPHIA	N02-CM-62212	(5,411)	
Contract #HHSN272201100035C-Option 2	93.RD	(99,939)	-			(99,939)	
Unknown	93.RD	-	74,852	UNIVERSITY OF BERN INSTITUTE FOR SOCIALUND PREVENT	U01AI069924	74,852	
Unknown	93.RD	-	71,379	JOHNS HOPKINS UNIVERSITY	205742	71,379	
Unknown	93.RD	-	54,332	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG-ACRIN	54,332	
Unknown	93.RD	-	42,048	BIRMINGHAM AIDS OUTREACH	CNVA00055333 (129659-3)	42,048	
Unknown	93.RD	-	34,986	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5001GH000526-03	34,986	
Unknown	93.RD	-	24,961	NRG ONCOLOGY INC	NRG NCRP	24,961	
Unknown	93.RD	-	9,958	OREGON HEALTH & SCIENCES UNIVERSITY	SWOG	9,958	
Unknown	93.RD	-	2,758	MAYO CLINIC ROCHESTER	1UG1CA189823-01	2,758	
Unknown	93.RD	-	(864)	MINNESOTA HEALTHSOLUTIONS CORPORATION	R44HD086660	(864)	
CFDA 93.RD Total		10,556,894	1,150,466			11,707,360	3,986,711
Total Department of Health and Human Services		277,443,492	28,523,965			305,967,457	57,664,744
Corporation for National and Community Services							
Contract #19VSSAL003	94.RD	410,526	-			410,526	
CFDA 94.RD Total		410,526	-			410,526	-
Total Corporation for National and Community Services		410,526	-			410,526	-
Department of Homeland Security							
Contract #70RSAT18CB0000042	97.RD	112,744	-			112,744	
CFDA 97.RD Total		112,744	-			112,744	-
Total Department of Homeland Security		112,744	-			112,744	-
U. S. Agency for International Development							
USAID Foreign Assistance for Programs Overseas	98.001	-	132,347	INTL AIDS VACCINE INITIATIVE	AID-OAA-A-16-00032	132,347	
USAID Foreign Assistance for Programs Overseas	98.001	-	5,509	NATL ACADEMY OF SCIENCES	AID-263-A-15-00002	5,509	
CFDA 98.001 Total		-	137,856			137,856	-
Total U. S. Agency for International Development		-	137,856			137,856	-
TOTAL RESEARCH AND DEVELOPMENT Cluster		308,769,553	33,216,834			341,986,387	62,922,417
STUDENT FINANCIAL ASSISTANCE Cluster							
Department of Education							
Federal Supplemental Education Opportunity Grant	84.007	1,543,319	-			1,543,319	
CFDA 84.007 Total		1,543,319	-			1,543,319	-
Federal Work-Study Program	84.033	893,604	-			893,604	
CFDA 84.033 Total		893,604	-			893,604	-
Federal Perkins Loan - Outstanding loans at fiscal year beginning	84.038	9,685,873	-			9,685,873	
CFDA 84.038 Total		9,685,873	-			9,685,873	-

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Federal Pell Grant	84.063	23,943,356	-			23,943,356	
CFDA 84.063 Total		23,943,356	-			23,943,356	-
Direct Student Loans	84.268	166,625,040	-			166,625,040	
CFDA 84.268 Total		166,625,040	-			166,625,040	-
Teacher Education Assistance for College and Higher Education Grants (TEACH)	84.379	29,621	-			29,621	
CFDA 84.379 Total		29,621	-			29,621	-
Total Department of Education		202,720,813	-			202,720,813	-
Department of Health and Human Services							
Nurse Faculty Loan Program - Outstanding loans at fiscal year beginning	93.264	2,772,883	-			2,772,883	
Nurse Faculty Loan Program - New loans issued during fiscal year	93.264	747,540	-			747,540	
CFDA 93.264 Total		3,520,423	-			3,520,423	-
Health Professions Student Loans - Outstanding loans at fiscal year beginning	93.342	1,395,330	-			1,395,330	
Health Professions Student Loans - New loans issued during fiscal year	93.342	69,841	-			69,841	
CFDA 93.342 Total		1,465,171	-			1,465,171	-
Nurse Faculty Loan Program ARRA - Outstanding loans at fiscal year beginning	93.408	74,064	-			74,064	
CFDA 93.408 Total		74,064	-			74,064	-
Total Department of Health and Human Services		5,059,658	-			5,059,658	-
TOTAL STUDENT FINANCIAL ASSISTANCE Cluster		207,780,471	-			207,780,471	-
HEAD START Cluster							
Department of Health and Human Services							
Head Start	93.600	996,933	-			996,933	134,996
CFDA 93.600 Total		996,933	-			996,933	134,996
Total Department of Health and Human Services		996,933	-			996,933	134,996
TOTAL HEAD START Cluster		996,933	-			996,933	134,996
Department of Transportation - Highway Planning and Construction Cluster							
Highway Planning and Construction	20.205	-	1,015	ALABAMA DEPT OF TRANSPORTATION	930-914	1,015	
Highway Planning and Construction	20.205	-	(1,059)	ALABAMA DEPT OF TRANSPORTATION	930-935	(1,059)	
CFDA 20.205 Total		-	(44)			(44)	-
Total Department of Transportation - Highway Planning and Construction Cluster		-	(44)			(44)	-
Department of Transportation - Federal Transit Cluster							
Federal Transit_Capital Investment Grants	20.500	-	(3,407)	ALABAMA DEPT OF TRANSPORTATION	K-17-0022	(3,407)	
CFDA 20.500 Total		-	(3,407)			(3,407)	-
Total Department of Transportation - Federal Transit Cluster		-	(3,407)			(3,407)	-
Department of Education - TRIO Cluster							
TRIO_Student Support Services	84.042	681,173	-			681,173	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
TRIO_Upward Bound	84.047	346,730	-			346,730	-
CFDA 84.047 Total		346,730	-			346,730	-
TRIO_McNair Post-Baccalaureate Achievement	84.217	176,433	-			176,433	-
CFDA 84.217 Total		176,433	-			176,433	-
Total Department of Education - TRIO Cluster		1,204,336	-			1,204,336	-
Department of Health and Human Services - Aging Cluster							
Nutrition Services Incentive Program	93.053	194,458	-			194,458	67,346
CFDA 93.053 Total		194,458	-			194,458	67,346
Total Department of Health and Human Services - Aging Cluster		194,458	-			194,458	67,346
OTHER PROGRAMS							
Department of Agriculture							
Child and Adult Care Food Program	10.558	-	10,054	ALABAMA DEPT OF EDUCATION	ADS-0000	10,054	-
Child and Adult Care Food Program	10.558	-	3,463	ALABAMA DEPT OF HUMAN RESOURCES	ADS-0000	3,463	-
CFDA 10.558 Total		-	13,517			13,517	-
Distance Learning and Telemedicine Loans and Grants	10.855	(115,769)	-			(115,769)	-
CFDA 10.855 Total		(115,769)	-			(115,769)	-
Contract	10.U00	-	(1,011)	ALABAMA DEPT OF EDUCATION	B9C-0000	(1,011)	-
CFDA 10. Total		-	(1,011)			(1,011)	-
Total Department of Agriculture		(115,769)	12,506			(103,263)	-
Department of Defense							
Contract - Army Health Profession Students	12.U01	374,133	-			374,133	-
Contract - Navy Medicine/Dentistry/Optomety	12.U02	823,176	-			823,176	-
Contract - Air Force Medical, Dentistry, Optometry	12.U03	340,878	-			340,878	-
Contract - Go Army	12.U04	94,750	-			94,750	-
Contract - Air Force Unknown	12.U05	46,918	-			46,918	-
Contract - Navy Unknown	12.U06	11,154	-			11,154	-
Contract - Army Corp of Engineers	12.U07	7,500	-			7,500	-
Contract - Coast Guard Unknown	12.U08	1,500	-			1,500	-
CFDA 12. Total		1,700,009	-			1,700,009	-
Total Department of Defense		1,700,009	-			1,700,009	-
Department of Justice							
Drug Court Discretionary Grant Program	16.585	-	335,142	JEFFERSON COUNTY COMMISSION	201-DC-BX-0025	335,142	-
CFDA 16.585 Total		-	335,142			335,142	-
Comprehensive Opioid Abuse Site-Based Program	16.838	-	271,208	JEFFERSON COUNTY COMMISSION	2018-AR-BX-K013	271,208	-
CFDA 16.838 Total		-	271,208			271,208	-
Total Department of Justice		-	606,350			606,350	-
Department of Labor							
H-1B Job Training Grants	17.268	1,751,293	-			1,751,293	1,324,242
CFDA 17.268 Total		1,751,293	-			1,751,293	1,324,242
Total Department of Labor		1,751,293	-			1,751,293	1,324,242

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Department of Transportation							
Contract	20.U09	-	69,486	ALABAMA DEPT OF TRANSPORTATION	K-15-1884	69,486	
Contract	20.U10	-	12,292	ALABAMA DEPT OF TRANSPORTATION	DBE/SS	12,292	
CFDA 20. Total		-	81,778			81,778	-
Total Department of Transportation		-	81,778			81,778	-
Appalachian Regional Commission							
Appalachian Research, Technical Assistance, and Demonstration Projects	23.011	118,550	-			118,550	
CFDA 23.011 Total		118,550	-			118,550	-
Total Appalachian Regional Commission		118,550	-			118,550	-
National Foundation on the Arts and the Humanities							
Promotion of the Arts_Grants to Organizations and Individuals	45.024	20,000	-			20,000	
CFDA 45.024 Total		20,000	-			20,000	-
Total National Foundation on the Arts and the Humanities		20,000	-			20,000	-
Department of Education							
Graduate Assistance in Areas of National Need	84.200	226,550	-			226,550	
CFDA 84.200 Total		226,550	-			226,550	-
Research in Special Education	84.324	71,639	-			71,639	
CFDA 84.324 Total		71,639	-			71,639	-
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325	394,688	-			394,688	
CFDA 84.325 Total		394,688	-			394,688	-
Gaining Early Awareness and Readiness for Undergraduate Programs	84.334	3,394,882	-			3,394,882	1,162,179
CFDA 84.334 Total		3,394,882	-			3,394,882	1,162,179
Child Care Access Means Parents in School	84.335	176,744	-			176,744	
CFDA 84.335 Total		176,744	-			176,744	-
English Language Acquisition State Grants	84.365	1,076,399	-			1,076,399	
CFDA 84.365 Total		1,076,399	-			1,076,399	-
Improving Teacher Quality State Grants	84.367	-	230,879	ALABAMA DEPT OF EDUCATION	PL 107-110	230,879	
CFDA 84.367 Total		-	230,879			230,879	-
Investing in Innovation (i3) Fund	84.411	-	79,804	NATIONAL WRITING PROJECT	U411A160004	79,804	
CFDA 84.411 Total		-	79,804			79,804	-
Student Support and Academic Enrichment Program	84.424	-	870	ALABAMA DEPT OF EDUCATION	1H79SM080971-01	870	
CFDA 84.424 Total		-	870			870	-
COVID-19 Higher Education Emergency Relief Fund (HEERF) Student Portion	84.425E	6,065,628	-			6,065,628	
COVID-19 Higher Education Emergency Relief Fund (HEERF) Institutional Portion	84.425F	4,955,058	-			4,955,058	
CFDA 84.425 Total		11,020,686	-			11,020,686	-
Total Department of Education		16,361,588	311,553			16,673,141	1,162,179

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Department of Education							
Unknown	84.U11	-	(51)	ALABAMA DEPT OF CHILDREN'S AFFAIRS	16DEV50601UAB1	(51)	-
CFDA 84. Total		-	(51)			(51)	-
Total Department of Education		-	(51)			(51)	-
Consumer Product Safety Commission							
Contract #61320619N0138 Base	87.U12	126,910	-			126,910	-
Contract #61320619N0138 Option 1	87.U13	11,270	-			11,270	-
Contract #61320618N0009	87.U14	1,573	-			1,573	-
CFDA 87. Total		139,753	-			139,753	-
Total Consumer Product Safety Commission		139,753	-			139,753	-
Department of Health and Human Services							
Training in General, Pediatric, and Public Health Dentistry	93.059	32,368	-			32,368	-
CFDA 93.059 Total		32,368	-			32,368	-
Healthy Marriage Promotion and Responsible Fatherhood Grants	93.086	-	162	COLORADO SEMINARY/ UNIVERSITY OF DENVER	90FM0062-01-01	162	-
CFDA 93.086 Total		-	162			162	-
Enhance Safety of Children Affected by Substance Abuse	93.087	662,768	-			662,768	-
CFDA 93.087 Total		662,768	-			662,768	-
Area Health Education Centers Point of Service Maintenance and Enhancement Awards	93.107	1,069,807	-			1,069,807	832,944
CFDA 93.107 Total		1,069,807	-			1,069,807	832,944
Maternal and Child Health Federal Consolidated Programs	93.110	1,992,598	-			1,992,598	20,000
Maternal and Child Health Federal Consolidated Programs	93.110	-	10,029	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	UK2MC31456-03-01	10,029	-
Maternal and Child Health Federal Consolidated Programs	93.110	-	(3,856)	ALABAMA DEPT OF MENTAL HEALTH	1U4CMC32312-01-00	(3,856)	-
CFDA 93.110 Total		1,992,598	6,173			1,998,771	20,000
Project Grants and Cooperative Agreements for Tuberculosis Control Programs	93.116	-	106,250	ALABAMA DEPT OF PUBLIC HEALTH	C00119124-NU52PS910194-01-00	106,250	-
Project Grants and Cooperative Agreements for Tuberculosis Control Programs	93.116	-	34,721	ALABAMA DEPT OF PUBLIC HEALTH	C90116105-5NU52PS004653-05-00	34,721	-
CFDA 93.116 Total		-	140,971			140,971	-
Nurse Anesthetist Traineeships	93.124	48,792	-			48,792	-
CFDA 93.124 Total		48,792	-			48,792	-
Emergency Medical Services for Children	93.127	-	267,413	ALABAMA DEPT OF PUBLIC HEALTH	C00119038-H33MC06713/0AA 184 40S	267,413	-
CFDA 93.127 Total		-	267,413			267,413	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	509,400	-			509,400	24,063
CFDA 93.135 Total		509,400	-			509,400	24,063
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	746,017	-			746,017	125,000
CFDA 93.153 Total		746,017	-			746,017	125,000

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Human Genome Research	93.172	108,562	-			108,562	77,516
CFDA 93.172 Total		108,562	-			108,562	77,516
Research Related to Deafness and Communication Disorders	93.173	28,744	-			28,744	-
CFDA 93.173 Total		28,744	-			28,744	-
Disabilities Prevention	93.184	2,571,194	-			2,571,194	1,478,897
CFDA 93.184 Total		2,571,194	-			2,571,194	1,478,897
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	649,064	-			649,064	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	359,070	JEFFERSON COUNTY COMMISSION	1H79T081163-01	359,070	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	72,226	ALABAMA DEPT OF MENTAL HEALTH	HRSA-18-122	72,226	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	28,459	ALABAMA DEPT OF EDUCATION	1H79SM080971-01	28,459	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	9,500	ALABAMA DEPT OF PUBLIC HEALTH	C00119028-5H79SM062921-03	9,500	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	7,049	ALABAMA DEPT OF PUBLIC HEALTH	C90116084-5H79SM062921-03	7,049	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	3,159	JEFFERSON COUNTY COMMISSION	5H79T1026406-03	3,159	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	1,141	ALABAMA DEPT OF MENTAL HEALTH	5H79SM061560-05	1,141	-
CFDA 93.243 Total		649,064	480,604			1,129,668	-
Advanced Nursing Education Grant Program	93.247	956,707	-			956,707	155,848
CFDA 93.247 Total		956,707	-			956,707	155,848
Universal Newborn Hearing Screening	93.251	-	17,033	ALABAMA DEPT OF PUBLIC HEALTH	C90116157-H61MC00054	17,033	-
CFDA 93.251 Total		-	17,033			17,033	-
Drug Abuse and Addiction Research Programs	93.279	-	301	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R25DA028567-09	301	-
CFDA 93.279 Total		-	301			301	-
The Affordable Care Act: Centers for Disease Control and Prevention_Investigations and Technical Assistance	93.283	-	(31)	ALABAMA DEPT OF PUBLIC HEALTH	C06112049-5NU58DP003854	(31)	-
CFDA 93.283 Total		-	(31)			(31)	-
CSELS Partnership: Strengthening Public Health Laboratories	93.322	-	7,500	ASSOCIATION OF PUBLIC HEALTH LABORATORIES	1U60OE000103	7,500	-
CFDA 93.322 Total		-	7,500			7,500	-
Paralysis Resource Center	93.325	-	528	CHRISTOPHER & DANA REEVE FOUNDATION	90PRRC0002-02-00	528	-
CFDA 93.325 Total		-	528			528	-
Behavioral Risk Factor Surveillance System	93.336	-	269,690	ALABAMA DEPT OF PUBLIC HEALTH	C90116144-NU58DP006015	269,690	-
CFDA 93.336 Total		-	269,690			269,690	-
Nurse Education, Practice Quality and Retention Grants	93.359	1,119,978	-			1,119,978	-
CFDA 93.359 Total		1,119,978	-			1,119,978	-
Sickle Cell Treatment Demonstration Program	93.365	-	181,200	CAROLINAS HEALTHCARE SYSTEM	6U1EMC31108-02-01	181,200	-
Sickle Cell Treatment Demonstration Program	93.365	-	44,478	CAROLINAS HEALTHCARE SYSTEM	6 U1EMC31108-02-01	44,478	-
Sickle Cell Treatment Demonstration Program	93.365	-	7,506	CAROLINAS HEALTHCARE SYSTEM	6U1EMC31108-02-04	7,506	-
CFDA 93.365 Total		-	233,184			233,184	-
Prevention and Control of Chronic Disease and Associated Risk Factors in the U.S. Affiliated Pacific Islands, U.S. Virgin Islands, and Puerto Rico	93.377	171,668	-			171,668	79,870
CFDA 93.377 Total		171,668	-			171,668	79,870

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cancer Research Manpower	93.398	113,332	-			113,332	-
CFDA 93.398 Total		113,332	-			113,332	-
Improving Health of Americans through Prevention/Management of Diabetes/Heart Disease/Stroke	93.426	-	16,462	ALABAMA DEPT OF PUBLIC HEALTH	-C00119033-NU58DP006527	16,462	-
CFDA 93.426 Total		-	16,462			16,462	-
Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support	93.516	-	69,512	EMORY UNIVERSITY	5UB6HP31680-02-00	69,512	-
Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support	93.516	-	24,759	EMORY UNIVERSITY	5UB6H31680-03-00	24,759	-
CFDA 93.516 Total		-	94,271			94,271	-
University Centers for Excellence in Developmental Disabilities Education, Research, and Service	93.632	547,753	-			547,753	-
CFDA 93.632 Total		547,753	-			547,753	-
ACA - Reinvestment of Civil Money Penalties to Benefit Nursing Home Residents	93.636	-	551,425	ALABAMA DEPT OF PUBLIC HEALTH	C80629636	551,425	-
CFDA 93.636 Total		-	551,425			551,425	-
Foster Care Title IV-E	93.658	-	82,159	UNIVERSITY OF ALABAMA IN TUSCALOOSA	C200161203	82,159	-
CFDA 93.658 Total		-	82,159			82,159	-
Medical Student Education	93.680	53,173	-			53,173	-
CFDA 93.680 Total		53,173	-			53,173	-
PPHF-2012 Mental and Behavioral Health Education and Training Grants	93.732	323,604	-			323,604	-
CFDA 93.732 Total		323,604	-			323,604	-
Children's Health Insurance Program	93.767	-	281,254	ALABAMA DEPT OF PUBLIC HEALTH	C90116151-7590515	281,254	64,867
Children's Health Insurance Program	93.767	-	39,546	ALABAMA DEPT OF PUBLIC HEALTH	C80113063-7500515	39,546	-
CFDA 93.767 Total		-	320,800			320,800	64,867
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	-	72,594	ALABAMA DEPT OF PUBLIC HEALTH	C90116244-1U3REP150509	72,594	-
CFDA 93.817 Total		-	72,594			72,594	-
Cardiovascular Diseases Research	93.837	40,695	-			40,695	-
CFDA 93.837 Total		40,695	-			40,695	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	97,223	-			97,223	-
CFDA 93.847 Total		97,223	-			97,223	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	296,295	-			296,295	-
CFDA 93.853 Total		296,295	-			296,295	-
Allergy, Immunology and Transplantation Research	93.855	308	-			308	-
CFDA 93.855 Total		308	-			308	-

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Biomedical Research and Research Training	93.859	473,597	-			473,597	
CFDA 93.859 Total		<u>473,597</u>	<u>-</u>			<u>473,597</u>	<u>-</u>
Child Health and Human Development Extramural Research	93.865	829	-			829	175
CFDA 93.865 Total		<u>829</u>	<u>-</u>			<u>829</u>	<u>175</u>
Maternal, Infant and Early Childhood Home visiting Grant Program	93.870	-	129,365	ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION	X10MC32174	129,365	
CFDA 93.870 Total		<u>-</u>	<u>129,365</u>			<u>129,365</u>	<u>-</u>
Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	-	25,000	ALABAMA DEPT OF PUBLIC HEALTH	C90116195-NU58P006301	25,000	
Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	-	513	ALABAMA DEPT OF PUBLIC HEALTH	C80113172-1NU58DP006301-01	513	
Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	-	(1,005)	ALABAMA DEPT OF PUBLIC HEALTH	C70115253-1NU58DP006301-01-00	(1,005)	
CFDA 93.898 Total		<u>-</u>	<u>24,508</u>			<u>24,508</u>	<u>-</u>
HIV Care Formula Grants	93.917	-	347,337	UNITED WAY OF CENTRAL ALABAMA INC	X07HA00049	347,337	
HIV Care Formula Grants	93.917	-	30,000	ALABAMA DEPT OF PUBLIC HEALTH	C90116120-X07HA00049	30,000	
CFDA 93.917 Total		<u>-</u>	<u>377,337</u>			<u>377,337</u>	<u>-</u>
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	21,123	-			21,123	
CFDA 93.918 Total		<u>21,123</u>	<u>-</u>			<u>21,123</u>	<u>-</u>
HIV Prevention Activities_Health Department Based	93.940	-	619,511	ALABAMA DEPT OF PUBLIC HEALTH	C90116143-5NU62PS924533-02-00	619,511	
HIV Prevention Activities_Health Department Based	93.940	-	489,374	ALABAMA DEPT OF PUBLIC HEALTH	C90116115-5NU62PS924533-02-00	489,374	
HIV Prevention Activities_Health Department Based	93.940	-	365,998	ALABAMA DEPT OF PUBLIC HEALTH	C00119070-5 NU62PS924533-03-00	365,998	
HIV Prevention Activities_Health Department Based	93.940	-	288,777	ALABAMA DEPT OF PUBLIC HEALTH	C00119100-5NU62PS924533-03-00	288,777	
HIV Prevention Activities_Health Department Based	93.940	-	108,332	ALABAMA DEPT OF PUBLIC HEALTH	C90116138-5NU62PS924533-02-00	108,332	
HIV Prevention Activities_Health Department Based	93.940	-	100,000	ALABAMA DEPT OF PUBLIC HEALTH	C00119075-NU62PS924533	100,000	
HIV Prevention Activities_Health Department Based	93.940	-	78,186	ALABAMA DEPT OF PUBLIC HEALTH	C00119127-5NU62PS924533-03-00	78,186	
CFDA 93.940 Total		<u>-</u>	<u>2,050,178</u>			<u>2,050,178</u>	<u>-</u>
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	18,837	ALABAMA DEPT OF PUBLIC HEALTH	C90116185-5U01DP006235	18,837	
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	2,164	ALABAMA DEPT OF PUBLIC HEALTH	C10119151-5U01DP006235-05-00	2,164	
CFDA 93.946 Total		<u>-</u>	<u>21,001</u>			<u>21,001</u>	<u>-</u>
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	95,769	-			95,769	7,573
CFDA 93.978 Total		<u>95,769</u>	<u>-</u>			<u>95,769</u>	<u>7,573</u>
Maternal and Child Health Services Block Grant to the States	93.994	-	141,087	ALABAMA DEPT OF PUBLIC HEALTH	C90116197-B04MC32523	141,087	
Maternal and Child Health Services Block Grant to the States	93.994	-	74,818	MISSISSIPPI DEPT OF HEALTH	B04MC31497	74,818	
Maternal and Child Health Services Block Grant to the States	93.994	-	9,714	ALABAMA DEPT OF PUBLIC HEALTH	C00119105-B04MC33819	9,714	
Maternal and Child Health Services Block Grant to the States	93.994	-	1,148	ALABAMA DEPT OF PUBLIC HEALTH	C90116088-B04MC32523	1,148	
Maternal and Child Health Services Block Grant to the States	93.994	-	346	ALABAMA DEPT OF PUBLIC HEALTH	C90116113-B04MC32523	346	
CFDA 93.994 Total		<u>-</u>	<u>227,113</u>			<u>227,113</u>	<u>-</u>
Total Department of Health and Human Services		<u>12,731,368</u>	<u>5,390,741</u>			<u>18,122,109</u>	<u>2,866,753</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2020

Cluster/ Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Department of Health and Human Services							
Contract	93.U15	-	267,393	ALABAMA MEDICAID AGENCY	C200629856	267,393	
Contract	93.U16	-	131,128	BAVARIAN NORDIC A/S	HHSO100201700019C	131,128	
Contract	93.U17	-	16,306	ALABAMA DEPT OF EDUCATION	X10MC31125	16,306	
Contract	93.U18	-	12,005	ALABAMA DEPT OF EDUCATION	SP1AH000058	12,005	
Contract	93.U19	-	6,494	MISSISSIPPI DEPT OF HEALTH	PRAMS	6,494	
Contract	93.U20	-	2,553	CHILDREN'S HOSPITAL BOSTON	75D30120C07725	2,553	
Contract	93.U21	-	(20)	ADDIS ABABA UNIVERSITY	1R25TW011214-011	(20)	
Contract #18IPA1811220	93.U22	(1,074)	-			(1,074)	
Contract	93.U23	-	(1,957)	ALABAMA FAMILY PRACTICE RURAL HEALTH BOARD	AFPRH	(1,957)	
Contract	93.U24	-	(3,015)	ALABAMA DEPT OF EDUCATION	X10MC32174	(3,015)	
Unknown	93.U25	-	198,991	ALABAMA MEDICAID AGENCY	C190000006	198,991	
Unknown	93.U26	-	17,918	FLORIDA DEPARTMENT OF HEALTH	PRAMS FL	17,918	
CFDA 93. Total		(1,074)	647,796			646,722	-
Total Department of Health and Human Services		(1,074)	647,796			646,722	-
Department of the Treasury							
COVID-19 Coronavirus Relief Fund	21.019	-	6,982,487	STATE OF ALABAMA DEPARTMENT OF FINANCE	SLT0002/SLT0223	6,982,487	
COVID-19 Coronavirus Relief Fund	21.019	-	5,350,901	STATE OF ALABAMA DEPARTMENT OF FINANCE	SLT0002/SLT0223/2	5,350,901	
COVID-19 Coronavirus Relief Fund	21.019	-	3,368,856	STATE OF ALABAMA DEPARTMENT OF FINANCE	SLT0002/SLT0223 (Hospital)	3,368,856	
CFDA 21.019 Total		-	15,702,244			15,702,244	-
Total Department of the Treasury		-	15,702,244			15,702,244	-
COVID-19 Telehealth Program	32.006	-	759,651	Federal Communications Commission	CARES Act	759,651	
CFDA 32.006 Total		-	759,651			759,651	-
COVID-19 Testing for the Uninsured	93.461	2,018,540	-			2,018,540	
CFDA 93.461 Total		2,018,540	-			2,018,540	-
TOTAL OTHER PROGRAMS		34,724,258	23,512,568			58,236,826	5,353,174
SPECIAL FEDERAL APPROPRIATIONS							
Miscellaneous							
Lister Hill Center for Health Policy	93.U27	448,272	-			448,272	
John J. Sparkman Center	93.U28	304,185	-			304,185	
CFDA 93. Total		752,457	-			752,457	-
Total Miscellaneous		752,457	-			752,457	-
TOTAL SPECIAL FEDERAL APPROPRIATIONS		752,457	-			752,457	-
TOTAL FEDERAL		\$ 554,422,466	\$ 56,725,951			\$ 611,148,417	\$ 68,477,933

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Notes to Schedule of Expenditures of Federal Awards

Year Ended September 30, 2020

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the federal expenditures of The University of Alabama at Birmingham ("UAB"), a campus of the University of Alabama System, under programs of the federal government for the year ended September 30, 2020. Other campuses of the University of Alabama System are presented in separate reports. The amounts reported as federal expenditures were obtained from UAB's general ledger. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this Schedule may differ from amounts presented in, or used in the preparation of, the statements of net position, the related statements of revenues, expenses, and changes in net position and cash flows of UAB. The federal expenditures of Southern Research Institute ("SRI"), a discretely presented component unit of UAB, have not been included within the Schedule as they have been included in a separate schedule of expenditures of federal awards that has been audited by other auditors.

The blended component units of UAB include UAB Research Foundation, UAB Athletics Foundation, Alabama Care Plan, UAB Hospital Management, L.L.C, and Triton Health Systems, L.L.C. These component units do not expend federal awards and therefore are not subject to requirements of the Uniform Guidance.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between UAB and agencies and departments of the federal government and all subawards to UAB by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years. Catalog of Federal Domestic Assistance ("CFDA") numbers and pass-through numbers are provided when available.

2. Summary of Significant Accounting Policies

For purposes of the Schedule, expenditures for federal award programs are recognized on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance where certain types of expenditures are not allowable or are limited to reimbursement.

3. Facilities and Administrative Costs ("F&A Costs")

UAB applies its predetermined approved facilities and administrative rate when charging indirect cost to federal awards rather than the 10% de minimis cost rate described in Section 200.414 of the Uniform Guidance. UAB operates under predetermined fixed F&A cost rates which are effective from October 1, 2015 through September 30, 2020. The predetermined fixed rates were based on 2014 financial information. The base rate for on-campus research is 48.5% for the year ended September 30, 2020. Base rates for other F&A cost recoveries range from 5.4% to 48.5% for the year ended September 30, 2020.

The University of Alabama at Birmingham
Notes to Schedule of Expenditures of Federal Awards
Year Ended September 30, 2020

4. Federal Student Loan Programs

Direct Loan Programs

The Perkins, Health Professions Student Loan (“HPSL”), Nurse Faculty Loan Program (“NFLP”), and Loans to Disadvantaged Students (“LDS”) programs are administered directly by UAB, and balances and transactions relating to these programs are included in UAB’s basic financial statements.

The balances of loans outstanding at September 30, 2020 under the federal student loan programs are summarized as follows:

	Perkins (CFDA#84.038)	HPSL (CFDA#93.342)	NFLP (CFDA#93.264)	LDS (CFDA#93.342)	NFLP-ARRA (CFDA#93.408)	Total
Total loan balance outstanding, September 30, 2020	\$ 7,834,550	\$ 1,057,267	\$ 3,224,756	\$ 128,309	\$ 62,639	\$ 12,307,521

Federal Direct Loans

The Federal Direct Student Loan (FDSL) program (CFDA Number 84.268) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSL enables an eligible student or parent to obtain a loan to pay for the student’s cost of attendance directly through UAB rather than through private lenders. UAB began participation in the FDSL on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan origination process, including funds management and promissory note functions. UAB is not responsible for collection of these loans.

Part II
Schedule of Findings and Questioned Costs

**The University of Alabama at Birmingham
 Schedule of Findings and Questioned Costs
 Year Ended September 30, 2020**

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor's report issued: Unmodified opinion

Internal control over financial reporting:

Material weakness(es) identified? yes no

Significant deficiency(ies) identified that are not considered to be material weaknesses? yes none reported

Noncompliance material to financial statements noted? yes no

Federal Awards

Internal control over major programs:

Material weakness(es) identified? yes no

Significant deficiency(ies) identified that are not considered to be material weaknesses? yes none reported

Type of auditor's report issued on compliance for major programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance the with 2 CFR 200.516(a)? yes no

Identification of major programs:

CFDA Number(s)	Name of Federal Program or Cluster
Various	Research and Development Cluster
21.019	COVID-19 Coronavirus Relief Fund
84.425E	COVID-19 Higher Education Emergency Relief Fund (HEERF) Student Portion
84.425F	COVID-19 Higher Education Emergency Relief Fund (HEERF) Institutional Portion
93.184	Disabilities Prevention
93.600	Head Start Cluster

Dollar threshold used to distinguish between Type A and Type B Programs: \$ 3,000,000

Auditee qualified as low-risk auditee? yes no

Section II – Financial Statement Findings

No matters were noted

Section III – Federal Award Findings and Questioned Costs


No matters were noted

Part III
Summary Schedule of Prior Audit Findings

The University of Alabama at Birmingham
Summary Schedule of Prior Audit Findings
Year Ended September 30, 2020

There are no findings from prior years that require an update in this report.

Part IV
2020 Financial Report



2020

FINANCIAL REPORT

UAB
THE UNIVERSITY OF
ALABAMA AT BIRMINGHAM

UAB is an equal education opportunity institution,
and an equal employment opportunity employer.

This report is published by the UAB Senior Vice President
for Finance and Administration. Obtain additional copies
by writing:

Senior Vice President for Finance and Administration
The University of Alabama at Birmingham
Birmingham, Alabama 35294

University of Alabama at Birmingham

2020 Financial Report

Table of Contents

Introduction to UAB	2
Overview/Vision/Mission	
Highlights	3
Student Profile and Headcount	
Faculty and Staff Profile	
State Appropriations	
Sponsored Grants and Contracts	
Hospital	
Financial Section	
Management’s Responsibility for Financial Reporting	8
Report of Independent Auditors	9
Management’s Discussion and Analysis (Unaudited)	11
Financial Statements	
Statements of Net Position	20
Statements of Revenues, Expenses, and Changes in Net Position	22
Statements of Cash Flows	23
Discretely Presented Component Unit	
Statements of Net Position	25
Statements of Revenues, Expenses, and Changes in Net Position	26
Notes to Financial Statements	27
Required Supplementary Information (Unaudited)	70
UAB Administration	73
The Board of Trustees of The University of Alabama	74

Introduction to UAB

Vision

To be an internationally renowned research university — a first choice for education and health care.

Mission

UAB serves students, patients, the community and the global need for discovery, knowledge dissemination, education, creativity and the application of groundbreaking solutions. We are a leader among comprehensive public urban research universities with academic medical centers.

The University of Alabama at Birmingham (UAB) became an autonomous campus within The University of Alabama System in 1969 and, in the five decades since, has grown into a world-renowned research university and medical center, occupying more than 100 city blocks in Alabama's largest metropolitan area. UAB is the state's largest single-site employer with more than 23,000 employees. One in four Birmingham residents are UAB employees, students or patients.

2020 Overview

In fall 2020 UAB achieved a fifth consecutive year of record enrollment with 22,536 students as well as record retention of 86.4 percent. The freshman class is the most academically prepared ever, with an average ACT of 25.9 and an average high school GPA of 3.83. Underrepresented students make up 43 percent of the enrollment and 21 percent of undergraduates are first-generation college students.

UAB's research enterprise is more competitive than ever. In FY20, research awards reached a record \$638 million, marking the most successful five-year period of research funding in the university's history, with an increase of \$190 million (42 percent) from 2015 to 2020.

UAB ranks 15th (top 4 percent) in federal research funding and 9th (top 2 percent) in NIH funding, with nine School of Medicine departments ranked in the top 15 nationally.

UAB received the 2020 Higher Education Excellence in Diversity Award from INSIGHT into Diversity Magazine and is one of only 14 universities named a Diversity Champion.

As a globally respected academic medical center, UAB excels at translating research into leading-edge patient care. UAB is home to the 18th largest hospital in the U.S. (and 3rd largest public), the state's only Level 1 Adult Trauma Center, and the only National Cancer Institute-designated comprehensive cancer center in Alabama and a four-state region.

The new Proton Therapy Center, which opened in January 2020, offers the most advanced radiation technology available for treating cancer, and is one of only 36 such centers in the U.S. and the first in Alabama. *U.S. News & World Report* ranked UAB the number one hospital in Alabama, with 10 specialties among the nation's top 50.

At the same time, UAB continues to offer unrivaled research opportunities and novel academic programs, such as a new BS in cancer biology and PhD in neuro-engineering, the first programs of their kind in the nation. UAB graduate programs continue to rank highly in *US News & World Report*, with 17 programs in the top 25, including a Master's in Health Administration that is number one nationally.

UAB has an economic impact on Alabama that exceeds \$7.15 billion annually and is key in growing a robust tech and knowledge-based economy for the Birmingham region and Alabama.

The UAB Harbert Institute for Innovation and Entrepreneurship generated 83 intellectual property disclosures, 16 U.S. patents and seven start-up companies in FY2020 alone—the Institute's sixth straight year to achieve a positive bottom line, among only 20 percent of university tech transfer offices nationally to do so. Innovation Depot, in which UAB is a founding partner, is the largest high-tech business incubator in the Southeast, with 100 start-up companies and more than 1,000 employees.


UAB has been a leader in combating the COVID-19 pandemic through frontline patient care, research and shared expertise. Through November 2020, UAB treated over 2,000 COVID-positive patients, offering many of them the opportunity to take part in studies of new treatments available at only a handful of medical centers worldwide, including the first clinical trials of the antiviral drug Remdesivir as well as promising vaccines. UAB Infectious disease experts are routinely interviewed on major media outlets such as CNN, FOX News, and NBC with an estimated audience of 2.7 billion around the U.S. and the globe.

The information included in this introduction (pages 2-7) does not include data related to component units of UAB that are discussed in the notes to the financial statements.

Highlights

Student Profile

Total 22,080
As of Fall 2019




Student Headcount

Enrollment for the fall semester of the 2019-2020 school year is outlined in the following table.


Fall 2019				
	UNDERGRADUATE	GRADUATE	ADVANCED PROFESSIONAL *	TOTAL
SCHOOL OF ARTS AND SCIENCES	6,780	612	278	7,670
SCHOOL OF BUSINESS	2,659	704	—	3,363
SCHOOL OF EDUCATION	1,075	634	103	1,812
SCHOOL OF ENGINEERING	860	456	112	1,428
UNCLASSIFIED	—	156	2	158
SUBTOTAL	11,374	2,562	495	14,431
ACADEMIC HEALTH CENTER:				
SCHOOL OF MEDICINE	—	—	1,901	1,901
SCHOOL OF DENTISTRY	17	—	384	401
SCHOOL OF OPTOMETRY	—	1	219	220
SCHOOL OF NURSING	1,010	1,434	413	2,857
SCHOOL OF HEALTH PROFESSIONS	1,088	1,089	297	2,474
SCHOOL OF PUBLIC HEALTH	347	364	89	800
JOINT HEALTH SCIENCES	—	54	379	433
SUBTOTAL, ACADEMIC HEALTH CENTER	2,462	2,942	3,682	9,086
TOTAL ENROLLMENT	13,836	5,504	4,177	23,517

* Includes 1,146 first professionals and 1,437 advanced professionals.

Faculty Profile
 Total 2,966
 As of Fall 2019



Staff Profile *
 Total 20,825
 As of Fall 2019




* Non-Hospital includes Hospital Management LLC.

State Appropriations

State Appropriations for UAB are made by the Alabama State Legislature based upon a process which involves requests from the Board of Trustees of The University of Alabama, and budget recommendations by the Alabama Commission on Higher Education and the Governor. State funds are appropriated annually from the Educational Trust Fund (ETF) to UAB.

For the fiscal year ended September 30, 2020, UAB received \$307.0 million in State educational appropriations for operating purposes.

Appropriations Received
Fiscal Years Ended September 30
(Dollars in millions)




Sponsored Grants and Contracts

During fiscal year 2020, UAB recognized \$541.8 million in sponsored grants and contracts revenues (including \$100.6 million of indirect cost recovery). Various federal agencies provided the majority of support for these projects, with the National Institutes of Health (NIH) being the primary sponsor. Nonfederal funding sources include state agencies, local governmental agencies, and a wide variety of private sponsors.

Revenues from grants and contracts (including indirect cost recovery) increased from \$529.5 million during fiscal year 2019 to \$541.8 million during fiscal year 2020, an increase of 2.3% for the period.

Refer to Note 1 for COVID-19 non-operating grants and contract funding received during 2020.



Hospital

Overview

The University of Alabama Hospital (the "Hospital" or "University Hospital"), a 1,157-bed quaternary and tertiary care medical facility is the flagship facility of the UAB Health System and is the primary teaching hospital for University of Alabama School of Medicine. Its facilities consist of the UAB Women and Infants Center, the Hazelrig-Salter Radiation Oncology Center, the North Pavilion Diagnostic and Treatment Center, Spain Rehabilitation Center, the Center for Psychiatric Medicine, UAB Highlands, and the Gardendale Freestanding Emergency Department. University Hospital operates The Kirklin Clinic and The Whitaker Clinic. The University Hospital also has strong ties with other governmental and private non-profit institutions located within and adjacent to the UAB campus, including Veterans Affairs Medical Center and Children's Hospital. Other healthcare facilities in the UAB Health System include the UAB Callahan Eye Hospital Authority, Medical West Hospital Authority, and The Health Care Authority for Baptist Health.

University Hospital Awards and Accolades

This year's U.S. News and World Report's "Best Hospitals" special edition issue ranked eight UAB Medicine specialties among the nation's top 50 and six specialties among the top 25. U.S. News and World Report also ranked hospitals in adult procedures and conditions. University Hospital is ranked high performing, which is the highest ranking conferred, in eight adult procedures and conditions. Becker's Hospital Review named University Hospital as one of the 2020 "100 Great Hospitals in America," a compilation of hospitals that are considered industry innovators and known nationally for excellence in clinical care. In November 2019, University Hospital was named a Magnet-designated organization for the fifth consecutive time by the American Nurses Credentialing Center Magnet Recognition Program®. University Hospital is only the 21st hospital worldwide to receive this designation five consecutive times. Magnet hospitals are recognized for excellence in nursing care and patient outcomes. Additionally, University Hospital was named Best in Class, and designated as one of the top 10 hospitals in the country on the Consumer Loyalty list, based on results from NRC Health's Market Insights survey, the largest database of health care consumer responses in the country. Once again, University Hospital was named as an LGBTQ Healthcare Equality Leader for 2020, scoring a perfect 100 in the organization's five criteria.

Operations

In January 2020, the World Health Organization declared the novel Coronavirus (COVID-19) a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for healthcare organizations. These disruptions were evident in the decreases in the University Hospital's data points disclosed below:

For the fiscal year 2020, inpatient discharges decreased 3.8% and adjusted patient discharges decreased 6.6%. Operating room cases decreased 7.2% over fiscal year 2019. Also emergency room visits decreased 5.0% during fiscal year 2020. The Hospital had an increase in net position of \$138 million in fiscal year 2020.

Selected Hospital operating statistics are outlined below:

	2020	2019
Beds in service	1,126	1,128
Patient discharges	50,579	52,602
Adjusted patient discharges	82,418	88,273
Patient days	363,854	378,744
Adjusted patient days	592,899	635,578
Operating room cases	34,811	37,529
Emergency department visits	118,839	125,065
Patient origin:		
Jefferson County	47.2%	46.6%
Other Alabama counties	47.2%	47.3%
Out of state	5.6%	6.1%

Management's Responsibility for Financial Reporting


The accompanying financial statements of the University of Alabama at Birmingham (UAB) for the years ended September 30, 2020 and 2019 were prepared by UAB's management in conformity with accounting principles generally accepted in the United States of America.

The management of UAB is responsible for the integrity and objectivity of these financial statements, which are presented on the accrual basis of accounting and, accordingly, include some amounts based upon judgement. Other financial information in the annual report is consistent with that in the financial statements. The system of internal accounting controls is designed to help ensure that the financial reports and the books properly reflect the transactions of the institution, in accordance with established policies and procedures as implemented by qualified personnel.

The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the financial and accounting operations of the institution, including the review and discussion of periodic financial statements and the evaluation and adoption of budgets. The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the basis of engagement and reporting of independent auditors.



G. Allen Bolton, Jr.
Senior Vice President for Finance
and Administration



Stephanie Mullins
UAB Chief Financial Officer

1030 Administration Building
701 20th Street South
205.934.5493
Fax 205.934.3610

Mailing Address:
AB 1030
1720 2ND AVE S
BIRMINGHAM AL 35294-0110



Report of Independent Auditors

To the Board of Trustees of The University of Alabama:

Report on the Financial Statements

We have audited the accompanying financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2020 and 2019, and the related statements of revenues, expenses, and changes in net position and of cash flows (where applicable) for the years then ended, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express opinions on the financial statements based on our audits. We did not audit the financial statements of Southern Research Institute ("SRI"), UAB's discretely presented component unit, as of December 27, 2019 and December 28, 2018 and for the years then ended. Those statements were audited by other auditors whose report thereon has been furnished to us, and our opinion, insofar as it relates to the amounts included for SRI, is based solely on the report of the other auditors. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation, and UAB Research Foundation were not audited in accordance with *Government Auditing Standards*.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to UAB's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.



Opinions

In our opinion, based on our audits and the report of other auditors, the financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham as of September 30, 2020 and 2019 and the respective changes in financial position and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 1, the financial statements of UAB are intended to present the financial position, the changes in financial position and, where applicable, the cash flows of only that portion of the business-type activities of the financial reporting entity of The University of Alabama System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of The University of Alabama System as of September 30, 2020 and 2019, the changes in its financial position, or, where applicable, its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

Other Matters

Required Supplementary Information

The accompanying management's discussion and analysis on pages 11 through 19 and the accompanying supplementary information on pages 70 through 72 are required by accounting principles generally accepted in the United States of America to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audits of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Other Information

Our audits were conducted for the purpose of forming opinions on the financial statements that collectively comprise UAB's basic financial statements. The introductory information on pages 2 through 7 and the management's report on page 8 are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information has not been subjected to the auditing procedures applied in the audits of the basic financial statements, and accordingly, we do not express an opinion or provide any assurance on it.



Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated January 21, 2021, on our consideration of UAB's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters for the year ended September 30, 2020. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the UAB's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Birmingham, Alabama
January 21, 2021

The University of Alabama at Birmingham

Management's Discussion and Analysis (Unaudited)

The objective of management's discussion and analysis is to help readers of UAB's financial statements better understand the financial position and operating activities for the fiscal years ended September 30, 2020 and 2019. This discussion has been prepared by management along with the financial statements and related note disclosures and should be read in conjunction with the financial statements and notes. The financial statements, notes, required supplementary information, and this discussion are the responsibility of management. In January 2020, the World Health Organization declared the novel Coronavirus ("COVID-19") a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and healthcare organizations and has impacted several areas of UAB and University Hospital's financial statements as further discussed within the MD&A and Note 1.

Overview of Financial Statements

UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the University of Alabama Hospital (the "Hospital" or "University Hospital"), and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 15. GASB Statement No. 14, *The Financial Reporting Entity* (GASB Statement No. 14), as amended by GASB Statement No. 61, *The Financial Reporting Entity: Omnibus-an amendment of GASB Statements No. 14 and No. 34* (GASB Statement No. 61), requires governmental entities to include in their financial statements as component units, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable.

Southern Research Institute (SRI) is a discretely presented component unit of UAB. SRI's performance is not discussed below. However, SRI's Statement of Net Position and Statements of Revenues, Expenses, and Changes in Net Position are disclosed on pages 25-26.

Blended component units included within the financial information of UAB are UAB Research Foundation (UABRF), UAB Athletics Foundation (UABAF), Alabama Care Plan (ACP), Hospital Management L.L.C. (LLC), and Triton Health Systems, L.L.C. (Triton).

The following discussion and analysis provides an overview of UAB's financial activities. UAB's financial position remained strong, as assets totaled \$5.93, \$5.53, and \$5.05 billion at September 30, 2020, 2019, and 2018, respectively. Increases of \$399.6 million or 7.2% from September 30, 2019 to September 30, 2020 were primarily due to increases in cash and cash equivalents, investments, and capital assets. Increases of \$479.0 million or 9.5% from September 30, 2018 to September 30, 2019 were primarily due to increases in investments, cash designated for capital activities, and capital assets.

Total liabilities decreased \$101.4 million or 2.9% from September 30, 2019 to September 30, 2020. The decrease results primarily from a decrease in the OPEB liability. Total liabilities increased \$255.7 million or 7.8% from September 30, 2018 to September 30, 2019. The increase results primarily from the issuance of bonds during fiscal year 2019. The increase also relates to growth in accounts payable and accrued liabilities as well as an increase in the OPEB liability.

The change in net position reflects the operating, nonoperating and other activity of UAB, which results from revenues, expenses, and gains and losses, and is summarized for the years ended September 30, 2020, 2019, and 2018, as follows:

	2020	2019	2018
TOTAL OPERATING REVENUES	\$ 3,712,470,836	\$ 3,602,383,812	\$ 3,404,474,421
TOTAL OPERATING EXPENSES	3,953,876,475	3,772,700,839	3,583,867,788
NET OPERATING LOSS	(241,405,639)	(170,317,027)	(179,393,367)
TOTAL NONOPERATING INCOME, CAPITAL, ENDOWMENT AND OTHER ACTIVITIES	450,349,699	403,275,983	415,697,356
INCREASE IN NET POSITION	\$ 208,944,060	\$ 232,958,956	\$ 236,303,989

Statements of Net Position

The statement of net position presents the financial position of UAB at the end of the fiscal year, and includes all assets, deferred outflows, liabilities, and deferred inflows recorded on the accrual basis of accounting. The changes in net position are indicators of whether the overall financial condition of UAB has improved or

worsened during the year. A summarized comparison of UAB's assets, deferred outflows, liabilities, deferred inflows, and net position at September 30, 2020, 2019, and 2018, is as follows:

	2020	2019	2018
ASSETS AND DEFERRED OUTFLOWS OF RESOURCES			
Current assets	\$ 2,536,697,047	\$ 2,071,860,183	\$ 1,829,451,447
Capital assets, net	\$ 1,784,230,411	\$ 1,723,027,158	\$ 1,647,560,771
Other assets	1,610,622,655	1,737,076,833	1,575,960,784
TOTAL ASSETS	5,931,550,113	5,531,964,174	5,052,973,002
Deferred outflows from debt refundings	13,336,713	12,305,553	13,259,304
Deferred outflows pension and OPEB related	305,494,017	301,435,989	284,267,363
TOTAL DEFERRED OUTFLOWS OF RESOURCES	318,830,730	313,741,542	297,526,667
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 6,250,380,843	\$ 5,845,705,716	\$ 5,350,499,669
LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION			
Current liabilities	\$ 800,205,475	\$ 544,331,398	\$ 532,298,414
Noncurrent liabilities	2,640,898,752	2,998,164,006	2,754,500,058
TOTAL LIABILITIES	3,441,104,227	3,542,495,404	3,286,798,472
Deferred inflows from debt refundings	—	40,878	54,307
Deferred inflows pension and OPEB related	521,937,116	224,773,994	218,210,406
TOTAL DEFERRED INFLOWS OF RESOURCES	521,937,116	224,814,872	218,264,713
Net position	2,287,339,500	2,078,395,440	1,845,436,484
TOTAL LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION	\$ 6,250,380,843	\$ 5,845,705,716	\$ 5,350,499,669

At September 30, 2020, the major categories of current assets consist primarily of cash and cash equivalents, short-term investments, and accounts receivable, which totaled \$2.40 billion of the \$2.54 billion and increased \$464.8 million or 22.4% from 2019. The increase is a result of more cash held on hand, some growth in short term investments due to an increase in earnings reinvested, temporary cost cutting measures out of precaution of pandemic impact, and deferred payments of the employer share of Social Security taxes allowable under the CARES Act

At September 30, 2019, the major categories of current assets consist primarily of cash and cash equivalents, short-term investments, and accounts receivable, which totaled \$1.95 billion of the \$2.07 billion and increased \$242.4 million or 13.3% from 2018. The increase is a result of growth in short term investments and accounts receivable.

At September 30, 2020, total current liabilities of \$800.2 million consist primarily of accounts payable, accrued payroll and related benefits, and unearned revenue, which totaled \$746.4 million, compared to \$493.2 million

at September 30, 2019, an increase of \$253 million or 51.3% from 2019. The increase is primarily due to an increase in hospital related payables.

At September 30, 2019, total current liabilities of \$544.3 million consist primarily of accounts payable, accrued payroll and related benefits, and unearned revenue, which totaled \$493.2 million, compared to \$483.4 million at September 30, 2018, an increase of \$10 million or 2.0% from 2018. The increase is a result of an increase in salary and benefits related accruals.

UAB's endowment and life income investments increased \$2.5 million or 0.5% to \$540.0 million from September 30, 2019 to September 30, 2020. This increase resulted from the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments throughout the year, offset by investment performance.

UAB's endowment and life income investments increased \$12.7 million or 2.4% to \$537.5 million from September 30, 2018 to September 30, 2019. This increase resulted from the establishment of new endowment funds through gifts and the creation of Board-

designated quasi-endowments throughout the year, offset by investment performance.

UAB's endowment funds are invested in common investment pools established by The Board of Trustees of The University of Alabama (the Board). The funds are invested to maximize total return over the long term, with an appropriate level of risk. Any short term reduction in the fair value of the endowment portfolio will not have a meaningful immediate impact on the portion of investment income available to support current year operating expenses since such distributions are made pursuant to The University of Alabama System's (the System) spending rate policy. UAB's endowment funds consists of both permanent and quasi-endowments. Permanent endowment funds are those funds received from donors with the requirement that the principal remain unspent and invested in perpetuity to produce income to be expended for the purposes specified by the donor. Quasi- endowments consist of restricted or unrestricted funds that have been set aside by actions of the Board to produce income for an established purpose until the time the Board reverses its action. Endowment income supports scholarships, fellowships, professorships, research efforts, and other programs and activities of UAB.

At September 30, 2020, 2019, and 2018 respectively, UAB's investment in the Professional Liability Trust Fund (PLTF) totaled approximately \$59.9, \$60.3, and \$67.3 million. The \$0.4 million decrease from September 30, 2019 to September 30, 2020 is a result of a decline in investment values at September 30, 2020. The \$7.0 million decrease from September 30, 2018 to September 30, 2019 is a result of a decline in investment values at September 30, 2019.

At September 30, 2020, deferred outflows from pension obligations were \$198.6 million and deferred inflows from pension obligations were \$90.2 million. At September 30, 2019, deferred outflows from pension obligations were \$185.1 million and deferred inflows from pension obligations were \$142.7 million. The increase in deferred outflows from pension obligations is a result of the net difference between projected and actual earnings on pension plan investments. The decrease in deferred inflows from pension obligations is the result of the net difference between projected and actual earnings on pension plan investments.

At September 30, 2019, deferred outflows from pension obligations were \$185.1 million and deferred inflows from pension obligations were \$142.7 million. At September 30, 2018, deferred outflows from pension obligations were \$160.5 million and deferred inflows from pension obligations were \$147.1 million. The increase in deferred outflows from pension obligations is a result of an increase in differences between expected and actual experience. The decrease in deferred inflows from pension obligations is the result of a decrease in

differences between expected and actual experience, changes in proportion, and differences between employer contributions and proportionate share of contributions.

At September 30, 2020, deferred outflows from OPEB obligations were \$106.9 million and deferred inflows from OPEB obligations were \$431.8 million. At September 30, 2019, deferred outflows from OPEB obligations were \$116.4 million and deferred inflows from OPEB obligations were \$82.1 million. The decrease in the deferred outflows from OPEB obligations is a result of a changes in proportion and differences between employer contributions and proportionate share of contributions. The increase in deferred inflows from OPEB obligation is a result of a difference between expected and actual experience.

At September 30, 2019, deferred outflows from OPEB obligations were \$116.4 million and deferred inflows from OPEB obligations were \$82.1 million. At September 30, 2018, deferred outflows from OPEB obligations were \$123.7 million and and deferred inflows from OPEB obligations were \$71.1 million. The decrease in the deferred outflows from OPEB obligations is a result of changes in proportion and differences between employer contributions and proportionate share of contributions. The increase in deferred inflows from OPEB obligation is a result of a change in proportion and differences between employer contributions and proportionate share of contributions.

GASB Statements No. 68 and 75 require governmental employers participating in multi-employer cost-sharing pension and healthcare benefit plans to recognize liabilities for their proportionate share of the unfunded liability for plans whose actuarial liabilities exceed the plan's net assets. As required by Alabama statute, all eligible employees of a qualifying public educational employer must be a member of the Teacher's Retirement System of Alabama (TRS). As a qualifying employer, UAB is required to make certain employer contributions on behalf of its employees participating in TRS's defined benefit pension plan. Additionally, Alabama statutes permitted UAB to opt-in to provide its eligible retirees with healthcare benefits through the Public Education Employees' Health Insurance Plan (PEEHIP).

The employer contribution rates for both plans are established annually by TRS and PEEHIP, and adopted by the Alabama Legislature. Both the TRS employer contribution rate and the employer's PEEHIP cost for retiree coverage are based upon the actuarial valuations performed by TRS and PEEHIP, respectively. Although the liabilities recognized under GASB 68 and 75 meet GASB's definition of a liability within GASB's framework for accounting standards, UAB does not believe that the associated recorded liabilities constitute legal liability for UAB, nor do they open UAB to other claims on its resources.

At September 30, 2020, deferred outflows from debt refundings were \$13.3 million with no deferred inflows from debt refundings. At September 30, 2019, deferred outflows from debt refundings were \$12.3 million and deferred inflows from debt refundings were \$41 thousand. The increase of \$1.0 million in deferred outflows from September 30, 2019 to September 30, 2020 is the result of new debt issuances.

At September 30, 2019, deferred outflows from debt refundings were \$12.3 million and deferred inflows from debt refundings were \$41 thousand. At September 30, 2018, deferred outflows from debt refundings were \$13.3 million and deferred inflows from debt refundings were \$54 thousand. These changes from September 30, 2018 to September 30, 2019 are related to the annual amortization of these balances.

Capital and Debt Activities

An aspect of UAB's continued growth is an emphasis on the expansion and maintenance of capital assets. UAB continues to implement its long-range capital plan. Capital assets primarily include land, buildings, fixed equipment systems, and inventoried equipment. The original costs of capital assets increased approximately \$184.3 million and \$188.3 million from September 30, 2019 to September 30, 2020 and from September 30, 2018 to September 30, 2019, respectively. The year over year increase consists primarily of additions totaling \$214.4 million (offset primarily by \$30.0 million in disposals) and \$227.0 million (offset primarily by \$38.7 million in disposals) in 2020 and 2019, respectively. Capital additions are comprised primarily of renovation and new construction of student, research and health care facilities, as well as additions to improve information technology systems.

Annual additions were funded with capital funds, grants, gifts of \$1.9 million and \$0.8 million, debt proceeds of \$63.1 million and \$29.6 million, and the remainder by UAB

funds designated for capital purchases in 2020 and 2019, respectively.

Capital projects in process at September 30, 2020 include Central Utilities, McCallum Building renovations, Green Hall (a new residence hall) and Information and Technology Center. Capital projects in process at September 30, 2019 include Central Utilities, McCallum Building renovations, Science and Engineering Building, Honors College, and Information and Technology Center.

UAB's long-term debt related to capital assets, consisting of bonds and capital leases, totaled \$1.13, \$1.16, and \$0.94 billion at September 30, 2020, 2019, and 2018, respectively. The decrease in debt during 2020 consisted primarily of the principal payments made in accordance with the debt instruments. The increase in debt during 2019 consisted primarily of the \$170.7 million General Revenue Bonds, Series 2019 issued during the year.

Net Position

Net position represents the residual interest in UAB's assets and deferred outflows after liabilities and deferred inflows are deducted.

UAB's net position at September 30, 2020, 2019, and 2018, is summarized as follows:

	2020	2019	2018
NET INVESTMENT IN CAPITAL ASSETS	\$ 769,281,767	\$ 759,496,749	\$ 744,768,861
RESTRICTED			
Nonexpendable	405,615,948	401,733,396	386,738,832
Expendable	353,055,159	377,422,933	354,341,414
UNRESTRICTED	759,386,626	539,742,362	359,587,377
TOTAL NET POSITION	\$ 2,287,339,500	\$ 2,078,395,440	\$ 1,845,436,484

Net position invested in capital assets represent UAB's capital assets, net of accumulated depreciation and outstanding principal of debt in excess of related bond proceeds attributable to the acquisition, construction, or improvement of those assets. The \$9.8 million increase in 2020 reflects the growth in capital assets net of annual depreciation expense, along with the decrease in total debt related to the annual principal payments. The \$14.7 million increase in 2019 reflects continued

capital asset development in accordance with UAB's long-range capital plan, offset by the increase in debt related to the bonds issued during the year.

Restricted nonexpendable net position includes UAB's permanent endowment funds and annuity and life income assets that will ultimately become pure endowment funds. The \$3.9 million increase in 2020 and the \$15.0 million increase in 2019 relates to contributions made and investment performance at year-end.

Restricted expendable net position is subject to externally imposed restrictions governing its use. Restricted expendable net position includes UAB's assets whose use is restricted by an external restriction. The \$24.4 million decrease in 2020 is the result of fewer new gifts received during the year. The \$23.1 million increase in 2019 resulted primarily from new gifts received during the year.

Unrestricted net position includes UAB's assets whose use is not restricted by an external entity. Unrestricted net

position increased by \$219.6 million or 40.7% in 2020 and increased by \$180.2 million or 50.1% in 2019, respectively. Although unrestricted net position is not subject to externally imposed restrictions, UAB has designated available unrestricted net position to be used for academic and research programs as well as capital projects.

Statements of Revenues, Expenses, and Changes in Net Position

The statement of revenues, expenses, and changes in net position presents UAB's results of operations, as well as the nonoperating revenues and expenses. Annual state appropriations are classified as nonoperating revenues according to governmental accounting standards, even though the state-appropriated funds are used to support the operations of UAB.

Without the nonoperating revenues, in particular the state appropriations and private gifts, UAB would not be able to cover its costs of operations. A summarized comparison of UAB's revenues, expenses and changes in net position for the years ended September 30, 2020, 2019, and 2018 is presented below:

	2020	2019	2018
OPERATING REVENUES			
Student tuition and fees, net	\$ 244,929,737	\$ 239,912,344	\$ 253,707,923
Grants and contracts	483,921,582	494,047,342	461,633,394
Sales and services	2,931,632,967	2,791,635,652	2,623,643,380
Other revenues	51,986,550	76,788,474	65,489,724
TOTAL OPERATING REVENUES	3,712,470,836	3,602,383,812	3,404,474,421
OPERATING EXPENSES			
Operating expenses	3,953,876,475	3,772,700,839	3,583,867,788
OPERATING LOSS	(241,405,639)	(170,317,027)	(179,393,367)
NONOPERATING REVENUES (EXPENSES)			
Economic relief funds	71,281,070	—	—
State educational appropriations	306,964,712	287,691,735	273,351,124
Grants and contracts	57,856,589	35,451,482	34,611,638
Private gifts	18,705,016	48,327,432	37,989,901
Investment income	15,735,962	32,247,107	90,152,323
Interest expense	(40,126,392)	(29,755,042)	(28,964,461)
Net other nonoperating revenue (expense)	322,621	419,384	(11,334,915)
NET NONOPERATING REVENUES	430,739,578	374,382,098	395,805,610
OTHER CHANGES IN NET POSITION	19,610,121	28,893,885	19,891,746
INCREASE IN NET POSITION	208,944,060	232,958,956	236,303,989
Net Position, beginning of year as previously reported	2,078,395,440	1,845,436,484	2,147,505,940
Adoption of GASB 75	—	—	(538,373,445)
Net Position, beginning of year as restated as of October 1, 2017	2,078,395,440	1,845,436,484	1,609,132,495
NET POSITION, END OF YEAR	\$ 2,287,339,500	\$ 2,078,395,440	\$ 1,845,436,484

Figures A and A1 are graphic illustrations of revenues by source (both operating and nonoperating), which are used to fund UAB’s operating activities for the years ended September 30, 2020 and 2019, respectively.

Figure A : Revenue Streams 2020






Figure A1: Revenue Streams 2019



Operating revenues:

Gross tuition and fees revenue increased by \$10.2 million and \$17.1 million in 2020 and 2019, respectively. Total student headcount of 22,080 and 21,923 increased by 157 or 0.7% in Fall 2019 and increased by 1,021 or 4.9% in Fall 2018. Gross tuition and fees revenue in 2020 and 2019 is offset by scholarship allowances of \$85.5 million and \$80.2 million, respectively.

UAB receives grant and contract revenue from federal, state, local governments and private agencies totaling \$483.9, \$494.0, and \$461.6 million, a decrease of 2.0% from 2019 to 2020 and an increase of 7.0% from 2018 to 2019, respectively.

Net hospital sales and service revenue totaled \$2.11, \$2.01, and \$1.86 billion, an increase of 5.1% and 7.7% from 2019 to 2020 and 2018 to 2019, respectively. These increases resulted from increased volume, contract improvements, and ongoing revenue-cycle improvement activities.

Net auxiliary sales and service revenue totaled \$762.4, \$715.7, and \$690.4 million, an increase of 6.5% and 3.7% from 2019 to 2020 and 2018 to 2019, respectively. These increases resulted from Triton premium revenue growth offset by a decrease in University auxiliary revenues.

Other sources:

Net educational sales and service revenue totaled \$59.4, \$67.6, and \$68.5 million, a decrease of 12.2% and 1.2% from 2019 to 2020 and 2018 to 2019, respectively. The current year decrease is due to a decline in clinical activity revenues.

Other operating revenue totaled \$52.0, \$76.8, and \$65.5 million, a decrease of 32.3% from 2019 to 2020 and an increase of 17.3% from 2018 to 2019, respectively. The current year decrease is due to a decline in HSF support.

Nonoperating revenues:

UAB receives state educational appropriations and capital funding from the State of Alabama. UAB recognized educational appropriations and capital funding from the State of Alabama totaling \$307.0, \$287.7, and \$273.4 million, of which \$297.7, \$273.5, and \$265.0 million was primarily from the Educational Trust Fund (ETF), which is included as nonoperating revenue.

Economic relief funds primarily consisted of the University Hospital receiving and recognizing \$67.3 million in federal CARES Act provider relief funding and \$3.2 million State CARES Act funding through September, 2020.

Net investment income decreased \$16.5 million from 2019 to 2020 and decreased \$57.9 million from 2018 to 2019. The decrease was a result of a decrease in the fair value of investments at the end of the year.

UAB recognized \$38, \$77, and \$59 million in gift revenue (composed partially of \$18, \$28, and \$18 million and \$1.9, \$0.8, and \$2.3 million in capital and endowment gifts, respectively) for the years ended September 30, 2020, 2019, and 2018, respectively.

Figures B and B1 below are illustrations of the breakout of the funding sources for grant and contract revenue for the years ended September 30, 2020 and 2019, respectively. UAB receives grant and contract revenue from federal,

state, local, and private agencies. These funds are used to further the mission of UAB: research, education, and public service.

Figure B: Grants and Contract Revenues 2020





Figure B1: Grants and Contract Revenues 2019



Operating Expenses


A comparative summary of UAB's operating expenses for the years ended September 30, 2020, 2019, and 2018, is as follows:

	2020	2019	2018
Salaries, wages, and benefits	\$ 1,766,044,825	\$ 1,749,060,938	\$ 1,674,990,688
Supplies and services	2,001,552,207	1,846,254,490	1,734,410,959
Depreciation	150,994,130	148,344,143	146,686,513
Scholarships and fellowships	35,285,313	29,041,268	27,779,628
TOTAL OPERATING EXPENSES	\$ 3,953,876,475	\$ 3,772,700,839	\$ 3,583,867,788



Salaries, wages, and benefits increased \$17.0 million or 1.0% during 2020 and \$74.1 million or 4.4% during 2019. These increases are primarily due to the growth of UAB's salary base and rising benefit costs related to growth in salary base. Supplies and services expenses increased \$155.3 million or 8.4% and \$111.8 million or 6.4% during 2020 and 2019, respectively. This increase is primarily attributable to UAB's continued growth. In addition to natural classifications, operating expenses are reported by functional classifications as defined by the National Association of College and University Business Officers ("NACUBO").

The functional classification of an operating expense (Instruction, Research, etc.) is assigned to a department based on the nature of the activity, which represents the material portion of the activity attributable to the department. This method reflects, by function of UAB's, amounts expended in areas such as instruction, research, and operations and maintenance and is used most commonly for comparative reporting purposes among colleges and universities. Graphic illustrations of UAB's operating expenses by function for the years ended September 30, 2020 and 2019, respectively, are presented as follows:

2020 Operating Expenses by Function



2019 Operating Expenses by Function



Economic Factors That Will Affect The Future

As a labor-intensive organization, UAB faces competitive pressures related to attracting and retaining faculty and staff.

The State of Alabama appropriates money each year to UAB for operating costs and nonoperating cash requirements, including capital expenditures. Because the State is mandated by its Constitution to operate with a balanced budget, the State occasionally has reduced its appropriations, through a process known as “proration,” when its annual revenues are not expected to meet budgeted appropriations. As the State could potentially implement proration in future years, UAB continues to implement cost-saving measures in order to minimize the impact of any future proration.

Private gifts are an important part of the fundamental support of UAB. Economic pressures affecting donors may also affect the future level of support UAB receives from corporate and individual giving. In fiscal year 2014, UAB launched its largest fundraising campaign to date known as “Give something change everything.” The fundraising goal of \$1 billion was surpassed by UAB in November 2018, reaching its stated goal of achieving the milestone by the end of 2018.

During fiscal year 2020, 67.6% of UAB students received financial aid, including \$194.3 million of Federal Financial Aid. In recent years, financial aid reform and reauthorization of existing aid programs have been topics in legislative sessions. Management is monitoring proposed future legislation in order to respond in a manner to assist current and future students.

The Hospital faces significant challenges in a dynamic healthcare sector and volatile economic environment. The demand for health care services and the cost of providing them are increasing significantly while the revenues to support these services are diminishing. In addition to cost increases such as rising salary and benefit costs, the Hospital also faces additional costs associated with new technologies, the education and training of health care professionals and provision of care for a disproportionate share of the medically underserved in Alabama. In recent years, federal legislation has been enacted to slow future rate increases in Medicare and Medicaid and reduce medical education and disproportionate share funding. Management is committed to staying abreast of pertinent issues; implementing appropriate management actions and continuing to provide quality care for all patients.

In January 2020, the World Health Organization declared the novel Coronavirus (“COVID-19”) a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and healthcare organizations and has impacted several areas of UAB and University Hospital's financial statements as further discussed within Note 1.

These financial statements are prepared to provide a general overview of the University of Alabama at Birmingham and to demonstrate UAB's accountability. Questions concerning any information provided in this report or requests for additional information should be addressed to the Office of the Senior Vice President for Finance and Administration, The University of Alabama at Birmingham, AB 1030, 1720 2ND AVE S, BIRMINGHAM AL 35294-0106.

The University of Alabama at Birmingham
Statements of Net Position
September 30, 2020 and 2019

	2020	2019
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 641,920,794	\$ 380,593,397
Short term investments	1,196,891,055	1,084,308,490
Accounts receivable, net	565,381,018	481,727,985
Loans receivable, current portion	1,994,471	2,272,848
Pledges receivable, current portion	10,732,083	18,436,977
Inventories	35,827,726	30,625,249
Prepaid expenses and unearned scholarships	71,948,834	62,681,894
Other current assets	12,001,066	11,213,343
Total current assets	2,536,697,047	2,071,860,183
Noncurrent Assets:		
Cash designated for capital activities	63,098,686	141,695,284
Restricted cash and cash equivalents	269,648	169,594
Investments for capital activities	797,791,901	825,529,381
Endowment and life income investments	539,974,716	537,457,828
Investment in Professional Liability Trust Fund	59,920,845	60,291,989
Other long-term investments	107,735,412	115,426,770
Loans receivable, net	8,347,250	10,980,614
Pledges receivable	29,408,901	45,409,739
Capital assets, net	1,784,230,411	1,723,027,158
Other noncurrent assets	4,075,296	115,634
Total noncurrent assets	3,394,853,066	3,460,103,991
Total Assets	5,931,550,113	5,531,964,174
DEFERRED OUTFLOWS OF RESOURCES		
Bond deferred refundings	13,336,713	12,305,553
Pension and OPEB related obligations	305,494,017	301,435,989
Total Deferred Outflows of Resources	318,830,730	313,741,542
Total Assets and Deferred Outflows of Resources	\$ 6,250,380,843	\$ 5,845,705,716

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Net Position
September 30, 2020 and 2019

	2020	2019
LIABILITIES		
Current Liabilities:		
Accounts payable and accrued liabilities	\$ 596,371,343	\$ 342,830,127
Deposits	15,078,378	15,788,813
Unearned revenue-grants	50,928,154	44,550,216
Unearned revenue-other	99,077,929	105,781,493
Long-term debt, current portion	38,749,671	35,380,749
Total current liabilities	800,205,475	544,331,398
Noncurrent Liabilities:		
Federal advances-loan funds	8,483,518	11,056,522
Long-term debt, noncurrent portion	1,087,186,699	1,127,090,695
Pension liability	1,245,083,000	1,168,305,000
OPEB liability	271,431,941	677,611,841
Other noncurrent liabilities	28,713,594	14,099,948
Total noncurrent liabilities	2,640,898,752	2,998,164,006
Total Liabilities	3,441,104,227	3,542,495,404
DEFERRED INFLOWS OF RESOURCES		
Bond deferred refundings	—	40,878
Pension and OPEB related obligations	521,937,116	224,773,994
Total Deferred Inflows Of Resources	521,937,116	224,814,872
NET POSITION		
Net investment in capital assets	769,281,767	759,496,749
Restricted		
Nonexpendable	405,615,948	401,733,396
Expendable	353,055,159	377,422,933
Unrestricted	759,386,626	539,742,362
Total Net Position	2,287,339,500	2,078,395,440
Total Liabilities, Deferred Inflows and Net Position	\$ 6,250,380,843	\$ 5,845,705,716

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Revenues, Expenses, and Changes in Net Position
Years Ended September 30, 2020 and 2019

	2020	2019
Operating Revenues		
Tuition and fees	\$ 330,385,766	\$ 320,141,055
Less: scholarship allowance	(85,456,029)	(80,228,711)
Tuition and fees, net	244,929,737	239,912,344
Grants and contracts:		
Federal	392,328,131	399,343,773
State	9,637,192	10,967,871
Local	2,743,274	2,535,753
Private	79,212,985	81,199,945
Sales and services:		
Educational activities	59,351,275	67,616,490
Hospital, net of bad debt expense of \$187.9 million in 2020 and \$157.7 million in 2019	2,109,833,577	2,008,319,151
Other auxiliary enterprises, net of scholarship allowance of \$2.4 million in 2020 and \$2.9 million in 2019	762,448,115	715,700,011
Other operating revenues	51,986,550	76,788,474
Total operating revenues	3,712,470,836	3,602,383,812
Operating Expenses		
Salaries, wages and benefits	1,766,044,825	1,749,060,938
Supplies and services	2,001,552,207	1,846,254,490
Depreciation	150,994,130	148,344,143
Scholarships and fellowships	35,285,313	29,041,268
Total operating expenses	3,953,876,475	3,772,700,839
Operating loss	(241,405,639)	(170,317,027)
Nonoperating Revenues (Expenses)		
Economic Relief Funds	71,281,070	—
State educational appropriations	306,964,712	287,691,735
Grants and contracts	57,856,589	35,451,482
Gifts	18,705,016	48,327,432
Investment income	15,735,962	32,247,107
Interest expense	(40,126,392)	(29,755,042)
Loss on asset dispositions, net	(567,152)	(112,196)
Other nonoperating income, net	889,773	531,580
Net nonoperating revenues	430,739,578	374,382,098
Income before other changes in net position	189,333,939	204,065,071
Other Changes in Net Position		
Capital gifts and grants	1,854,223	789,319
Endowment gifts	17,755,898	28,104,566
Total other changes in net position	19,610,121	28,893,885
Increase in net position	208,944,060	232,958,956
Net Position, beginning of year	2,078,395,440	1,845,436,484
Net Position, end of year	\$ 2,287,339,500	\$ 2,078,395,440

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Cash Flows
Years Ended September 30, 2020 and 2019

	2020	2019
Cash flows from operating activities		
Student tuition and fees	\$ 246,333,703	\$ 222,500,106
Grants and contracts:		
Federal	398,734,987	392,986,127
State	12,733,355	10,493,650
Local	1,981,861	3,007,393
Private	82,655,623	83,027,558
Receipts from sales and services of:		
Educational activities	59,175,998	68,089,396
Patient services	2,058,613,804	1,988,861,614
Auxiliary enterprises, net	35,084,704	47,914,492
Premium and administrative fees collected	716,906,063	669,167,299
Payment to employees and related benefits	(1,311,156,619)	(1,337,749,307)
Payment for contract labor	(448,114,236)	(402,775,436)
Payment to suppliers	(1,835,715,862)	(1,874,194,939)
Payment for scholarships and fellowships	(35,285,313)	(29,041,268)
Other receipts	50,574,552	71,385,889
Net cash provided by (used in) operating activities	32,522,620	(86,327,426)
Cash flows from noncapital financing activities		
Economic relief funds	67,325,616	—
State educational appropriations	306,964,712	287,691,735
Private gifts	59,428,944	74,368,931
Student direct lending receipts	167,856,685	169,048,223
Student direct lending disbursements	(166,625,040)	(167,141,859)
Other deposits	60,226,262	39,131,649
Deposits from affiliates	(5,468,313)	1,374,539
Net cash provided by noncapital financing activities	489,708,866	404,473,218
Cash flows from investing activities		
Interest and dividends from investments, net	96,970,912	90,095,472
Proceeds from notes receivable	85,697	139,076
Proceeds from sales and maturities of investments	8,342,944	30,531,014
Purchases of investments	(167,556,803)	(206,880,373)
Net cash used in investing activities	(62,157,250)	(86,114,811)
Cash flows from capital and related financing activities		
Proceeds from issuance of capital debt	11,037,858	217,842,498
Capital gifts, grants and contracts	2,591,924	3,517,265
Proceeds from sale of capital assets	380,128	3,267,701
Purchases of capital assets	(220,801,455)	(219,539,415)
Principal payments on capital debt	(35,296,312)	(35,308,922)
Interest payments on capital debt	(35,155,526)	(34,218,980)
Net cash used in capital and related financing activities	(277,243,383)	(64,439,853)
Net increase in cash and cash equivalents	182,830,853	167,591,128
Cash and cash equivalents, beginning of year	522,458,275	354,867,147
Cash and cash equivalents, end of year	\$ 705,289,128	\$ 522,458,275

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Cash Flows (continued)
Years Ended September 30, 2020 and 2019

	2020	2019
Reconciliation of cash and cash equivalents to the statements of net position		
Cash and cash equivalents	\$ 641,920,794	\$ 380,593,397
Cash designated for capital activities	63,098,686	141,695,284
Restricted cash and cash equivalents	269,648	169,594
Total cash and cash equivalents	705,289,128	\$ 522,458,275
Reconciliation of operating loss to net cash provided by (used in) operating activities		
Operating loss	\$ (241,405,639)	\$ (170,317,027)
Adjustments to reconcile operating loss to net cash provided by (used in) operating activities		
Depreciation expense	150,994,130	148,344,143
Pension expense	112,188,000	76,255,000
OPEB expense	(25,185,389)	52,845,769
Changes in assets and liabilities:		
Accounts receivable, net	165,975,517	(49,790,075)
Prepaid expenses and other assets	(17,806,662)	(17,744,379)
Accounts payable and accrued liabilities	9,577,611	(12,188,034)
Pension obligations	(98,485,000)	(97,999,000)
OPEB obligations	(22,187,000)	(21,360,942)
Unearned Revenue	(1,142,948)	5,627,119
Net cash provided by (used in) operating activities	32,522,620	\$ (86,327,426)
Supplemental noncash activities information		
Capital assets acquired included in accounts payable	\$ 22,430,684	\$ 23,431,082
Capital assets acquired through capital lease	109,947	341,253
Interest capitalized	—	2,722,115
Non-cash transfer of funds from the STLP to the LCRP	547,946,709	—
Debt proceeds immediately transferred into escrow	81,890,469	—
Payment of outstanding bonds principal and interest via escrow	80,027,733	—

See accompanying notes to financial statements.

Southern Research Institute
(A Discretely Presented Component Unit)
Statements of Net Position
December 28, 2019 and December 29, 2018

	2020	2019
Current Assets:		
Cash and cash equivalents	\$ 470,327	\$ 24,474
Investments	15,321,444	19,911,409
Restricted cash and investments	11,933,466	10,721,291
Accounts receivable, net	17,182,332	16,109,295
Other receivables	1,411,383	2,008,305
Materials and supplies, net	986,730	1,073,368
Prepayments and other current assets	756,048	839,722
Total current assets	48,061,730	50,687,864
Noncurrent Assets:		
Net OPEB asset	1,187,434	623,594
Capital assets:		
Land and improvements	6,274,425	6,273,110
Buildings and major plant equipment	67,746,523	68,640,869
Laboratory equipment and fixtures	64,804,143	61,419,728
Office furniture and equipment	3,622,526	3,559,598
Intangible assets, net	1,707,790	2,466,397
	144,155,407	142,359,702
Less accumulated depreciation	(91,792,022)	(88,734,253)
	52,363,385	53,625,449
Construction-in-progress	667,583	1,777,846
Total capital assets, net	53,030,968	55,403,295
Total noncurrent assets	54,218,402	56,026,889
Total Assets	102,280,132	106,714,753
Deferred Outflows of Resources		
OPEB	319,792	403,238
Total Assets and Deferred Outflows of Resources	\$ 102,599,924	\$ 107,117,991
Current Liabilities:		
Accounts payable	\$ 4,400,559	\$ 5,382,732
Accrued liabilities	6,038,919	6,302,610
Unearned contract revenue	5,192,267	4,790,805
Current maturities of long-term debt and capital lease obligations	987,380	625,110
Note payable	172,370	806,353
Total current liabilities	16,791,495	17,907,610
Noncurrent Liabilities:		
Long-term debt and capital lease obligations	14,063,162	14,050,649
Total noncurrent liabilities	14,063,162	14,050,649
Total Liabilities	30,854,657	31,958,259
Deferred Inflows of Resources		
OPEB	1,472,708	1,079,066
Net Position		
Net investment in capital assets	37,980,426	40,727,536
Restricted		
Expendable	12,462,984	11,939,885
Unrestricted	19,829,149	21,413,245
Total Net Position	70,272,559	74,080,666
Total Liabilities, Deferred Inflows Of Resources, and Net Position	\$ 102,599,924	\$ 107,117,991

See accompanying notes to financial statements.

Southern Research Institute
(A Discretely Presented Component Unit)
Statements of Revenues, Expenses, and Changes in Net Position
Years Ended December 28, 2019 and December 29, 2018

	2019	2018
Operating Revenues		
Contract revenues	\$ 76,296,491	\$ 65,188,876
Intellectual property revenues, net of direct expenses	1,748,981	2,333,215
Total operating revenues	78,045,472	67,522,091
Operating Expenses		
Salaries, wages and benefits	46,123,903	46,596,897
Supplies and services	30,641,540	29,358,326
Depreciation and amortization	6,563,411	6,949,310
Total operating expenses	83,328,854	82,904,533
Operating loss	(5,283,382)	(15,382,442)
Nonoperating Revenues (Expenses)		
Contributions	312,507	491,792
Investment income (loss)	3,258,840	(1,724,659)
Interest expense	(384,463)	(369,510)
Gain (loss) on disposal of assets	(1,711,609)	(5,523,672)
Net nonoperating revenues (expenses)	1,475,275	(7,126,049)
Change in net position	(3,808,107)	(22,508,491)
Net Position, beginning of year	74,080,666	96,589,157
Net Position, end of year	\$ 70,272,559	\$ 74,080,666

See accompanying notes to financial statements.

The University of Alabama at Birmingham

Notes to Financial Statements

Years Ended September 30, 2020 and 2019

(1) Organization and Summary of Significant Accounting Policies

The University of Alabama at Birmingham ("UAB") is one of three universities of The University of Alabama System ("the System"), which is a component unit of the State of Alabama ("the State"). The financial statements of UAB are intended to present the financial position, changes in financial position, and the cash flows of only that portion of the business-type activities of the financial reporting entity of the System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of the System, its changes in financial position or cash flows in accordance with accounting principles generally accepted in the United States of America. The System is recognized as an organization exempt from Federal income tax under Section 501(a) of the Internal Revenue Code as an organization described in Section 501(c)(3) of the Internal Revenue Code.

UAB, as a public institution, prepares its financial statements in accordance with accounting principles generally accepted in the United States of America, as prescribed by the Governmental Accounting Standards Board (GASB).

GASB Statement No. 35, *Basic Financial Statements and Management's Discussion and Analysis for Public Colleges and Universities*, establishes standards for external financial reporting for public colleges and universities and requires that resources be classified for accounting and reporting purposes into the following three net position categories:

- **Net Investment in Capital Assets:**

Capital assets, net of accumulated depreciation and outstanding principal balances of debt attributable to the acquisition, construction, or improvement of those assets.

- **Restricted:**

Nonexpendable: Net position subject to externally imposed stipulations that they be maintained permanently by UAB. Such assets include UAB's permanent endowment funds.

Expendable: Net position whose use by UAB is subject to externally imposed stipulations that can be fulfilled by actions of UAB pursuant to those stipulations or that expire by the passage of time.

- **Unrestricted:**

The net position that is not subject to externally imposed stipulations. Unrestricted net position may be designated for specific purposes by action of management. Substantially all of the unrestricted net position is designated for academic and research programs and initiatives and capital programs.

UAB reports as a business type activity, as defined by GASB Statement No. 35. Business type activities are those financed in whole or in part by fees charged to external parties for goods or services.

UAB policy states that operating activities as reported by the statement of revenues, expenses, and changes in net position are those that generally result from exchange transactions such as payments received for providing services and payments made for services or goods received. Certain significant revenue streams relied upon for operations are recorded as nonoperating revenues, as defined by GASB Statement No. 35.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The estimates susceptible to significant changes include those used in determining the allowance for contractual adjustments and uncollectible accounts, valuation of investments, accruals related to compensated absences, allowance for self-insurance, estimated amounts due to or from third-party payors, and reserves for general and professional liability claims. Although some variability is inherent in these estimates, management believes that the amounts provided are adequate.

Scope of Statements

UAB is principally comprised of a university ("the University") and the University of Alabama Hospital ("the Hospital" or "University Hospital") which are UAB's reportable segments as defined by GASB Statement No. 37, *Basic Financial Statements and Management's Discussion and Analysis-For State and Local Governments: Omnibus an Amendment of GASB Statements No. 21 and No. 34*. UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the Hospital, and UAB's blended component units. Condensed financial information of UAB's reportable

segments is presented at Note 15. Refer to Note 2 for information regarding UAB's component units.

UAB is affiliated with the UAB Educational Foundation ("UABEF"), the University of Alabama Health Services Foundation, P.C. ("HSF"), UAB Health System ("UABHS"), Medical West, Cooper Green Mercy Health Services Authority, and the Valley Foundation ("VF"). UAB is not financially accountable for UABEF, HSF, UABHS or VF; therefore, they do not constitute component units under the provisions of GASB Statement No. 14, *The Financial Reporting Entity*, as amended. These entities are not required to be presented as component units under GASB Statement No. 39, *Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14* and No. 61, *The Financial Reporting Entity – an Amendment of GASB Statement No. 14 and 34*. More information regarding HSF, UABHS and VF can be found at Note 16.

UABEF provides funds and certain facilities to UAB for its educational and scientific functions. UABEF has 13 board members, including seven outside members not affiliated with UAB. UABEF leases certain facilities to UAB, with rental expense of approximately \$2.2 million for the year ended September 30, 2020 and \$2.1 million for the year ended September 30, 2019. UABEF made contributions to UAB which totaled approximately \$4.2 million for the year ended June 30, 2020 and approximately \$4.6 million for the year ended June 30, 2019.

Implementation of new standards: During 2020, UAB adopted GASB Statement No. 89, *Accounting for Interest Cost*, which aims to enhance comparability of capital assets information and simplify accounting for interest cost incurred before the end of a construction period. The impact from its adoption of GASB 89 was not material to the financial statements.

Other significant accounting policies are as follows:

Cash and Cash Equivalents: For purposes of the statement of cash flows, UAB considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents representing assets of UAB's endowment, life income, and other long-term investments are included in noncurrent assets.

Investments: UAB's investments are reported at fair value. The majority of UAB's investment portfolio is invested in separate investment pools sponsored by the System. Fair value for the investment pools is provided by the System, based on the fair value of the underlying investment securities held by each investment pool. Fair value of the underlying securities held in each investment pool is based on quoted market prices or dealer quotes, where available, or determined using net asset values provided by underlying investment partnerships or companies. Fair value for equity securities, debt securities, mutual funds and U.S. government and agency

obligations held by UAB is determined from quoted market prices or market prices of similar instruments. Real estate held as investments is reported at fair value based upon appraisals, acquisition value at the date of donation, and other valuations typically based on management assumptions or expectations. Investments received by gift are reported at fair value at date of receipt. Net investment income, including realized and unrealized gains and losses, is reported as nonoperating revenues (expenses) in the statements of revenues, expenses, and changes in net position.

Investments are reported in four categories in the statement of net position. Investments recorded as endowment and life income investments are those invested funds that cannot be used to fund current operations and thus are included in noncurrent assets. Investments held for future capital projects are included in noncurrent assets. Other long-term investments include amounts resulting from UAB's equity investment in other entities, as discussed in Note 4 and Note 8. All other investments are included as short-term investments.

Inventories: Inventories are carried at the lower of cost or market. Inventories consist primarily of medical supplies and pharmaceuticals.

Accounts Receivable: Accounts receivable consist primarily of patient receivables, tuition charged to students and amounts due from federal, state, and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

Capital Assets: All capital assets are carried at cost on date of acquisition (or in the case of gifts, at acquisition value on the date of donation), less accumulated depreciation (or in the case of assets leased under capital leases, net of accumulated amortization). UAB computes depreciation for buildings and building improvements (15-40 years) and for fixed equipment systems (3-20 years) using a component method. Depreciation of land improvements (40 years), library collection (10 years), and inventoried equipment (3-20 years) is computed on a straight-line basis. The Hospital uses guidelines established by the American Hospital Association to assign useful lives to inventoried equipment.

Capital assets acquired under capital leases are amortized over the shorter of the lives of the respective leases or the estimated useful lives of the assets. Capital assets acquired through federal grants and contracts in which the Federal government retains a reversionary interest are capitalized and depreciated.

Computer software capitalization, which is included as inventoried equipment, includes the costs of software and implementation. Implementation costs include consulting expenses and allocation of internal salaries and fringes for the core implementation team.

Pledges: UAB receives gift pledges and bequests of financial support. Revenue is recognized when a pledge representing an unconditional promise to give is received and all eligibility requirements, including time requirements, have been met. In the absence of such a promise, revenue is recognized when the gift is received. Pledges are recorded at their gross, undiscounted amount. Endowment pledges do not meet eligibility requirements and are not recorded as assets until the related gift is received in accordance with the requirements of GASB Statement No. 33, *Accounting and Financial Reporting for Nonexchange Transactions*. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

Endowment Spending: The State Legislature adopted the Alabama Uniform Prudent Management of Institutional Funds Act ("UPMIFA"), effective January 1, 2009, which permits the Board of Trustees of the University of Alabama (the "Board") to appropriate an amount of realized and unrealized endowment appreciation as the Board determines to be prudent. UPMIFA prescribes guidelines for the expenditure of donor-restricted endowment funds in the absence of overriding, explicit donor stipulations. UPMIFA focuses on the entirety of a donor-restricted endowment fund, that is, both the original gift amount(s) and net appreciation. UPMIFA eliminates UMIFA's historic-dollar-value threshold, an amount below which an organization could not spend from the fund, in favor of a more robust set of guidelines about what constitutes prudent spending, explicitly requiring consideration of the duration and preservation of the fund.

UAB's policy is to retain the endowment realized and unrealized appreciation within an endowment after the spending rate distributions in a manner consistent with the standards of prudence prescribed by UPMIFA. The Board approved a spending rate for fiscal years September 30, 2020 and 2019 of 4.5%, based on a moving five-year average of the market (unit) value.

Prepaid Expenses and Unearned Scholarships: Prepaid expenses are composed of future expenses that have been paid in advance and include prepaid postage, travel, and other miscellaneous expenses. Unearned scholarship expense results from the Fall academic term spanning across the fiscal year-end. UAB prorates scholarship expense to recognize only the amounts incurred in each fiscal year.

Unearned Revenue: Unearned revenue consists primarily of student tuition and fees related predominantly to future fiscal years and amounts received from grant and contract sponsors that have not yet been earned under the terms of the agreements and, therefore, have not yet been included in the net position.

Federal Refundable Loans: Certain loans to students are administered by UAB with funding primarily supported by the federal government. UAB's statements of net position include both the notes receivable and the related federal refundable loan liability representing federal capital contributions and related activity owed upon termination of the program. The Federal Perkins Loan Program expired June 30, 2018. The University will continue operating the program and remit any excess cash annually for the pro rata federal and institutional capital contributions. As of September 30, 2020, \$1.4 million is payable to the Department of Education for its portion of the excess cash available at June 30, 2019.

Compensated Absences: UAB accrues annual leave for employees at rates based upon length of service and job classification. UAB accrues compensatory time based upon job classification and hours worked. These amounts are included in accounts payable and accrued liabilities.

Deferred Outflows of Resources: Deferred outflows of resources consist of bond deferred refunding amounts, pension obligations, and OPEB obligations (Trust and UAB Plan). Pension obligations include employer contributions to the Teachers' Retirement System subsequent to the Plan's measurement date, differences between expected and actual experience, and changes in actuarial and other assumptions. The Trust's obligations include employer contributions to the Alabama Retired Education Employees' Health Care Trust subsequent to the Trust's measurement date, differences between expected and actual experience, and changes in proportion and differences between employer contributions and proportionate share of contributions. The UAB Plan's obligations include employer contributions to the UAB Health Care Plan subsequent to the Plan's measurement date for eligible disabled retirees.

Deferred Inflows of Resources: Deferred inflows of resources are composed of bond deferred refunding amounts, pension obligations, and OPEB obligations (Trust and UAB Plan). Pension obligations include differences between expected and actual experience, changes in proportion and differences between employer contributions and proportionate share of contributions, and net difference between projected and actual earnings on pension plan investments. The Trust's obligations include changes in actuarial and other assumptions and net difference between projected and actual earnings on OPEB plan investments. The UAB Plan's obligations include differences between expected and actual experience and changes in actuarial and other assumptions.

Student Tuition and Fees and Scholarship Allowances and Student Aid: Student tuition and fees are presented net of scholarships and fellowships applied to student accounts, while stipends and other payments made directly to students are presented as scholarships and fellowships expense.

Grant and Contract Revenue: UAB receives grant and contract revenue from governmental and private sources. UAB recognizes revenue associated with the sponsored programs in accordance with GASB Statement No. 33, based on the terms of the individual grant or contract.

Hospital Revenue: Net patient service revenue is reported at the Hospital's estimated net realizable amounts from patients, third-party payors, and others for services rendered, including estimated retroactive revenue adjustments due to revenue audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered.

The Hospital provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its estimated rates. Because the Hospital does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

Auxiliary Enterprise Revenue: Auxiliary enterprise revenues primarily represent revenues generated by intercollegiate athletics and parking as well as subscriber premiums for Triton Health Systems, L.L.C.

Other Revenue: Other revenue represents primarily revenues generated by UAB for activities such as intellectual property income and the University of Alabama Health Services Foundation, P.C. ("HSF") transfers.

Equity Investments: Investments in affiliated companies where UAB can exercise significant influence and for which UAB's ownership interest is 50% or less are accounted for using the equity method. The investment in the Professional Liability Trust Fund ("PLTF") also is accounted for using the equity method. See Notes 4 and 8.

Nonoperating Revenues (Expenses): Nonoperating revenues and expenses include State educational appropriations, federal appropriations, Federal Pell grants, private gifts for other than capital purposes, investment income, net unrealized appreciation or depreciation in the fair value of investments, interest expense, loss on asset dispositions, and for fiscal year 2020 CARES Act funds.

COVID-19 Pandemic: In January 2020, the World Health Organization declared the novel Coronavirus (COVID-19) a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and healthcare organizations. The outbreak has also negatively impacted both the global financial markets and UAB's investments, including the investments held within the System Pools, and may continue to do so. Other adverse consequences of COVID-19 in the future may include, but are not limited to, decline in enrollment, decline in demand for University housing, decline in demand for University programs that

involve travel, and additional volatility within UAB's investments. UAB believes it has sufficient liquidity to meet its operating and financing needs; however, given the difficulty in predicting the ultimate duration and severity of the impact of COVID-19 on UAB, the economy and the financial markets, the ultimate impact is unknown and cannot be reasonably quantified at this time.

The Coronavirus Aid, Relief and Economic Security ("CARES") Act: The CARES Act was signed into law in March 2020 in order to provide economic assistance for businesses and individuals that have been negatively impacted by the COVID-19 pandemic. During 2020, the University received payments primarily from two CARES Act programs, the Higher Education Emergency Relief Fund ("HEERF") and the Coronavirus Relief Fund ("CRF") which are included in nonoperating grants in the accompanying statements of revenues, expenses and changes in net position. The Higher Education Emergency Relief Fund is administered through the U.S. Department of Education and was designed to facilitate the distribution of emergency financial aid grants directly to students, as well as to provide funding for institutions negatively impacted by the COVID-19 pandemic. Under the terms of the student portion of this program, revenue is recognized once eligible expenditures associated with the distribution of aid to students have been incurred. For the institutional portions of this program, revenue is recognized as UAB identifies eligible expenditures or lost revenues which qualify for reimbursement. Revenue recognized from the HEERF totaled \$6.1 million student aid relief and \$5.0 million institutional relief. The Coronavirus Relief Fund is administered through the State of Alabama Department of Finance. The purpose of the Coronavirus Relief Fund appropriation is for the funds to be used to prevent, prepare for, and respond to coronavirus only. The CRF covers only those costs that are necessary expenditures incurred due to the public health emergency with respect to COVID-19. Eligibility to receive payment from the State's portion of funds from the CRF is contingent upon certifying that UAB will: (1) use the funds in a lawful manner consistent with Section 601(d) of the Coronavirus Relief Fund and (2) will comply with any and all policies and directives issued by the Alabama Department of Finance related to the Coronavirus Relief Funds. At September 30, 2020, UAB was awarded \$37.0 million of CRF funds to assist with state testing and exposure notifications, including a \$6.0 million advance payment. At September 30, 2020, UAB had recognized \$5.4 million of revenue for actual expenses incurred.

University Hospital received and recognized \$67.3 million in federal CARES Act provider relief funding through September, 2020 and recognized and recorded a receivable for \$3.2 million in CARES funds allocated from the State of Alabama.

In addition, University Hospital received \$180.2 million in advanced payments from the Centers for Medicare and

Medicaid Services ("CMS") Accelerated and Advanced Payments Program reported as due to third party payors and advances payable, net on the Statements of Net Position. The Medicare advance payment amount is classified as a current liability based on guidance as of September 30, 2020, however guidance issued subsequent to September 30, 2020 provides for the advance payments to be repaid over a period extending beyond 12 months.

(2) Component Unit(s)

GASB Statement No. 14, *The Financial Reporting Entity*, as amended by GASB Statement No. 39, *Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14*, No. 61, *The Financial Reporting Entity – an Amendment of GASB Statement No. 14 and 34* and No. 80, *Blending Requirements for Certain Component Units – an amendment of GASB Statement No. 14*, requires governmental entities to include in their financial statements as a component unit, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable. The primary objective of these statements is to determine whether all entities associated with a primary government are potential component units and should be evaluated for inclusion in the financial reporting entity. The statements as amended provide additional guidance to determine whether certain organizations for which the primary government is not financially accountable should be reported as component units based on the nature and significance of their relationship with the primary government.

The by-laws and corporate charter of the Southern Research Institute (SRI) allow UAB to appoint a majority of the board of directors. Management has determined that SRI is a discretely presented component unit of UAB under GASB Statements No. 14 and No. 61. SRI reports financial results under principles prescribed under the GASB. SRI offers research and technology services to support industry and federal government agencies primarily in the areas of drug design and evaluation, environmental controls, materials engineering, and chemical and biological defense. The activities of SRI are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. The financial results of SRI are discretely presented in these financial statements.

UAB includes five blended component units, as follows: UAB Research Foundation ("UABRF"), UAB Athletics Foundation ("UABAF"), Alabama Care Plan ("ACP"), UAB Hospital Management, L.L.C. ("LLC") and Triton Health Systems, L.L.C. ("Triton"). The by-laws and corporate

charters of UABRF allow UAB to appoint a majority of the board of directors and allow UAB to impose its will on the entity. UABRF operates for the exclusive benefit of UAB. UABAF was organized to support the UAB Athletics Department in its quest for excellence in all programs. UABAF operates as an extension of the UAB Athletics Department and it almost exclusively benefits the University. The by-laws of ACP allow UAB to appoint a majority of the members of the Member Board, as defined, which operates in a consultative capacity with the ACP Board of Directors. The by-laws allow the ACP Member Board certain operational and financial protective rights. Additionally, LLC and Triton have governing bodies that are substantively the same as the governing body of UAB and there is a financial benefit or burden relationship between UAB and these entities. Therefore, management has determined that UABRF, UABAF, ACP, LLC and Triton (the Blended Component Units) constitute blended component units of UAB under GASB Statements No. 14 and No. 61. The Blended Component Units report financial results under principles prescribed under the GASB.

UABRF was organized exclusively for charitable, scientific, and educational purposes in order to benefit UAB. UABAF was formed in November 2015 as a nonprofit corporation organized to build loyalty and philanthropic support for the UAB athletic program and support the staff in coordinating, developing and improving a superior inter-collegiate athletics program. UABAF encourages alumni and friends to generously support the Athletics Department and contribute to scholarship funding for UAB's student athletes. ACP was formed in September 2014 to apply to become certified by the Alabama Medicaid Agency as a probationary regional care organization ("RCO"), with the goal at the time of being eligible to become a fully certified RCO by July 1, 2017. Effective October 17, 2016, ACP resolved to cease its pursuit of full regional care organization certification from the Alabama Medicaid Agency and cease efforts to enter into a risk contract with Medicaid to provide RCO services to Medicaid beneficiaries. On July 27, 2017, the Alabama Medicaid Agency abandoned its development of regional care organizations. The current Alabama Medicaid Health Home program ended on September 30, 2019 and the new Medicaid program Alabama Coordinated Health Network (ACHN), began October 1, 2019. ACP's members are the University Hospital, St. Vincent's Health System and Triton. Effective September 28, 2020, ACP was dissolved. The LLC was organized for the exclusive purpose of supporting UAB in connection with the management, administration, and operation of the University Hospital, including, without limitation, providing management, administrative, and staffing services to the University Hospital. Triton was formed to advance the educational and research mission of UAB and to educate and train physicians and other health care professionals. Triton is owned 99% by UAB and 1% by The UABEF.

UABRF, ACP and LLC maintain a September 30 year-end. UABAF maintains a June 30 year-end. The activities of Triton are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. However, interfund cash transactions during the period

from January 1 through September 30 have been eliminated. Since Triton qualifies as a major component unit under GASB Statement No. 61, financial information for the years ended December 31, 2019 and 2018 is presented on the subsequent page.

TRITON HEALTH SYSTEMS, LLC	2020	2019
CONDENSED STATEMENT OF NET POSITION		
Current assets	\$ 261,535,804	\$ 238,243,098
Capital assets, net	3,946,551	4,242,844
Other assets	107,264,624	115,104,269
TOTAL ASSETS	372,746,979	357,590,211
Current liabilities	100,010,425	101,474,939
Other noncurrent liabilities	899,448	1,169,296
TOTAL LIABILITIES	100,909,873	102,644,235
Net investment in capital assets	3,946,551	4,242,844
Restricted nonexpendable	100,000	100,000
Unrestricted	267,790,555	250,603,132
TOTAL NET POSITION	271,837,106	254,945,976
TOTAL LIABILITIES AND NET POSITION	\$ 372,746,979	\$ 357,590,211
CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION		
Operating revenues	\$ 810,684,944	\$ 760,532,147
Operating expenses	(766,075,475)	(709,709,115)
Depreciation and amortization expense	(1,286,839)	(955,707)
OPERATING INCOME	43,322,630	49,867,325
Investment income	10,566,733	3,426,512
Interest expense	—	(200)
Income tax expense	(2,800,679)	(3,698,885)
INCOME BEFORE OTHER CHANGES IN NET POSITION	51,088,684	49,594,752
Distributions to members	(34,197,554)	(18,694,856)
INCREASE IN NET POSITION	16,891,130	30,899,896
Net position, beginning of year	254,945,976	224,046,080
NET POSITION, END OF YEAR	\$ 271,837,106	\$ 254,945,976
CONDENSED STATEMENT OF CASH FLOWS		
Net cash provided by (used in):		
Operating activities	\$ 833,764	\$ 20,705,580
Noncapital financing activities	(34,197,554)	(18,694,856)
Capital and related financing activities	(990,546)	(2,450,710)
Investing activities	7,670,724	(16,453,527)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(26,683,612)	(16,893,513)
Cash and cash equivalents, beginning of year	171,026,899	187,920,412
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 144,343,287	\$ 171,026,899

(3) Cash and Cash Equivalents

The Board approves, by resolution, all banks or other financial institutions utilized as depositories for UAB funds. Prior to approval, each proposed depository must provide evidence of its designation by the Alabama state treasurer as a qualified public depository under the Security for Alabama Funds Enhancement Act (SAFE). From time to time, the Board may request that the depository provide evidence of its continuing designation as a qualified public depository. In the past, the bank pledged collateral directly to each individual public entity. Under the mandatory SAFE program, each qualified public depository (QPD) is required to hold collateral for all its public deposits on a pooled basis in a custody account established for the State Treasurer as SAFE administrator. In the unlikely event a public entity should suffer a deposit loss due to QPD insolvency or default, a claim form would be filed with the state treasurer, who would use the SAFE pool collateral or other means to reimburse the loss. As of September 30, 2020 and 2019, respectively, UAB had cash and cash equivalents totaling \$705.3 million and \$522.5 million

(4) Investments

The Board has the responsibility for the establishment of the investment policy and the oversight of the investments for the System and related entities. In order to facilitate System-wide investment objectives and achieve economies of scale, the Board previously established three distinct investment pools based primarily on the projected investment time-horizons for System funds: the Pooled Endowment Fund ("PEF"), Long Term Reserve Pool Fund ("LTRP") and the Short Term Liquidity Pool Fund ("STLP"); collectively, the "System Pools". In April 2020, the Board approved a merger of the STLP and the LTRP into one pool, the Liquidity and Capital Reserve Pool ("LCRP"). In July 2020, the Board closed the STLP and transferred the assets to the LTRP to create the new merged pool, with a new asset allocation. Pursuant to Board investment policies, each System or related entity may include all or a portion of their investments within the System sponsored investment pools. These investment funds are considered "internal" investment pools under GASB Statement No. 31, *Accounting and Financial Reporting for Certain Investments and for External Investment Pools* with the assets pooled on a market value basis. Separately managed funds that reside with each entity are to be

invested consistent with the asset mix of the corresponding System investment pool. UAB applies the same investment policies for separately held investments as those of the System Pools.

The following disclosures relate to both the System Pools, which include the investments of other System entities and other affiliated entities, and the UAB-specific investment portfolio.

Pooled Endowment Fund

The purpose of the PEF is to pool endowment and similar funds to support the System universities, Hospital and related entities in carrying out their respective missions over a perpetual time frame. Accordingly, the primary investment objectives of the PEF are to preserve the purchasing power of the principal and provide a stable source of perpetual financial support to the endowment beneficiaries. To satisfy the long-term rate of return objective, the PEF relies on a total return strategy in which investment returns are achieved through both capital appreciation and natural income. Asset allocation targets are established to meet return objectives while providing adequate diversification in order to minimize investment volatility.

Long Term Reserve Pool Fund (effective July 1, 2020, merger with the STLP to form the LCRP)

The LTRP was a longer-term pool used as an investment vehicle to manage operating reserves with a time horizon of three to seven years. This fund had an investment objective of growth and income and was invested in a diversified asset mix of liquid, semi-liquid and illiquid securities. This fund can invest no more than 10% in illiquid assets.

Short Term Liquidity Pool Fund (effective July 1, 2020, merger with the LTRP to form the LCRP)

The STLP served as an investment vehicle to manage operating reserves with a time horizon of one to three years. This fund was also used to balance the other funds when looking at the System's entire asset allocation of operating reserves relative to its investment objectives. The STLP had an investment objective of income with preservation of capital and is invested in intermediate term fixed income securities. The fund held at least one large mutual fund to provide daily liquidity.

Liquidity and Capital Reserve Pool

The LCRP serves as an investment vehicle to manage operating reserves of the System universities, hospital, and related entities with an investment strategy that matches the duration of reserves to their projected needs. The goals of the pool are to preserve and grow capital, maximize returns without undue exposure to risk, and maintain sufficient liquidity for credit ratings. The pool is invested in a diversified asset mix of liquid, semi-liquid, and illiquid securities. The pool can invest no more than 15% in illiquid assets and must invest no less than 60% in liquid assets as defined by Board Rule 404.

Fair Value Measurements

GASB 72 sets forth the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under GASB 72 are described as follows:

- Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that UAB has the ability to access.
- Level 2 – Inputs to the valuation methodology include:
 - Quoted prices for similar assets or liabilities in active markets;
 - Quoted prices for identical or similar assets or liabilities in inactive markets;
 - Inputs other than quoted prices that are observable for the assets or liabilities;
 - Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect UAB's own assumptions about the inputs market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable inputs are developed based on the best information available in the circumstances and may include UAB's own data.

GASB 72 allows for the use of net asset value ("NAV") as a practical expedient for valuation purposes for investment that do not have readily determinable fair value. Investments that use NAV in determining fair value are disclosed separately from the valuation hierarchy as presented herein.

The level within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The determination of what constitutes observable requires judgment by UAB's management. UAB management considers observable data to be that market data which is readily available, regularly distributed or updated, reliable, and verifiable, not proprietary, and provided by multiple independent sources that are actively involved in the relevant market.

The categorization of an investment within the hierarchy is based upon the relative observability of the inputs to its fair value measurement and does not necessarily correspond to UAB management's perceived risk of that investment.

The following is a description of the valuation methods and assumptions used by UAB to estimate the fair value of its investments. There have been no changes in the methods and assumptions used at September 30, 2020. The methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. UAB management believes its valuation methods are appropriate and consistent with other market participants. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

When available, quoted prices are used to determine fair value. When quoted prices in active markets are available, investments are classified within Level 1 of the fair value hierarchy. UAB's Level 1 investments primarily consist of investments in mutual funds, exchange traded funds, and both domestic and foreign equity funds. When quoted prices in active markets are not available, fair values are based on evaluated prices received from UAB's custodian of investments.

UAB's Level 2 investments consist of mutual funds that are priced or traded at the end of the day.

UAB's Level 3 investments primarily consist of very illiquid securities. The inputs or methodologies used for valuing securities are not necessarily an indication of the risks associated with investing in those securities. Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. Valuation techniques utilized by UAB are appraisals, entry price at the date of donation, and other valuations typically based on management assumptions or expectations.

At September 30, 2020 and 2019, the fair value of UAB's investments based on the inputs used to value them is summarized as follows:

	2020				Total
	Level 1	Level 2	Level 3	NAV	
Cash and equivalents:					
Commercial paper	\$ 100,000	\$ —	\$ —	\$ —	\$ 100,000
Equities:					
Common Stock	422,310	—	—	—	422,310
Fixed Income Securities:					
Corporate bonds	—	139,341,911	—	—	139,341,911
Commingled Funds:					
U.S. equity funds	—	1,478,656	—	—	1,478,656
Non-U.S. equity funds	—	15,625	—	—	15,625
Real Estate	—	—	159,600	—	159,600
	\$ 522,310	\$ 140,836,192	\$ 159,600	\$ —	\$ 141,518,102
				Equity investments in partnerships	59,920,845
				UAB Portion of System Pool Investments:	
				Endowment Fund	541,012,824
				Liquidity and Capital Reserve Pool Fund	1,959,862,158
				Total Net Asset Value with System Pooled Investments	\$ 2,702,313,929

	2019				Total
	Level 1	Level 2	Level 3	NAV	
Cash and equivalents:					
Commercial paper	\$ 100,000	\$ —	\$ —	\$ —	\$ 100,000
Equities:					
Common Stock	371,776	—	—	—	371,776
Fixed Income Securities:					
Corporate bonds	—	136,048,332	—	—	136,048,332
Commingled Funds:					
U.S. equity funds	—	1,197,867	—	—	1,197,867
Non-U.S. equity funds	—	278,220	—	—	278,220
Real Estate	—	—	159,600	—	159,600
	\$ 471,776	\$ 137,524,419	\$ 159,600	\$ —	\$ 138,155,795
				Equity investments in partnerships	60,291,989
				UAB Portion of System Pool Investments:	
				Endowment Fund	538,535,105
				Long Term Reserve Pool	1,347,111,275
				Short Term Liquidity Pool	538,920,294
				Total Net Asset Value with System Pooled Investments	\$ 2,623,014,458

At September 30, 2020 and 2019, the fair value of investments for the System Pools based on the inputs used to value them is summarized as follows:

POOLED ENDOWMENT FUND					
	2020				Total
	Level 1	Level 2	Level 3	NAV	
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 588,314
Total Receivables	—	—	—	—	588,314
Cash Equivalents:					
Money Market Funds	42,770,410	—	—	—	42,770,410
Total Cash Equivalents	42,770,410	—	—	—	42,770,410
Equities:					
U.S. Common Stock	114,821,118	—	—	—	114,821,118
Foreign Stock	38,691,556	—	—	—	38,691,556
Total Equities	153,512,674	—	—	—	153,512,674
Fixed Income Securities:					
U.S. Government Obligations	—	6,061,927	—	—	6,061,927
Mortgage Backed Securities	—	13,435,270	—	—	13,435,270
Corporate Bonds	—	19,124,922	—	—	19,124,922
Non-U.S. Bonds	—	3,975,272	—	—	3,975,272
Total Fixed Income Securities	—	42,597,391	—	—	42,597,391
Commingled Funds:					
U.S. Bond Funds	—	212,441,977	—	—	212,441,977
Hedge Funds	—	—	—	508,475,822	508,475,822
Non-U.S. Bond Funds	—	38,073,557	—	—	38,073,557
Private Equity Funds	—	—	2,297,985	256,095,913	258,393,898
Real Estate Funds	—	—	36,566,136	207,118,536	243,684,672
Total Commingled Funds	—	250,515,534	38,864,121	971,690,271	1,261,069,926
Total Fund Investments	196,283,084	293,112,925	38,864,121	971,690,271	1,499,950,401
Total Fund Assets	\$ 196,283,084	\$ 293,112,925	\$ 38,864,121	\$ 971,690,271	\$ 1,500,538,715
Total Fund Liabilities					(337,805)
Affiliated Entity Investments					(237,483,192)
Total Net Asset Value					\$ 1,262,717,718

POOLED ENDOWMENT FUND

	2019				Total
	Level 1	Level 2	Level 3	NAV	
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 794,850
Total Receivables	—	—	—	—	794,850
Cash Equivalents:					
Money Market Funds	45,659,810	—	—	—	45,659,810
Total Cash Equivalents	45,659,810	—	—	—	45,659,810
Equities:					
U.S. Common Stock	74,012,517	—	—	—	74,012,517
U.S. Preferred Stock	190,932	—	—	—	190,932
Foreign Stock	32,734,298	—	—	—	32,734,298
Total Equities	106,937,747	—	—	—	106,937,747
Fixed Income Securities:					
U.S. Government Obligations	—	9,526,821	—	—	9,526,821
Mortgage Backed Securities	—	16,998,880	—	—	16,998,880
Corporate Bonds	—	23,590,299	—	—	23,590,299
Non-U.S. Bonds	—	4,633,620	—	—	4,633,620
Total Fixed Income Securities	—	54,749,620	—	—	54,749,620
Commingled Funds:					
Non-U.S. Equity Funds	—	230,373,319	—	—	230,373,319
U.S. Bond Funds	—	53,608,300	—	—	53,608,300
Hedge Funds	—	—	—	476,844,586	476,844,586
Private Equity Funds	—	—	—	183,800,862	183,800,862
Real Estate Funds	—	—	28,480,271	312,302,228	340,782,499
Total Commingled Funds	—	283,981,619	28,480,271	972,947,676	1,285,409,566
Total Fund Investments	152,597,557	338,731,239	28,480,271	972,947,676	1,492,756,743
Total Fund Assets	\$ 152,597,557	\$ 338,731,239	\$ 28,480,271	\$ 972,947,676	\$ 1,493,551,593
Total Fund Liabilities					(283,955)
Affiliated Entity Investments					(237,774,790)
Total Net Asset Value					\$ 1,255,492,848

LIQUIDITY AND CAPITAL RESERVE POOL FUND

	2020				
	Level 1	Level 2	Level 3	NAV	Total
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 3,681,520
Total Receivables	—	—	—	—	3,681,520
Cash Equivalents:					
Money Market Funds	122,282,756	—	—	—	122,282,756
Total Cash Equivalents	122,282,756	—	—	—	122,282,756
Equities:					
U.S. Common Stock	210,853,767	—	—	—	210,853,767
Foreign Stock	76,692,824	—	—	—	76,692,824
Total Equities	287,546,591	—	—	—	287,546,591
Fixed Income Securities:					
U.S. Government Obligations	—	74,438,886	—	—	74,438,886
Mortgage Backed Securities	—	253,871,960	—	—	253,871,960
Collateralized Mortgage Obligations	—	22,981,714	—	—	22,981,714
Corporate Bonds	—	169,834,304	—	—	169,834,304
Non-U.S. Bonds	—	85,166,218	—	—	85,166,218
Total Fixed Income Securities	—	606,293,082	—	—	606,293,082
Commingled Funds:					
U.S. Equity Funds	—	145,228,505	—	—	145,228,505
Non-U.S. Equity Funds	—	356,462,581	—	—	356,462,581
U.S. Bond Funds	—	306,086,677	—	—	306,086,677
Hedge Funds	—	—	—	916,173,748	916,173,748
Real Asset Funds	—	—	—	131,654,699	131,654,699
Total Commingled Funds	—	807,777,763	—	1,047,828,447	1,855,606,210
Total Fund Investments	409,829,347	1,414,070,845	—	1,047,828,447	2,871,728,639
Total Fund Assets	\$ 409,829,347	\$ 1,414,070,845	\$ —	\$ 1,047,828,447	\$ 2,875,410,159
Total Fund Liabilities					(791,152)
Affiliated Entity Investments					(214,311,956)
Total Net Asset Value					\$ 2,660,307,051

LONG TERM RESERVE POOL FUND

	2019				Total
	Level 1	Level 2	Level 3	NAV	
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 1,432,688
Total Receivables	—	—	—	—	1,432,688
Cash Equivalents:					
Money Market Funds	67,436,949	—	—	—	67,436,949
Total Cash Equivalents	67,436,949	—	—	—	67,436,949
Equities:					
U.S. Common Stock	176,170,860	—	—	—	176,170,860
U.S. Preferred Stock	376,551	—	—	—	376,551
Foreign Stock	60,626,225	—	—	—	60,626,225
Total Equities	237,173,636	—	—	—	237,173,636
Fixed Income Securities:					
U.S. Government Obligations	—	17,123,633	—	—	17,123,633
Mortgage Backed Securities	—	28,505,448	—	—	28,505,448
Corporate Bonds	—	43,571,551	—	—	43,571,551
Non-U.S. Bonds	—	8,045,325	—	—	8,045,325
Total Fixed Income Securities	—	97,245,957	—	—	97,245,957
Commingled Funds:					
U.S. Equity Funds	—	80,732,164	—	—	80,732,164
Non-U.S. Equity Funds	—	443,683,561	—	—	443,683,561
U.S. Bond Funds	—	91,511,322	—	—	91,511,322
Non-U.S. Bond Funds	—	41,238,753	—	—	41,238,753
Hedge Funds	—	—	—	718,659,741	718,659,741
Real Asset Funds	—	—	—	194,011,040	194,011,040
Total Commingled Funds	—	657,165,800	—	912,670,781	1,569,836,581
Total Fund Investments	304,610,585	754,411,757	—	912,670,781	1,971,693,123
Total Fund Assets	\$ 304,610,585	\$ 754,411,757	\$ —	\$ 912,670,781	\$ 1,973,125,811
Total Fund Liabilities					(503,247)
Affiliated Entity Investments					(132,196,336)
Total Net Asset Value					\$ 1,840,426,228

SHORT TERM LIQUIDITY POOL FUND					
	2019			NAV	TOTAL
	Level 1	Level 2	Level 3		
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 3,481,503
Total Receivables	—	—	—	—	3,481,503
Cash Equivalents:					
Money Market Funds	77,781,811	—	—	—	77,781,811
Total Cash Equivalents	77,781,811	—	—	—	77,781,811
Fixed Income Securities:					
U.S. Government Obligations	—	106,695,991	—	—	106,695,991
Mortgage Backed Securities	—	256,770,944	—	—	256,770,944
Collateralized Mortgage Obligations	—	18,530,989	—	—	18,530,989
Corporate Bonds	—	149,581,841	—	—	149,581,841
Non-U.S. Bonds	—	66,304,810	—	—	66,304,810
Total Fixed Income Securities	—	597,884,575	—	—	597,884,575
Commingled Funds:					
U.S. Bond Funds	—	185,315,252	—	—	185,315,252
Total Commingled Funds	—	185,315,252	—	—	185,315,252
Total Fund Investments	77,781,811	783,199,827	—	—	860,981,638
Total Fund Assets	\$ 77,781,811	\$ 783,199,827	\$ —	\$ —	\$ 864,463,141
Total Fund Liabilities					(286,331)
Affiliated Entity Investments					(100,903,160)
Total Net Asset Value					\$ 763,273,650

Additional information on fair values, unfunded commitments, remaining life, and redemption for investments measured at the NAV for the System Pools at September 30, 2020 and 2019 is as follows:

POOLED ENDOWMENT FUND					
	2020		Remaining Life	Redemption Notice Period	Redemption Restrictions
	Fair Value	Unfunded Commitments			
Hedge funds - absolute return, credit, long/short equities	\$ 508,475,822	\$ —	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Private equity - private credit, buyouts, venture, secondary	256,095,913	185,895,557	1-10 years	Partnerships ineligible for redemption	Not redeemable
Real assets - public real estate, natural resources, and infrastructure	44,328,885	—	No limit	Monthly and Quarterly	None
Real assets - private real estate, natural resources, and infrastructure	162,789,651	92,293,798	1-15 years	Partnerships ineligible for redemption	Not redeemable
	\$ 971,690,271	\$ 278,189,355			

POOLED ENDOWMENT FUND					
2019					
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 476,844,586	\$ —	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Private equity - private credit, buyouts, venture, secondary	183,800,862	151,340,710	1-10 years	Partnerships ineligible for redemption	Not redeemable
Real assets - public real estate, natural resources, and infrastructure	147,852,025	—	No limit	Monthly and Quarterly	None
Real assets - private real estate, natural resources, and infrastructure	164,450,203	99,981,416	1-15 years	Partnerships ineligible for redemption	Not redeemable
	<u>\$ 972,947,676</u>	<u>\$ 251,322,126</u>			

LIQUIDITY AND CAPITAL RESERVE FUND					
2020					
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 916,173,748	\$ —	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Real assets - public real estate, natural resources, and infrastructure	131,654,699	—	No limit	Monthly and Quarterly	None
	<u>\$ 1,047,828,447</u>	<u>\$ —</u>			

LONG TERM RESERVE POOL FUND					
2019					
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 718,659,741	\$ —	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Real assets - public real estate, natural resources, and infrastructure	194,011,040	—	No limit	Monthly and Quarterly	None
	<u>\$ 912,670,781</u>	<u>\$ —</u>			

Investment Risk Factors

There are many factors that can affect the value of investments. Some, such as custodial credit risk, concentration of credit risk and foreign currency risk, may affect both equity and fixed income securities. Equity securities respond to such factors as economic conditions, individual company earnings performance and market liquidity, while fixed income securities are particularly sensitive to credit risks and changes in interest rates.

Credit Risk

Fixed income securities are subject to credit risk, which is the chance that a bond issuer will fail to pay interest or principal in a timely manner, or that negative perceptions of the issuer's ability to make these payments will cause security prices to decline. These circumstances may arise due to a variety of factors such as financial weakness, bankruptcy, litigation, and/or adverse political developments. Certain fixed income securities, primarily

obligations of the U.S. government or those explicitly guaranteed by the U.S. government, are not considered to have significant credit risk.

The investment policy recognizes that credit risk is appropriate in balanced investment pools such as the PEF and LCRP, and the credit quality of underlying fund investments is monitored on an ongoing basis. Fixed income investments within the PEF and LCRP include corporate, mortgage backed, asset backed, collateralized mortgage and U.S. treasury and/or agency bonds. In addition, approximately \$202.6 million and \$39.4 million in the PEF and LTRP (2019)/LCRP (2020), collectively, at September 30, 2020 and 2019, respectively, is invested in unrated fixed income securities, excluding fixed income commingled funds. Fixed income commingled funds and money market funds were approximately \$509.2 million and \$299.5 million in the PEF and LTRP (2019)/LCRP (2020), collectively, at September 30, 2020 and 2019, respectively.

The STLP fixed income investments included corporate, mortgage backed, asset backed, collateralized mortgage and U.S. treasury and/or agency bonds. For September 30, 2019, approximately \$173.2 million was invested by the STLP in unrated fixed income securities, excluding commingled bond funds, and money market

funds. Fixed income commingled funds totaled approximately \$263.1 million at September 30, 2019.

The credit risk for fixed and variable income securities, for the System Pools, at September 30, 2020 and 2019 is as follows:

	POOLED ENDOWMENT FUND		LCRP FUND		LRTP FUND		STLP FUND	
	2020	2019	2020	2019	2019	2019	2019	
Fixed or Variable Income Securities								
U.S. Government Obligations	\$ 6,061,927	\$ 9,526,821	\$ 74,438,886	\$ 17,123,633	\$ 106,695,991			
Other U.S. Denominated:								
AAA	1,759,641	1,445,545	68,457,473	2,399,062	82,360,918			
AA	2,522,307	4,937,086	36,093,014	8,500,014	49,502,664			
A	6,820,070	8,922,674	113,181,471	16,639,285	87,465,527			
BBB	9,988,712	10,537,413	110,647,518	19,983,283	91,050,594			
BB	4,393,666	4,105,601	11,683,200	6,954,906	6,106,262			
B	—	595,375	150,423	963,425	1,140,474			
C and < C	—	—	46,695	—	343,702			
Unrated	11,051,069	14,679,105	191,594,402	24,682,349	173,218,443			
Commingled Funds:								
U.S. Bond Funds: Unrated	38,073,557	53,608,300	306,086,677	91,511,322	185,315,252			
Non-U.S. Bond Funds: Unrated	—	—	—	41,238,753	—			
Money Market Funds: Unrated	42,770,410	45,659,810	122,282,756	67,436,949	77,781,811			
TOTAL	\$ 123,441,359	\$ 154,017,730	\$ 1,034,662,515	\$ 297,432,981	\$ 860,981,638			

In accordance with the Board policy disclosed previously, credit risk for UAB's fixed and variable income securities held outside of the System Pools is managed by diversifying across issuers and limiting the amount of portfolio assets that are invested in non-investment grade securities.

The credit risk for fixed and variable income securities of UAB's separately held investments at September 30, 2020 and 2019 is as follows:

	2020	2019
Fixed or Variable Income Securities		
U.S. Government Guaranteed	\$ —	\$ —
Other U.S. and Non U.S. Denominated:		
AAA	139,341,911	136,048,332
AA	—	—
A	—	—
BBB	—	—
BB	—	—
B	—	—
CCC	—	—
CC	—	—
Unrated	—	—
Commingled Funds:		
U.S. Bond Funds: Unrated	—	—
Non-U.S. Bond Funds: Unrated	—	—
Money Market Funds: Unrated	—	—
Commercial Paper: Unrated	100,000	100,000
TOTAL	\$ 139,441,911	\$ 136,148,332

Custodial Credit Risk

Custodial credit risk is the risk that in the event of the corporate failure of the custodian, the investment securities may not be returned.

Investment securities in the System Pools and UAB's separately held investments are registered in the Board's name by the custodial bank as an agent for the System. Other types of investments (e.g. open-ended mutual funds, money market funds) represent ownership interests that do not exist in physical or book-entry form. As a result, custodial credit risk is remote.

Concentration of Credit Risk

Concentration of credit risk is the risk associated with a lack of diversification, such as having substantial investments in a few individual issuers, thereby exposing the organization to greater risks resulting from adverse economic, political, regulatory, geographic, or credit developments.

As previously mentioned, credit risk in each investment pool and UAB's separately held portfolio is managed primarily by diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities.

As of September 30, 2020 and 2019, there was no investment in a single issuer that represents 5% or more of total investments held by any single investment manager of the System Pools or UAB's separately held investment portfolio except for investments issued by the U.S. government and money market fund investments.

Interest Rate Risk

Interest rate risk is the risk that the value of fixed income securities will decline because of changing interest rates. The prices of fixed income securities with a longer time to maturity, measured by effective duration, tend to be more sensitive to changes in interest rates and, therefore, more volatile than those with shorter durations. Effective duration is the approximate change in price of a security resulting from a 100 basis point (1 percentage point) change in the level of interest rates. It is not a measure of time.

The Board does not have a specific policy relative to interest rate risk. As such, there are no restrictions on weighted average maturity for each investment pool as they are managed relative to the investment objectives and liquidity demands of the investors.

The effective durations in years for fixed or variable income securities, for the System Pools at September 30, 2020 and 2019 are as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	LRTP FUND	STLP FUND
	2020	2019	2020	2019	2019
U.S. Government Obligations	11.9	9.2	3.4	9.2	2.1
Corporate Bonds	7.3	6.3	3.0	6.3	1.8
Non-US Bonds	7.3	6.3	3.0	6.3	1.8
Commingled Bond Funds	3.3	3.6	2.9	2.0	2.7

Investments may also include mortgage pass through securities and collateralized mortgage obligations that may be considered to be highly sensitive to changes in interest rates due to the existence of prepayment or conversion features.

At September 30, 2020 and 2019, the fair market values of these investments in the System Pools are as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	LRTP FUND	STLP FUND
	2020	2019	2020	2019	2019
Mortgage Backed Securities	\$ 13,435,270	\$ 16,998,880	\$ 253,871,960	\$ 28,505,448	\$ 256,770,944
Collateralized Mortgage Obligations	—	—	22,981,714	—	18,530,989
TOTAL FIXED	\$ 13,435,270	\$ 16,998,880	\$ 276,853,674	\$ 28,505,448	\$ 275,301,933

Mortgage Backed Securities. These securities are issued by the Federal National Mortgage Association ("Fannie Mae"), Government National Mortgage Association ("Ginnie Mae") and Federal Home Loan Mortgage Association ("Freddie Mac") and include short embedded prepayment options. Unanticipated prepayments by the

obligees of the underlying asset reduce the total expected rate of return.

Collateralized Mortgage Obligations. Collateralized mortgage obligations ("CMOs") generate a return based upon either the payment of interest or principal on mortgages in an underlying pool. The relationship between interest rates and prepayments makes the fair

value highly sensitive to changes in interest rates. In falling interest rate environments, the underlying mortgages are subject to a higher propensity of prepayments. In a rising interest rate environment, the opposite is true.

At September 30, 2020 and 2019, the effective durations for these securities held in the System Pools are as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	L RTP FUND	STLP FUND
	2020	2019	2019	2019	2019
Mortgage Backed Securities	2.9	3.6	2.0	3.7	1.5
Collateralized Mortgage	—	—	2.6	—	1.7

There are no mortgage backed securities or CMOs in UAB's separately held investments at September 30, 2020 and 2019.

Foreign Currency Risk

The strategic asset allocation policy for the PEF, the LCRP, and UAB's separately held investments includes an allocation to non-United States equity and fixed income securities. Currency hedging of foreign bonds and stocks is allowed under System policy. As of September 30, 2020 and 2019, all foreign investments in the System Pools and UAB's separately held investments are denominated in U.S. dollars and are in international commingled funds, which in turn invest in equity securities and bonds of foreign issuers except for foreign stock and non-U.S. bond funds denominated in U.S. dollars and held by each of the three pools as disclosed in previous tables.

Securities Lending

The System permits security lending as a mechanism to augment income. Loans of the securities are required to be collateralized by cash, letters of credit or securities issued or guaranteed by the U.S. Government or its agencies. The collateral must equal at least 102% of the current market value of the loaned securities. Securities lending contracts must state acceptable collateral for securities loaned, duties of the borrower, delivery of loaned securities and acceptable investment of the collateral. At September 30, 2020 and 2019, there were no securities on loan from the investment pools.

Joint Ventures

UAB accounts for its ownership of the PLTF as a joint venture, using the equity method in the amount of approximately \$59.9 million and \$60.3 million at September 30, 2020 and 2019, respectively. See Note 8 for further discussion of the PLTF.

(5) Receivables

Account receivable:

Accounts receivable consist of patient receivables, tuition charged to students and amounts due from federal, state and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

The composition of accounts receivable at September 30, 2020 and 2019 is summarized as follows:

	2020	2019
Patient care	\$ 473,302,106	\$ 397,838,014
Receivables from sponsoring agencies	89,713,630	84,934,092
Student accounts	56,979,455	64,237,628
Other	123,950,135	95,222,427
Total accounts receivable	\$ 743,945,326	\$ 642,232,161
Less: Allowances for doubtful accounts from patient care	172,792,838	153,011,998
Less: Allowances for doubtful accounts from student accounts	2,819,990	4,427,039
Less: Allowances for doubtful accounts, other	2,951,480	3,065,139
ACCOUNTS RECEIVABLE, NET	\$ 565,381,018	\$ 481,727,985

Loans receivable:

Loans receivable represent all amounts owed on promissory notes from debtors, including student loans made under the Federal Perkins Loan Program and other loan programs. The principal repayment and interest rate terms of federal and university loans vary considerably. The allowance for doubtful accounts only applies to University-funded notes and the University portion of federal student loans, since the University is not obligated to fund the federal portion of uncollected student loans. Federal loan programs are funded principally with federal advances to UAB under the Perkins and various health professions loan programs.

The composition of loans receivable at September 30, 2020 and 2019 is summarized in the table as follows:

	2020	2019
Federal loan program	12,307,521	13,928,150
University loan funds	2,306,822	2,348,143
Other	139,751	317,153
Total loans receivable	\$ 14,754,094	\$ 16,593,446
Less allowance for doubtful accounts	4,412,373	3,339,984
Total loans receivable, net	\$ 10,341,721	\$ 13,253,462
Less: current portion	1,994,471	2,272,848
TOTAL LOANS RECEIVABLE OUTSTANDING, NONCURRENT	\$ 8,347,250	\$ 10,980,614

Pledges receivable:

Pledges receivable represent unconditional promises to give from third party donors. Pledges for permanent endowments do not meet eligibility requirements, as defined by GASB Statement No. 33, until the related gift is received. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

The composition of pledges receivable at September 30, 2020 and 2019 is summarized in the following table.

	2020	2019
Operations	\$ 29,874,012	\$ 52,842,041
Capital	10,266,972	11,004,675
Total gift pledges	\$ 40,140,984	\$ 63,846,716
Less: current portion	10,732,083	18,436,977
TOTAL GIFT PLEDGES, NONCURRENT	\$ 29,408,901	\$ 45,409,739

(6) Capital Assets

Capital assets as of September 30, 2020 and 2019 are summarized as follows:

	BEGINNING BALANCE	ADDITIONS	SALES/ RETIREMENTS/ TRANSFERS	ENDING BALANCE
	October 1, 2019			September 30, 2020
UNIVERSITY AND BLENDED COMPONENT UNITS				
Capital assets not being depreciated				
Land	\$ 86,066,970	\$ 1,048,200	\$ (40,000)	\$ 87,075,170
Construction in progress	52,312,275	25,490,404	(47,475,578)	30,327,101
	138,379,245	26,538,604	(47,515,578)	117,402,271
Capital assets being depreciated				
Land Improvements	52,732,629	8,849,962	—	61,582,591
Buildings	1,694,240,428	111,536,098	(2,849,547)	1,802,926,979
Fixed Equipment Systems	88,599,723	799,254	—	89,398,977
Equipment	384,302,938	17,248,606	(7,577,185)	393,974,359
Library Materials	126,377,432	7,126,420	—	133,503,852
	2,346,253,150	145,560,340	(10,426,732)	2,481,386,758
Total Capital Assets	2,484,632,395	172,098,944	(57,942,310)	2,598,789,029
Less: Accumulated Depreciation	1,356,183,436	78,035,445	(8,502,169)	1,425,716,710
Total Net Capital Assets	\$ 1,128,448,959	\$ 94,063,499	\$ (49,440,141)	\$ 1,173,072,319
HOSPITAL				
Capital assets not being depreciated				
Land	\$ 20,813,545	\$ —	\$ —	\$ 20,813,545
Construction in progress	19,849,958	8,050,915	(13,729,910)	14,170,963
	40,663,503	8,050,915	(13,729,910)	34,984,508
Capital assets being depreciated				
Land Improvements	656,874	—	—	656,874
Buildings	953,749,732	29,042,588	—	982,792,320
Fixed Equipment Systems	10,217,842	—	—	10,217,842
Equipment	529,229,236	66,364,704	(19,581,787)	576,012,153
	1,493,853,684	95,407,292	(19,581,787)	1,569,679,189
Total Capital Assets	1,534,517,187	103,458,207	(33,311,697)	1,604,663,697
Less: Accumulated Depreciation	939,938,988	72,958,684	(19,392,069)	993,505,603
Total Net Capital Assets	\$ 594,578,199	\$ 30,499,523	\$ (13,919,628)	\$ 611,158,094
TOTAL UAB				
Capital assets not being depreciated				
Land	\$ 106,880,515	\$ 1,048,200	\$ (40,000)	\$ 107,888,715
Construction in progress	72,162,233	33,541,319	(61,205,488)	44,498,064
	179,042,748	34,589,519	(61,245,488)	152,386,779
Capital assets being depreciated				
Land Improvements	53,389,503	8,849,962	—	62,239,465
Buildings	2,647,990,160	140,578,686	(2,849,547)	2,785,719,299
Fixed Equipment Systems	98,817,565	799,254	—	99,616,819
Equipment	913,532,174	83,613,310	(27,158,972)	969,986,512
Library Materials	126,377,432	7,126,420	—	133,503,852
	3,840,106,834	240,967,632	(30,008,519)	4,051,065,947
Total Capital Assets	4,019,149,582	275,557,151	(91,254,007)	4,203,452,726
Less: Accumulated Depreciation	2,296,122,424	150,994,129	(27,894,238)	2,419,222,315
TOTAL NET CAPITAL ASSETS	\$ 1,723,027,158	\$ 124,563,022	\$ (63,359,769)	\$ 1,784,230,411

	BEGINNING BALANCE	ADDITIONS	SALES/ RETIREMENTS/ TRANSFERS	ENDING BALANCE
	October 1, 2018			September 30, 2019
UNIVERSITY AND BLENDED COMPONENT UNITS				
Capital assets not being depreciated				
Land	\$ 85,662,783	\$ 404,187	\$ —	\$ 86,066,970
Construction in progress	59,110,295	42,263,313	(49,061,333)	52,312,275
	144,773,078	42,667,500	(49,061,333)	138,379,245
Capital assets being depreciated				
Land Improvements	42,895,811	9,836,818	—	52,732,629
Buildings	1,602,407,782	108,657,687	(16,825,041)	1,694,240,428
Fixed Equipment Systems	88,052,934	546,789	—	88,599,723
Equipment	373,701,621	20,366,246	(9,764,929)	384,302,938
Library Materials	119,960,486	6,416,946	—	126,377,432
	2,227,018,634	145,824,486	(26,589,970)	2,346,253,150
Total Capital Assets	2,371,791,712	188,491,986	(75,651,303)	2,484,632,395
Less: Accumulated Depreciation	1,303,919,327	76,202,181	(23,938,072)	1,356,183,436
Total Net Capital Assets	\$ 1,067,872,385	\$ 112,289,805	\$ (51,713,231)	\$ 1,128,448,959
HOSPITAL				
Capital assets not being depreciated				
Land	\$ 20,813,545	\$ —	\$ —	\$ 20,813,545
Construction in progress	15,341,646	16,866,103	(12,357,791)	19,849,958
	36,155,191	16,866,103	(12,357,791)	40,663,503
Capital assets being depreciated				
Land Improvements	656,874	—	—	656,874
Buildings	929,151,630	24,598,102	—	953,749,732
Fixed Equipment Systems	10,217,842	—	—	10,217,842
Equipment	482,842,594	58,468,886	(12,082,244)	529,229,236
	1,422,868,940	83,066,988	(12,082,244)	1,493,853,684
Total Capital Assets	1,459,024,131	99,933,091	(24,440,035)	1,534,517,187
Less: Accumulated Depreciation	879,335,745	72,137,318	(11,534,075)	939,938,988
Total Net Capital Assets	\$ 579,688,386	\$ 27,795,773	\$ (12,905,960)	\$ 594,578,199
TOTAL UAB				
Capital assets not being depreciated				
Land	\$ 106,476,328	\$ 404,187	\$ —	\$ 106,880,515
Construction in progress	74,451,941	59,129,416	(61,419,124)	72,162,233
	180,928,269	59,533,603	(61,419,124)	179,042,748
Capital assets being depreciated				
Land Improvements	43,552,685	9,836,818	—	53,389,503
Buildings	2,531,559,412	133,255,789	(16,825,041)	2,647,990,160
Fixed Equipment Systems	98,270,776	546,789	—	98,817,565
Equipment	856,544,215	78,835,132	(21,847,173)	913,532,174
Library Materials	119,960,486	6,416,946	—	126,377,432
	3,649,887,574	228,891,474	(38,672,214)	3,840,106,834
Total Capital Assets	3,830,815,843	288,425,077	(100,091,338)	4,019,149,582
Less: Accumulated Depreciation	2,183,255,072	148,339,499	(35,472,147)	2,296,122,424
TOTAL NET CAPITAL ASSETS	\$ 1,647,560,771	\$ 140,085,578	\$ (64,619,191)	\$ 1,723,027,158

(7) Long-Term Debt

During fiscal year 2020, Standard & Poor's Ratings Services reaffirmed its AA rating on UAB's general revenue bonds. The outlook is stable. Long-term debt activity for the years ended September 30, 2020 and 2019 is summarized as follows:

	BEGINNING BALANCE	NEW DEBT	PRINCIPAL REPAYMENT	ENDING BALANCE	CURRENT PORTION
	October 1, 2019			September 30, 2020	
UNIVERSITY					
Direct Borrowings and Direct Placement Other					
Leases Payable, 3.19% due annually through 2020 and 4.47% due monthly through 2021	\$ 345,339	\$ 109,947	\$ 160,953	\$ 294,333	\$ 97,295
General Receipts Bonds					
Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually through 2021	6,620,000	—	3,230,000	3,390,000	3,390,000
Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2025	44,715,000	—	34,635,000	10,080,000	1,895,000
Birmingham General Revenue Bonds Series 2010B, 1.0% to 5.8% due annually through 2020	45,040,000	—	45,040,000	—	—
Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2025	10,645,000	—	3,495,000	7,150,000	1,645,000
Birmingham General Revenue Bonds Series 2013A-1, 1.1% due annually through 2021	6,525,000	—	3,245,000	3,280,000	3,280,000
Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044	72,595,000	—	—	72,595,000	—
Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2030	30,380,000	—	3,135,000	27,245,000	3,205,000
Birmingham General Revenue Bonds Series 2013C, 1.0% to 1.45% due annually through 2020	525,000	—	525,000	—	—
Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2024	11,655,000	—	2,240,000	9,415,000	2,285,000
Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044	78,325,000	—	—	78,325,000	—
Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028	24,485,000	—	2,730,000	21,755,000	2,865,000
Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027	24,495,000	—	—	24,495,000	3,300,000
Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044	95,585,000	—	—	95,585,000	—
Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2022 through 2030	24,775,000	—	—	24,775,000	—
Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2031 through 2049	145,940,000	—	—	145,940,000	—
Birmingham General Revenue Bonds Series 2019C, 3.0% to 5.0% due annually from 2021 through 2041	—	39,820,000	—	39,820,000	1,325,000
Birmingham General Revenue Bonds Series 2019D, 2.15% to 4.0% due annually from 2021 through 2041	—	35,725,000	—	35,725,000	195,000
	\$ 622,650,339	\$ 75,654,947	\$ 98,435,953	\$ 599,869,333	\$ 23,482,295
Less (Plus): unamortized bond discount (premium)				(25,215,240)	—
TOTAL UNIVERSITY DEBT				\$ 625,084,573	\$ 23,482,295
HOSPITAL					
Direct Borrowings and Direct Placement Other					
Lease Payable, 2.0% to 3.75% due monthly through 2020	\$ 4,564,178	\$ —	\$ 1,590,544	\$ 2,973,634	\$ 1,512,694
Note payable UAB Health System, 3.0% to 5.0% due annually through 2048	76,861,182	—	1,106,762	75,754,420	1,149,682
General Receipts Bonds					
Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027	11,989,000	—	1,363,000	10,626,000	1,400,000
UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022	33,620,000	—	11,075,000	22,545,000	11,205,000
UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041	302,530,000	—	—	302,530,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027	18,385,000	—	—	18,385,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042	44,810,000	—	—	44,810,000	—
	\$ 492,759,360	\$ —	\$ 15,135,306	\$ 477,624,054	\$ 15,267,376
Less (Plus): unamortized bond discount (premium)				(23,227,743)	—
TOTAL HOSPITAL DEBT				\$ 500,851,797	\$ 15,267,376
TOTAL UAB	\$ 1,115,409,699	\$ 75,654,947	\$ 113,571,259	\$ 1,077,493,387	\$ 38,749,671
Less (Plus): unamortized bond discount (premium)				(48,442,983)	—
TOTAL UAB DEBT				\$ 1,125,936,370	\$ 38,749,671

	BEGINNING BALANCE	NEW DEBT	PRINCIPAL REPAYMENT	ENDING BALANCE	CURRENT PORTION
	October 1, 2018			September 30, 2019	
UNIVERSITY					
Direct Borrowings and Direct Placement Other					
Leases Payable, 3.19% due annually through 2019 and 4.47% due monthly through 2020	\$ 434,443	\$ 341,253	\$ 430,357	\$ 345,339	\$ 135,538
General Receipts Bonds					
Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually through 2021	9,710,000	—	3,090,000	6,620,000	3,230,000
Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2025	46,430,000	—	1,715,000	44,715,000	1,800,000
Birmingham General Revenue Bonds Series 2010B, 1.0% to 5.8% due annually through 2020	46,590,000	—	1,550,000	45,040,000	1,605,000
Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2025	12,165,000	—	1,520,000	10,645,000	1,600,000
Birmingham General Revenue Bonds Series 2013A-1, 11.1% due annually through 2021	9,730,000	—	3,205,000	6,525,000	3,245,000
Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044	72,595,000	—	—	72,595,000	—
Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2030	33,465,000	—	3,085,000	30,380,000	3,135,000
Birmingham General Revenue Bonds Series 2013C, 1.0% to 1.45% due annually through 2020	1,030,000	—	505,000	525,000	525,000
Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2024	13,855,000	—	2,200,000	11,655,000	2,240,000
Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044	78,325,000	—	—	78,325,000	—
Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028	27,090,000	—	2,605,000	24,485,000	2,730,000
Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027	24,495,000	—	—	24,495,000	—
Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044	95,585,000	—	—	95,585,000	—
Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2022 through 2030	—	24,775,000	—	24,775,000	—
Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2031 through 2049	—	145,940,000	—	145,940,000	—
	\$ 471,499,443	\$ 171,056,253	\$ 19,905,357	\$ 622,650,339	\$ 20,245,538
Less (Plus): unamortized bond discount (premium)				(22,534,845)	—
TOTAL UNIVERSITY DEBT				\$ 645,185,184	\$ 20,245,538
HOSPITAL					
Direct Borrowings and Direct Placement Other					
Lease Payable, 2.0% to 3.75% due monthly through 2020	\$ 7,556,927	\$ —	\$ 2,992,749	\$ 4,564,178	\$ 1,590,450
Note payable UAB Health System, 3.0% to 5.0% due annually through 2048	—	77,000,000	138,818	76,861,182	1,106,761
General Receipts Bonds					
Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027	13,316,000	—	1,327,000	11,989,000	1,363,000
UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022	44,565,000	—	10,945,000	33,620,000	11,075,000
UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041	302,530,000	—	—	302,530,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027	18,385,000	—	—	18,385,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042	44,810,000	—	—	44,810,000	—
	\$ 431,162,927	\$ 77,000,000	\$ 15,403,567	\$ 492,759,360	\$ 15,135,211
Less (Plus): unamortized bond discount (premium)				(24,526,900)	—
TOTAL HOSPITAL DEBT				\$ 517,286,260	\$ 15,135,211
TOTAL UAB	\$ 902,662,370	\$ 248,056,253	\$ 35,308,924	\$ 1,115,409,699	\$ 35,380,749
Less (Plus): unamortized bond discount (premium)				(47,061,745)	—
TOTAL UAB DEBT				\$ 1,162,471,444	\$ 35,380,749

Maturities and interest on Direct Borrowings and Direct Placement Other and General Receipts Bonds for the next five years and in subsequent five-year incremental periods are presented in the table below:

Direct Borrowings and Direct Placement Other

Year	UNIVERSITY			HOSPITAL			TOTAL		
	Principal	Interest	Total	Principal	Interest	Total	Principal	Interest	Total
2021	\$ 97,295	\$ 20,288	\$ 117,580	\$ 2,662,386	\$ 2,405,186	\$ 5,067,572	\$ 2,759,681	\$ 2,425,474	\$ 5,185,155
2022	101,799	14,226	116,025	2,577,944	2,344,524	4,922,468	2,679,743	2,358,750	5,038,493
2023	71,980	6,421	78,401	1,263,339	2,300,077	3,563,416	1,335,319	2,306,498	3,641,817
2024	23,262	1,430	24,692	1,244,791	2,274,672	3,519,463	1,268,053	2,276,102	3,544,155
2025	—	—	—	1,335,536	2,248,131	3,583,667	1,335,536	2,248,131	3,583,667
2026-2030	—	—	—	11,066,628	10,661,010	21,727,638	11,066,628	10,661,010	21,727,638
2031-2035	—	—	—	12,999,010	9,161,442	22,160,452	12,999,010	9,161,442	22,160,452
2036-2040	—	—	—	15,184,870	6,975,489	22,160,359	15,184,870	6,975,489	22,160,359
2041-2045	—	—	—	17,992,503	4,171,170	22,163,673	17,992,503	4,171,170	22,163,673
2046-2050	—	—	—	12,401,047	897,889	13,298,936	12,401,047	897,889	13,298,936
TOTAL	\$ 294,336	\$ 42,365	\$ 336,698	\$ 78,728,054	\$ 43,439,590	\$ 122,167,644	\$ 79,022,390	\$ 43,481,955	\$ 122,504,345

General Receipts Bonds

Year	UNIVERSITY			HOSPITAL			TOTAL		
	Principal	Interest	Total	Principal	Interest	Total	Principal	Interest	Total
2021	\$ 23,385,000	\$ 21,963,314	\$ 45,348,314	\$ 12,605,000	\$ 15,967,753	\$ 28,572,753	\$ 35,990,000	\$ 37,931,067	\$ 73,921,067
2022	21,690,000	21,259,481	42,949,481	12,777,000	15,796,814	28,573,814	34,467,000	37,056,295	71,523,295
2023	22,575,000	20,504,443	43,079,443	10,276,000	15,623,290	25,899,290	32,851,000	36,127,733	68,978,733
2024	22,460,000	19,750,277	42,210,277	10,711,000	15,145,280	25,856,280	33,171,000	34,895,557	68,066,557
2025	23,565,000	19,013,850	42,578,850	11,347,000	14,636,515	25,983,515	34,912,000	33,650,365	68,562,365
2026-2030	114,070,000	83,006,144	197,076,144	75,685,000	66,911,555	142,596,555	189,755,000	149,917,699	339,672,699
2031-2035	108,745,000	61,129,303	169,874,303	98,050,000	48,058,277	146,108,277	206,795,000	109,187,580	315,982,580
2036-2040	114,235,000	38,394,440	152,629,440	124,815,000	24,722,000	149,537,000	239,050,000	63,116,440	302,166,440
2041-2045	102,435,000	16,690,446	119,125,446	42,630,000	2,259,038	44,889,038	145,065,000	18,949,484	164,014,484
2046-2050	46,415,000	2,996,719	49,411,719	—	—	—	46,415,000	2,996,719	49,411,719
TOTAL	\$ 599,575,000	\$ 304,708,417	\$ 904,283,417	\$ 398,896,000	\$ 219,120,522	\$ 618,016,522	\$ 998,471,000	\$ 523,828,939	\$ 1,522,299,939

Pledged revenues for 2020 and 2019, as defined by the Series 2012A Hospital Revenue Trust Indenture, are as follows:

HOSPITAL BONDS	2020	2019
Total pledged revenues	\$ 2,147,652,347	\$ 2,046,900,133

Pledged revenues for 2020 and 2019, as defined by the Series 2005A, 2010A, 2010B, 2010C, 2013A, 2013B, 2013C, 2013D, 2015A, 2016A, 2016B, 2019A and 2019B General Revenue Trust Indentures, are as follows:

UNIVERSITY BONDS	2020	2019
Tuition fees	\$ 330,385,766	\$ 320,141,055
Indirect cost recovery	100,590,292	99,408,108
Sales and service of educational activities	59,351,275	67,616,490
Auxiliary sales and service	40,269,522	46,959,821
Endowment and investment income	36,426,430	47,116,443
Other sources	46,928,047	69,676,133
TOTAL PLEDGED REVENUES	\$ 613,951,332	\$ 650,918,050

The University defeased certain indebtedness during fiscal year 2020 with the 2019 Series C and D bond issuance. For this defeasance, funds were deposited in escrow trust accounts sufficient to provide for the subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, funds deposited in the trust accounts were invested in

obligations of the U.S. Government. The University estimates that the amounts on deposit will be sufficient to satisfy the debt service requirements on the defeased indebtedness and that the defeasance will result in lower overall debt service payments to the University. Should the amounts on deposit not be sufficient to retire the defeased indebtedness upon maturity, the University

would be responsible to satisfy the shortfall. The University remains legally obligated for the repayment of the defeased indebtedness. Neither the assets of the trust accounts nor the defeased indebtedness are included in the accompanying statements of net position. The principal outstanding on the 2019 defeased indebtedness at September 30, 2020 is approximately \$75.5 million.

The undiscounted cash flows required to service principal and interest under the old bonds as of September 30, 2020, would have been \$115.7 million compared to undiscounted cash flow requirements of \$105.1 million under the new bonds. The economic gain to the University of the bond refinancing in fiscal year 2020 was calculated to be approximately \$8.3 million using an effective interest rate of approximately 2.4% applied to the old and new bond cash flow requirements.

In November 2019, the University issued \$39.8 million and \$35.7 million in Series 2019C and Series 2019D General Revenue Bonds, respectively. The bonds pay interest at varying rates of 3.0% to 5.0% and 2.15% to 4.0%, respectively, with principal due annually through October 1, 2041. The proceeds of these offering are being used for the purposes of advance refunding Series 2010A, 2010B, and 2010C General Revenue Bonds; and paying costs and expenses associated with this issue. These bonds were issued at a premium of \$5.8 million resulting in total proceeds of \$81.4 million.

In June 2019, the University issued \$24.8 million in Series 2019A General Revenue Bonds. The bonds pay interest at a rate of 4.00% with principal due annually through October 1, 2029. In June 2019, the University issued \$145.9 million in Series 2019B General Revenue Bonds, \$75.1 million of which was in the form of Serial Bonds and \$71.9 million of which was in the form of Term Bonds. The bonds pay interest at varying rates of 3.0% to 5.0% with principal due annually through October 1, 2041 and October 1, 2048, respectively. The proceeds of both the Series 2019A and 2019B bonds will be used for the purposes of financing a portion of the cost of certain capital improvements to the UAB campus, as well as paying costs and expenses associated with this issue. These bonds were issued at a premium of \$16.4 million resulting in total cash received of \$187.1 million.

In June 2019, The UAB Medicine Finance Authority issued \$8.1 million in Series 2019A Revenue Bonds and \$103.4 million in Series 2019B Revenue Bonds, the proceeds of which were loaned to UAB Health System pursuant to Series 2019A and Series 2019B loan agreements. Concurrently, the Hospital entered into a loan agreement with UAB Health System to borrow \$77.0 million of the 2019A and 2019B bond proceeds for the purpose of financing capital improvement projects. Of this \$77.0 million, \$11 million was distributed to the Hospital as of September 30, 2020. As the Hospital is legally obligated to repay \$77.0 million and is currently paying principal and interest on this full amount, The Hospital has

reflected the full \$77.0 million on its statement of net position as long-term debt and \$34.5 million as Due from UAB Health System which is classified as Due from affiliate on the statement of net position. the Hospital pays interest to UAB Health System on the entire amount borrowed, regardless of the amount outstanding. There are no financial covenants related to the loan between the Hospital and UAB Health System.

The UAB general revenue bonds and the Hospital Revenue Trust Indentures are subject to certain covenants with the most restrictive being those on the Hospital's 2012A series issuance. These covenants, among other things, require the Hospital to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. UAB and the Hospital are in compliance with all financial covenants as of September 30, 2020.

The UAB Medicine Financing Authority's Revenue Trust Indentures are also subject to certain covenants. These covenants require the obligated group to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. The obligated group is in compliance with all financial covenants as of September 30, 2020

(8) Self-Insurance

UAB manages risks related to medical malpractice, general liability, and employee health care through a combination of self-insurance, risk pooling arrangements, and commercial insurance coverage.

UAB's medical malpractice liability is managed by PLTF, a professional liability trust fund. PLTF functions as a risk-sharing vehicle for UAB and more than ten nongovernmental organizations. PLTF covers liabilities of the covered parties, including UAB, arising from reported claims, claims that are incurred but not reported, and future costs of handling these claims. The liabilities are generally based on present value actuarial valuations discounted using interest rates from 2% to 5%. The discount rate used in both 2020 and 2019 was 2%. The associated risks of claims are subject to aggregate limits, with excess liability coverage provided by independent insurers to protect participants against losses should a claim arise that exceeds PLTF coverage limits. Although UAB is the sponsor of PLTF, it is not the predominant participant in the fund.

The PLTF's policy committee establishes the premium rate of participants based on recommendations from consulting actuaries and considering the assumption of risk from the PLTF's date of inception. Premiums paid to the PLTF are provided by UAB, HSF, and other participants. In addition, certain legal and administrative

services are provided to the PLTF by the University of Alabama System.

The PLTF agreement requires 10% of all PLTF assets to be held in liquid assets. At September 30, 2020 and 2019, the liquid assets of the PLTF, as defined by the agreement, were in compliance with the agreement.

As discussed in Note 4, UAB accounts for its ownership of the PLTF under the equity method of accounting and it is not included in the table below.

General liability is subject to various claims and aggregate limits, with excess liability coverage provided by an independent insurer. General liability and employee health care claims and expenses are reported when it is probable that a loss has occurred and the amount of the loss can be reasonably estimated. Those losses include an estimate of claims that have been incurred but not reported and the future costs of handling claims. The liabilities are based on actuarial valuations and are reported at present value. The discount rate used for the general liability was 2% in both 2020 and 2019.

Changes in the total self-insured liabilities for the years ended September 30, 2020 and 2019 are presented as follows for UAB:

SELF INSURED LIABILITIES	2020	2019
Balance, beginning of year	\$ 7,669,735	\$ 10,412,292
Claims incurred and changes in estimates	\$ 62,939,205	\$ 64,012,041
Claim payments	\$ (62,843,179)	\$ (66,754,598)
BALANCE, END OF YEAR	\$ 7,765,761	\$ 7,669,735

(9) Employee Benefits

Eligible employees of the University and Hospital participate in the mandatory Teachers' Retirement System of Alabama ("TRS"), a cost sharing, multiple-employer public retirement system designated as a defined benefit plan. In addition, eligible employees may elect to participate in a voluntary 403(b) defined contribution retirement plan. Prior to fiscal year 2020, the plan offered to eligible employees a choice between two recordkeepers, Teachers Insurance and Annuity Association ("TIAA") and the Variable Annuity Life Insurance Company ("VALIC"). Effective in fiscal year 2020, the System, in conjunction with its participating universities and with the Board's approval, transitioned to a single recordkeeper with TIAA serving as sole-vendor for the plan.

Defined Benefit Plan - TRS

Plan Description. The Teachers' Retirement System of Alabama, a cost-sharing multiple-employer public

employee retirement plan, was established as of September 15, 1939, under the provisions of Act 419 of the Legislature of 1939 for the purpose of providing retirement allowances and other specified benefits for qualified persons employed by State-supported educational institutions. The responsibility for the general administration and operation of the TRS is vested in its Board of Control. The TRS Board of Control consists of 15 members. The plan is administered by the Retirement Systems of Alabama (RSA). Title 16 Chapter 25 of the Code of Alabama grants the authority to establish and amend the benefit terms to the TRS Board of Control. The Plan issues a publicly available financial report that can be obtained at www.rsa-al.gov.

Benefits provided. State law establishes retirement benefits as well as death and disability benefits and any ad hoc increase in postretirement benefits for the TRS. Benefits for TRS members vest after 10 years of creditable service. TRS members who retire after age 60 with 10 years or more of creditable service or with 25 years of service (regardless of age) are entitled to an annual retirement benefit, payable monthly for life unless there is a return to full-time employment with a TRS or Employees' Retirement System (ERS) agency, or to temporary employment in excess of specified limits. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under the formula method, Tier 1 members of the TRS are allowed 2.0125% of their average final compensation (highest 3 of the last 10 years) for each year of service.

Act 377 of the Legislature of 2012 established a new tier of benefits (Tier 2) for members hired on or after January 1, 2013. Tier 2 TRS members are eligible for retirement after age 62 with 10 years or more of creditable service and are entitled to an annual retirement benefit, payable monthly for life unless there is a return to full-time employment with a TRS or ERS agency, or to temporary employment in excess of specified limits. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under formula method, Tier 2 members of the TRS are allowed 1.65% of their average final compensation (highest 5 of the last 10 years) for each year of service. Members are eligible for disability retirement if they have 10 years of creditable service, are currently in-service, and determined by the RSA Medical Board to be permanently incapacitated from further performance of duty. Pre-retirement death benefits are calculated and paid to the beneficiary based on the member's age, service credit, employment status and eligibility for retirement.

Contributions. Covered members of the TRS contributed 5% of earnable compensation to the TRS as required by statute until September 30, 2011. From October 1, 2011, to

September 30, 2012, covered members of the TRS were required by statute to contribute 7.25% of earnable compensation. Effective October 1, 2012, covered members of the TRS are required by statute to contribute 7.50% of earnable compensation. Certified law enforcement, correctional officers, and firefighters of the TRS contributed 6% of earnable compensation as required by statute until September 30, 2011. From October 1, 2011, to September 30, 2012, certified law enforcement, correctional officers, and firefighters of the TRS were required by statute to contribute 8.25% of earnable compensation. Effective October 1, 2012, certified law enforcement, correctional officers, and firefighters of the TRS are required by statute to contribute 8.50% of earnable compensation.

Tier 2 covered members of the TRS contribute 6% of earnable compensation to the TRS as required by statute. Tier 2 certified law enforcement, correctional officers, and

firefighters of the TRS are required by statute to contribute 7% of earnable compensation.

UAB's contractually required contribution rate for the year ended September 30, 2020 was 12.43% of annual pay for Tier 1 members and 11.34% of annual pay for Tier 2 members. UAB's contribution rate for the year ended September 30, 2019 was 12.41% of annual pay for Tier 1 members and 11.35% of annual pay for Tier 2 members.

These required contribution rates are a percent of annual payroll, actuarially determined as an amount that, when combined with member contributions, is expected to finance the costs of benefits earned by members during the year, with an additional amount to finance any unfunded accrued liability.

The total contribution requirement for fiscal years 2020, 2019 and 2018 is as follows:

	2020	2019	2018
Employer Contributions	\$ 98,485,000	\$ 97,824,000	\$ 94,481,000
Employee Contributions	57,688,000	57,345,000	56,754,000
TOTAL CONTRIBUTIONS	\$ 156,173,000	\$ 155,169,000	\$ 151,235,000

Pension Liabilities, Pension Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to Pensions. At September 30, 2020 and September 30, 2019, the financial statements of UAB reflected a liability of \$1.25 billion and \$1.17 billion, respectively, for its proportionate share of the collective net pension liability, as prescribed by GASB 68. At September 30, 2020, the collective net pension liability was measured as of September 30, 2019 and the total pension liability used to calculate the net pension liability was determined by an actuarial valuation as of September 30, 2018. At September 30, 2019, the collective net pension liability was measured as of September 30, 2018 and the total pension liability used to calculate the net pension liability was determined by an actuarial valuation as of September 30, 2017.

UAB's proportion of the collective net pension liability was based on the employers' shares of contributions to the pension plan relative to the total employer contributions of all participating TRS employers. As of September 30, 2019, UAB's proportion was 11.26%, which was a decrease of 0.49% from its proportion measured as of September 30, 2018. At September 30, 2018, UAB's proportion was 11.75%, which was a decrease of 0.06% from its proportion measured as of September 30, 2017.

For the years ended September 30, 2020 and September 30, 2019, UAB recognized pension expense of \$112.2 million and \$76.3 million, respectively. At September 30, 2020 and 2019, UAB reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

2020	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 18,408,000	\$ 41,292,000
Changes of assumptions	38,360,000	—
Net difference between projected and actual earnings on pension plan investments	43,354,000	—
Changes in proportion and differences between Employer contributions and proportionate share of contributions	—	48,878,000
Employer contributions subsequent to the measurement date	98,485,000	—
TOTAL	\$ 198,607,000	\$ 90,170,000

2019	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 25,212,000	\$ 35,589,000
Changes of assumptions	64,940,000	—
Net difference between projected and actual earnings on pension plan investments	—	88,187,000
Changes in proportion and differences between Employer contributions and proportionate share of contributions	—	18,915,000
Employer contributions subsequent to the measurement date	94,900,000	—
TOTAL	\$ 185,052,000	\$ 142,691,000

\$98.5 million reported as deferred outflows of resources related to pensions resulting from UAB contributions subsequent to the measurement date will be recognized as a reduction of the net pension liability in the year ending September 30, 2021. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to pensions will be recognized in pension expense (income) as follows:

Years ending September 30:		
2021	\$	(11,459)
2022		(7,904)
2023		13,669
2024		17,152
2025		(1,506)
Thereafter		—

Actuarial assumptions. The total pension liability was determined by an actuarial valuation as of September 30, 2018 using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.75%
Investment rate of return*	7.70%
Projected salary increases	3.25-5.00%

*Net of pension plan investment expenses

The actuarial assumptions used in the actuarial valuation as of September 30, 2018, were based on the results of an investigation of the economic and demographic experience for the TRS based upon participant data as of September 30, 2015. The Board of Control accepted and approved these changes in September 2016 which became effective the beginning of fiscal year 2016.

Mortality rates for TRS were based on the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for males and 112% for females age 78 and older.

The long-term expected rate of return on pension plan investments was determined using a log-normal distribution analysis in which best estimate ranges of expected future real rates of return (expected returns, net of pension plan investment expense and inflation) are

developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target asset allocation and best estimates of geometric real rates of return for each major asset class are as follows:

	Target Allocation	Long-Term Expected Rate of
Fixed Income	17.00 %	4.40 %
U.S. Large Stocks	32.00 %	8.00 %
U.S. Mid Stocks	9.00 %	10.00 %
U.S. Small Stocks	4.00 %	11.00 %
International Developed Market Stocks	12.00 %	9.50 %
International Emerging Market Stocks	3.00 %	11.00 %
Alternatives	10.00 %	10.10 %
Real Estate	10.00 %	7.50 %
Cash	3.00 %	1.50 %
TOTAL	100.00 %	

*Includes assumed rate of inflation of 2.50%.

Discount rate. The discount rate used to measure the total pension liability was 7.70%. The projection of cash flows used to determine the discount rate assumed that plan member contributions will be made at the current contribution rate and that the employer contributions will be made at rates equal to the difference between actuarially determined contribution rates and the member rate. Based on those assumptions, components of the pension plan's fiduciary net position were projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on pension plan investments was applied to all periods of projected benefit payments to determine the total pension liability.

Sensitivity of UAB's proportionate share of the net pension liability to changes in the discount rate. The following table reflects UAB's proportionate share of the net pension liability, as prescribed by GASB 68, calculated using the discount rate of 7.70%, as well as what UAB's proportionate share of the net pension liability would be if it were calculated using a discount rate

that is 1-percentage point lower (6.70%) or 1-percentage-point higher (8.70%) than the current rate:

	1% Decrease	Current Rate	1% Increase
UAB's proportionate share of collective net pension liability	\$1,690,274,000	\$1,245,083,000	\$ 868,348,000

Pension plan fiduciary net position. Detailed information about the pension plan’s fiduciary net position is available in the separately issued RSA Comprehensive Annual Report for the fiscal year ended September 30, 2019. The supporting actuarial information is included in the GASB Statement No. 67 Report for the TRS prepared as of September 30, 2019. The auditor’s report dated August 18, 2020, on the total pension liability, total deferred outflows of resources, total deferred inflows of resources, total pension expense for the sum of all participating entities as of September 30, 2019, along with supporting schedules is also available. The additional financial and actuarial information is available at www.rsa-al.gov.

Other Retirement Plans

As previously noted, certain employees also participate in a voluntary 403(b) plan, which is a defined contribution plan. In defined contribution plans, benefits depend solely on amounts contributed plus investment earnings. All full-time regular monthly employees are eligible to participate from the date of employment. UAB contributes a matching amount of up to 5% of total salaries for participating employees. UAB’s contribution is funded as it accrues and, along with that of the employee, is immediately and fully vested. The contributions for fiscal years 2020 and 2019, excluding employee amounts not eligible for matching, were approximately \$64.1 million and \$60.1 million, which included approximately \$32.0 million and \$30.1 million each from UAB and its employees, respectively.

The LLC sponsors a voluntary 403(b) retirement plan for eligible employees. The 403(b) plan is a voluntary, defined-contribution, tax-deferred as well as Roth after tax plan governed by Internal Revenue Code 403(b). TIAA is the administrator for the voluntary retirement program. Employees are vested after 3 years of employment. Eligibility for matching is for all full-time and part-time regular, twelve-hour shift, and weekend staff employees.

In fiscal year 2020, employer matching contributions in the voluntary 403(b) Plan (inclusive of The University of Alabama, The University of Alabama at Birmingham, The University of Alabama in Huntsville, and the UA System Office), and the UAB Hospital Management, LLC 403(b) Plan were temporarily suspended for the period of May 2020 through September 2020. The suspension was due to uncertainty concerning the potential financial impacts of the COVID-19 Pandemic and was a joint management decision by Senior Administration of the UA System and each University

The University, the Hospital, LLC and UABRF total salaries and wages for fiscal years 2020 and 2019 were approximately \$1.33 billion and \$1.25 billion, respectively. Total salaries and wages during fiscal years 2020 and 2019 for covered employees participating in TRS were approximately \$816.8 million and \$806.4 million, respectively. Total salaries and wages during fiscal years 2020 and 2019 for covered employees participating in the 403(b) Plan were approximately \$710.1 million and \$649.0 million, respectively.

Triton sponsors a 401(k) plan covering substantially all employees who have completed at least six months of service. Information regarding this benefit is presented in Triton’s annual report.

Compensated Absences

Certain UAB employees accumulate vacation and sick leave at varying rates depending upon their years of continuous service and their payroll classification, subject to maximum limitations. Upon termination of employment, employees are paid unused accrued vacation at their regular rate of pay up to a designated maximum number of days.

In accordance with GASB Statement No. 16, *Accounting for Compensated Absences*, the financial statements include accruals of approximately \$78 million and \$71 million as of September 30, 2020 and 2019, respectively, for accrued vacation pay and salary-related payments associated with vacation pay. There is no such accrual recognized for sick leave benefits because there is no terminal cash benefit available to employees for accumulated sick leave.

(10) Post-Employment Benefits

UAB offers other postemployment health care benefits (OPEB) to all employees who officially retire from UAB. Health care benefits are offered through the Alabama Retired Education Employees Health Care Trust Plan (PEEHIP) with TRS or certain retired employees may elect to continue to participate in UAB’s group health plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB’s health care plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS, in which case the retirees pay a portion of the PEEHIP premium, with UAB paying an allocation towards the cost of retiree coverage.

Certain retirees may also elect to continue their basic term life insurance coverage and accidental death and dismemberment insurance up to certain maximum

amounts. The retirees pay the full amount of the premiums in such cases. Retirees are not eligible for tuition assistance benefits themselves. However, their unmarried dependent children may qualify in some cases.

PEEHIP

Plan description. The Alabama Retired Education Employees' Health Care Trust (Trust) is a cost-sharing multiple-employer defined benefit postemployment healthcare plan that administers healthcare benefits to the retirees of participating state and local educational institutions. The Trust was established under the Alabama Retiree Health Care Funding Act of 2007 which authorized and directed the Public Education Employees' Health Insurance Board (Board) to create an irrevocable trust to fund postemployment healthcare benefits to retirees participating in PEEHIP. Active and retiree health insurance benefits are paid through the Public Education Employees' Health Insurance Plan. In accordance with GASB, the Trust is considered a component unit of the State of Alabama (State) and is included in the State's Comprehensive Annual Financial Report.

The PEEHIP was established in 1983 pursuant to the provisions of the Code of Alabama 1975, Title 16, Chapter 25A (Act 83-455) to provide a uniform plan of health insurance for active and retired employees of state and local educational institutions which provide instruction at any combination of grades K-14 (collectively, eligible employees), and to provide a method for funding the benefits related to the plan. The four-year universities participate in the plan with respect to their retired employees, and are eligible and may elect to participate in the plan with respect to their active employees. Responsibility for the establishment of the health insurance plan and its general administration and operations is vested in the Board. The Board is a corporate body for purposes of management of the health insurance plan. The Code of Alabama 1975, Section 16-25A-4 provides the Board with the authority to amend the benefit provisions in order to provide reasonable assurance of stability in future years for the plan. All assets of the PEEHIP are held in trust for the payment of health insurance benefits. The Teachers' Retirement System of Alabama (TRS) has been appointed as the administrator of the PEEHIP and, consequently, serves as the administrator of the Trust.

Benefits provided. PEEHIP offers a basic hospital medical plan to active members and non-Medicare eligible retirees. Benefits include inpatient hospitalization for a maximum of 365 days without a dollar limit, inpatient rehabilitation, outpatient care, physician services, and prescription drugs.

Active employees and non-Medicare eligible retirees who do not have Medicare eligible dependents can enroll in a health maintenance organization (HMO) in lieu of the basic hospital medical plan. The HMO includes hospital medical benefits, dental benefits, vision benefits, and an

extensive formulary. However, participants in the HMO are required to receive care from a participating physician in the HMO plan.

The PEEHIP offers four optional plans (Hospital Indemnity, Cancer, Dental, and Vision) that may be selected in addition to or in lieu of the basic hospital medical plan or HMO. The Hospital Indemnity Plan provides a per-day benefit for hospital confinement, maternity, intensive care, cancer, and convalescent care. The Cancer Plan covers cancer disease only and benefits are provided regardless of other insurance. Coverage includes a per-day benefit for each hospital confinement related to cancer. The Dental Plan covers diagnostic and preventative services, as well as basic and major dental services. Diagnostic and preventative services include oral examinations, teeth cleaning, x-rays, and emergency office visits. Basic and major services include fillings, general aesthetics, oral surgery not covered under a Group Medical Program, periodontics, endodontics, dentures, bridgework, and crowns. Dental services are subject to a maximum of \$1,250 per year for individual coverage and \$1,000 per person per year for family coverage. The Vision Plan covers annual eye examinations, eye glasses, and contact lens prescriptions.

PEEHIP members may opt to elect the PEEHIP Supplemental Plan as their hospital medical coverage in lieu of the PEEHIP Hospital Medical Plan. The PEEHIP Supplemental Plan provides secondary benefits to the member's primary plan provided by another employer. Only active and non-Medicare retiree members and dependents are eligible for the PEEHIP Supplemental Plan. There is no premium required for this plan, and the plan covers most out-of-pocket expenses not covered by the primary plan. The plan cannot be used as a supplement to Medicare, the PEEHIP Hospital Medical Plan, or the State or Local Governmental Plans administered by the State Employees' Insurance Board (SEIB).

Medicare eligible members and Medicare eligible dependents who are covered on a retiree contract were enrolled in the United Healthcare Group Medicare Advantage plan for PEEHIP retirees. Effective January 1, 2020, Humana Insurance Company replaced United Healthcare as the administrator of the PEEHIP Group Medicare Advantage (PPO) Plan. The plan is fully insured, and members are able to have all of their Medicare Part A (hospital insurance), Part B (medical insurance), and Part D (prescription drug coverage) in one convenient plan. Retirees can continue to see their same providers with no interruption and see any doctor who accepts Medicare on a national basis. Members have the same benefits in and out-of-network and there is no additional retiree cost share if a retiree uses an out-of-network provider and no balance billing from the provider.

Contributions. The Code of Alabama 1975, Section 16-25A-8 and the Code of Alabama 1975, Section, 16-25A-8.1 provide the Board with the authority to set the contribution requirements for plan members and the authority to set the employer contribution requirements for each required class, respectively. Additionally, the Board is required to certify to the Governor and the Legislature, the amount, as a monthly premium per active employee, necessary to fund the coverage of active and retired member benefits for the following fiscal year. The Legislature then sets the premium rate in the annual appropriation bill.

For employees who retired after September 30, 2005, but before January 1, 2012, the employer contribution of the health insurance premium set forth by the Board for each retiree class is reduced by 2% for each year of service less than 25 and increased by 2% percent for each year of service over 25 subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree.

For employees who retired after December 31, 2011, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by 4% for each year of service less than 25 and increased by 2% for each year over 25, subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree. For employees who retired after December 31, 2011, who are not covered by Medicare, regardless of years of service, the employer contribution to the health

insurance premium set forth by the Board for each retiree class is reduced by a percentage equal to 1% multiplied by the difference between the Medicare entitlement age and the age of the employee at the time of retirement as determined by the Board. This reduction in the employer contribution ceases upon notification to the Board of the attainment of Medicare coverage.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2020 and 2019, the financial statements of UAB reflected a liability of \$265.2 million and \$659.9 million, respectively for its proportionate share of collective net OPEB liability, as prescribed by GASB 75. The collective net OPEB liability was measured as of September 30, 2019 and the total OPEB liability used to calculate the net OPEB liability was determined by an actuarial valuation as of September 30, 2018. UAB's proportion of collective net OPEB liability was based on a projection of UAB's long-term share of contributions to the OPEB plan relative to the projected contributions of all participating employers, actuarially determined. At September 30, 2019, UAB's proportion was 7.03%, which was a decrease of 1% from its proportion measured as of September 30, 2018. At September 30, 2018, the UAB's proportion was 8.03%, which was a decrease of 0.64% from its proportion measured as of September 30, 2017.

For the years ended September 30, 2020 and 2019, UAB recognized an OPEB benefit of \$24.5 million and an OPEB expense of \$52.9 million, respectively with no special funding situations. At September 30, 2020 and 2019, UAB reported deferred outflows of resources and deferred inflows of resources related to the PEEHIP plan from the following sources:

2020	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 8,780,366	\$ 203,329,026
Changes of assumptions	12,677,222	109,839,367
Net difference between projected and actual earnings on OPEB plan investments	547,032	—
Changes in proportion and differences between Employer contributions and proportionate share of contributions	62,695,436	107,161,311
Employer contributions subsequent to the measurement date	20,775,402	—
TOTAL	\$ 105,475,458	\$ 420,329,704

2019	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 12,424,148	\$ —
Changes of assumptions	—	32,143,869
Net difference between projected and actual earnings on OPEB plan investments	—	3,535,812
Changes in proportion and differences between Employer contributions and proportionate share of contributions	82,105,791	44,278,802
Employer contributions subsequent to the measurement date	19,976,210	—
TOTAL	\$ 114,506,149	\$ 79,958,483

\$20.8 million reported as deferred outflows of resources related to OPEB resulting from UAB's contributions subsequent to the measurement date will be recognized as a reduction of the net OPEB liability in the year ending September 30, 2021. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Years ending September 30:		
2021	\$	(62,550,706)
2022		(62,550,706)
2023		(61,855,834)
2024		(68,568,036)
2025		(68,559,430)
Thereafter		(11,544,936)

Actuarial assumptions. The total OPEB liability for the PEEHIP was determined by an actuarial valuation as of September 30, 2018, using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.75%
Projected Salary Increase ¹	3.25%-5.00%
Long-Term Investment Rate of Return ²	7.25%
Municipal Bond Index Rate at the Measurement	3.00%
Municipal Bond Index Rate at the Prior	4.18%
Projected Year for Fiduciary Net Position (FNP) to be	2055
Single Equivalent Interest Rate the Measurement	5.50%
Single Equivalent Interest Rate the Prior	4.44%
Healthcare Cost Trend Rate	
Pre-Medicare Eligible	6.75%
Medicare Eligible	**
Ultimate Trend Rate	
Pre-Medicare Eligible	4.75% in 2026
Medicare Eligible	4.75% in 2024

¹Includes 3.00% wage inflation.

²Compounded annually, net of investment expense, and includes inflation.

**Initial Medicare claims are set based on scheduled increases through plan year 2022.

Mortality rates for the period after service retirement for both PEEHIP and UAB plan are according to the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for all ages for males and 112% for ages 78 and over for females. The rates of disabled mortality were based on the RP-2000 Disabled Mortality Table projected to 2020 using scale BB and adjusted 105% for males and 120% for females.

The decremental assumptions used in the valuation were selected based on the actuarial experience study prepared as of September 30, 2015, submitted to and adopted by the Teachers' Retirement System of Alabama Board on September 13, 2016.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) were based on the September 30, 2018 valuation, however updated Medicare Advantage premium rates which reflect the repeal of the ACA Health Insurer Fee, updated Optionals claims costs, and updated participation assumptions were used in this report.

The long-term expected return on plan assets is to be reviewed as part of regular experience studies prepared every five years, in conjunction with similar analysis for the Teachers' Retirement System of Alabama. Several factors should be considered in evaluating the long-term rate of return assumption, including long-term historical data, estimates inherent in current market data, and a log-normal distribution analysis in which best-estimate ranges of expected future real rates of return (expected return, net of investment expense and inflation), as developed for each major asset class. These ranges should be combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and then adding expected inflation. The assumption is intended to be a long-term assumption and is not expected to change absent a significant change in the asset allocation, a change in the inflation assumption, or a fundamental change in the market that alters expected returns in future years.

The long-term expected rate of return on the OPEB plan investments is determined based on the allocation of assets by asset class and by the mean and variance of real returns.

The target asset allocation and best estimates of expected geometric real rates of return for each major asset class is summarized below:

	Target Allocation	Long-Term Expected Real Rate of Return*
Fixed Income	30.00 %	4.40 %
U.S. Large Stocks	38.00 %	8.00 %
U.S. Mid Stocks	8.00 %	10.00 %
U.S. Small Stocks	4.00 %	11.00 %
International Developed Market Stocks	15.00 %	9.50 %
Cash	5.00 %	1.50 %
TOTAL	100.00 %	

* Geometric mean, includes 2.5% inflation

Discount Rate. The discount rate (also known as the Single Equivalent Interest Rate (SEIR), as described by GASB 74) used to measure the PEEHIP total OPEB liability at September 30, 2019 was 5.50%. The discount rate used to measure the total OPEB liability at the prior measurement date was 4.44%. Premiums paid to the Public Education Employees' Health Insurance Board for active employees shall include an amount to partially fund the cost of coverage for retired employees. The

projection of cash flows used to determine the discount rate assumed that plan contributions will be made at the current contribution rates. Each year, the State specifies the monthly employer rate that participating school systems must contribute for each active employee. Approximately, 24.245% of the employer contributions were used to assist in funding retiree benefit payments in 2019 and it is assumed that the amount will increase by 1.00% per year and continue into the future. The discount rate determination will use a municipal bond rate to the extent the trust is projected to run out of money before all benefits are paid. Therefore, the projected future benefit payments for all current plan members were projected through 2117. The long-term rate of return is used until the assets are expected to be depleted in 2055, after which the municipal bond rate is used.

Sensitivity of the UAB's proportionate share of the net OPEB liability to changes in the healthcare cost trend rates. The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the current healthcare trend rate, as well as what the net OPEB liability would be if calculated using one percentage point lower or one percentage point higher than the current rate. A one percent point decrease would change the current healthcare trend rate from 6.75% to 5.75%, the pre-Medicare from 4.75% to 3.75%, the Medicare eligible from 4.75% to 3.75%. A one percent point increase would change the current healthcare trend rate from 6.75% to 7.75%, the pre-Medicare from 4.75% to 5.75%, the Medicare eligible from 4.75% to 5.75%.

	1% Decrease	Current Healthcare Trend Rate	1% Increase
UAB's proportionate share of the collective net OPEB liability	\$ 212,627,147	\$ 265,180,609	\$ 331,369,313

The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the discount rate of 5.50%, as well as what the net OPEB liability would be if calculated using one percentage point lower or one percentage point higher than the current rate:

	1% Decrease (4.50%)	Current Discount Rate (5.50%)	1% Increase (6.50%)
UAB's proportionate share of the collective net OPEB liability	\$ 320,532,232	\$ 265,180,609	\$ 219,976,594

OPEB plan fiduciary net position. Detailed information about the OPEB plan's fiduciary net position is located in the Trust's financial statements for the fiscal year ended September 30, 2019. The supporting actuarial information is included in the GASB Statement No. 74 Report for PEEHIP prepared as of September 30, 2019. Additional financial and actuarial information is available at www.rsa-al.gov.

UAB Plan

Plan description. The UAB plan is considered a single-employer plan which is administered by University of Alabama at Birmingham (UAB). The UAB Plan offers its members hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their dependents. The portion of the UAB plan related to health care may be amended by the approval of the President of UAB upon recommendation from the Benefits Committee. The portion of the UAB plan related to the life insurance may be amended by the System.

Benefits provided. UAB employees can participate in the UAB plan as a retiree if the following condition are met; retiree has 25 years of creditable service, regardless of age (Tier I only), or retiree has 10 years of service and is 60 years old (62 years old for Tier II), or retiree has 10 years of service and is determined disabled the Social Security Administration or the Teachers' Retirement System of Alabama's Medical Board. These retired UAB employees may elect to continue to participate in UAB plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS. The UAB Plan consists of hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit.

Employees included in the actuarial valuation include active employees, retirees and disabled employees enrolled in the medical plan and retirees not enrolled in the medical plan with retiree life insurance. The following table summarizes the membership of the UAB Plan as of September 30, 2019, the Valuation Date.

Membership:	2020
Inactive Employees or Beneficiaries Currently Receiving Benefits	238
Inactive Members Entitled To But Not Yet Receiving Benefits	—
Active Employees	10,824
TOTAL MEMBERSHIP	11,062

Contributions. UAB retired employees make contributions to the plan by making premium payments associated with their selected health plan option. Eligible disabled retirees are responsible for only the employee portion of those premiums and UAB is responsible for the employer portion. All other UAB retirees are responsible for the full premium cost of the plan and in no case does the employer contribute to the plan.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2020 and 2019, UAB

reported a liability of \$6.3 million and \$17.7 million, respectively for the total OPEB liability (TOL). The TOL is based upon an actuarial valuation as of the valuation date, September 30, 2019. An expected TOL is determined as of September 30, 2018, the prior measurement date, using standard roll back techniques. The roll back calculation begins with the TOL, as of the Measurement Date, September 30, 2018, adds the expected benefit payments for the year, deducts interest at the Discount Rate for the year, and then subtracts the annual Normal Cost (also called the Service Cost).

For the years ended September 30, 2020 and 2019, UAB recognized an OPEB benefit of \$644,580 and an OPEB expense of \$576,312, respectively with no special funding situations. At September 30, 2020 and 2019, UAB reported deferred outflows of resources and deferred inflows of resources related to the UAB plan from the following sources:

2020	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ —	\$ 6,076,784
Changes of assumptions	—	5,360,627
Employer contributions subsequent to the measurement period	1,411,559	—
TOTAL	\$ 1,411,559	\$ 11,437,411

2019	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ —	\$ 698,451
Changes of assumptions	—	1,426,060
Employer contributions subsequent to the measurement period	1,877,839	—
TOTAL	\$ 1,877,839	\$ 2,124,511

Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Year ended September 30:		
2021	\$	(1,523,177)
2022		(1,523,177)
2023		(1,523,177)
2024		(1,523,177)
2025		(1,523,177)
Thereafter		(3,821,526)

Actuarial assumptions. The total OPEB liability for the UAB plan was determined by an actuarial valuation as of September 30, 2019, using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.75 %
Real Wage Growth	0.25 %
Projected Salary Increases ¹	3.25% - 5.00%
Wage inflation.	3.00 %
Municipal Bond Index Rate at the Measurement Date	2.66 %
Municipal Bond Index Rate at the Prior Measurement Date	4.18 %
Healthcare Cost Trend Rate	
Pre-Medicare Medical and Prescription Drug (decreasing to an ultimate rate of 4.75% by 2026)	6.75 %

¹Includes 3.00% wage inflation.

Mortality rates for the period after service retirement for the UAB plan are according to the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for all ages for males and 112% for ages 78 and over for females. The rates of disabled mortality were based on the RP-2000 Disabled Mortality Table projected to 2020 using scale BB and adjusted 105% for males and 120% for females.

The decremental assumptions used in the valuation were selected based on the actuarial experience study prepared as of September 30, 2015, and are reasonable expectations of anticipated experience under the Plan.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) used in the September 30, 2019 valuation were based on a review of recent plan experience performed concurrently with the September 30, 2019 valuation.

The UAB plan does not hold any plan assets, as such, there are no long-term expected rate of return or target allocation presented.

Discount Rate. The discount rate, as defined by Paragraph 155 of GASB 75 is to be a 20-year tax- exempt municipal bond (rating AA/Aa or higher) rate (Municipal Bond Index Rate). The Municipal Bond Index Rate used for this purpose is the September average of the Bond Buyer General Obligation 20-year Municipal Bond Index

published weekly by The Bond Buyer (www.bondbuyer.com) and was 2.66% as of the measurement date. On the prior measurement date, the Municipal Bond Index Rate was 4.18%.

Sensitivity of the UAB Plan's net OPEB liability to changes in the healthcare cost trend rates. The following table presents the total OPEB Liability of the UAB Plan, calculated using the current healthcare trend rate, as well as what the total OPEB Liability would be if calculated using one percentage point lower or one percentage point higher than the current rate. A one percent point decrease would change the current healthcare trend rate from 6.75% to 5.75% and pre-Medicare from 4.75% to 3.75%. A one percent point increase would change the current healthcare trend rate from 6.75% to 7.75% and the pre-Medicare from 4.75% to 5.75%.

	1% Decrease	Current Healthcare Trend Rate	1% Increase
UAB's total OPEB liability	\$ 6,110,885	\$ 6,251,332	\$ 6,399,963

The following table presents the total OPEB Liability of the UAB Plan, calculated using the discount rate of 2.66%, as well as what the total OPEB liability would be if calculated using one percentage point lower or one percentage point higher than the current rate:

	1% Decrease (1.66%)	Current (2.66%)	1% Increase (3.66%)
UAB's total OPEB liability	\$ 6,509,759	\$ 6,251,332	\$ 6,010,698

Changes in the Total OPEB Liability. Since the UAB Plan does not meet the definition within paragraph 4 of GASB Statement No 75, UAB is disclosing a schedule of changes in the total OPEB liability below:

	2020
Total OPEB Liability as of September 30, 2019	\$ 17,698,575
Changes for the year:	
Service cost	169,614
Interest on TOL and cash flows	708,983
Changes in benefit terms	—
Difference between expected and actual	(6,173,296)
Changes of assumptions or other inputs	(4,662,781)
Benefit payments	(1,489,763)
Net changes	\$ (11,447,243)
Total OPEB Liability as of September 30, 2020	\$ 6,251,332

*The service cost includes interest for the year.

(11) Federal Direct Student Loan Program

The Federal Direct Student Loan Program (FDSLPL) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSLPL enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through the university rather than through private lenders. UAB began participation in the FDSLPL on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan process, including funds management, as well as promissory note functions. UAB is not responsible for collection of these loans. During the years ended September 30, 2020 and 2019, UAB disbursed approximately \$166.6 million and \$167.1 million, respectively, under the FDSLPL.

(12) Grants and Contracts

At September 30, 2020 and 2019, UAB had been awarded approximately \$703.1 million and \$546.3 million, respectively, in grants and contracts which have not been expended. These awards, which represent commitments of sponsors to provide funds for specific research, training, and service projects, have not been reflected in the financial statements.

(13) Operating Expenses by Function

Total operating expenses by functional classification for the years ended September 30, 2020 and 2019 are as follows for UAB:

2020 Operating Expenses					
(by functional classification)					
	Salaries, Wages, and Benefits	Supplies and Services	Depreciation and Amortization	Scholarships and Fellowships	Total
Instruction	\$ 248,045,998	\$ 35,951,295	\$ —	\$ —	\$ 283,997,293
Research	181,566,808	112,611,840	—	—	294,178,648
Public service	109,176,136	58,006,813	—	—	167,182,949
Academic support	158,931,068	13,366,872	—	—	172,297,940
Student services	27,963,265	10,844,232	—	—	38,807,497
Institutional support	95,295,882	122,914,000	—	—	218,209,882
Operations and maintenance of plant	36,974,761	31,733,410	—	—	68,708,171
Scholarships and fellowships	—	—	—	35,285,313	35,285,313
Hospital	836,833,734	963,286,381	—	—	1,800,120,115
Auxiliary	71,257,173	652,837,364	—	—	724,094,537
Depreciation	—	—	150,994,130	—	150,994,130
TOTAL OPERATING EXPENSES	\$ 1,766,044,825	\$ 2,001,552,207	\$ 150,994,130	\$ 35,285,313	\$ 3,953,876,475

2019 Operating Expenses					
(by functional classification)					
	Salaries, Wages, and Benefits	Supplies and Services	Depreciation and Amortization	Scholarships and Fellowships	Total
Instruction	\$ 251,833,619	\$ 35,393,500	\$ —	\$ —	\$ 287,227,119
Research	181,672,641	121,470,937	—	—	303,143,578
Public service	114,342,866	50,114,594	—	—	164,457,460
Academic support	159,575,762	21,001,224	—	—	180,576,986
Student services	28,353,005	14,101,853	—	—	42,454,858
Institutional support	95,936,734	60,752,918	—	—	156,689,652
Operations and maintenance of plant	37,905,573	32,841,931	—	—	70,747,504
Scholarships and fellowships	—	—	—	29,041,268	29,041,268
Hospital	808,705,699	904,354,651	—	—	1,713,060,350
Auxiliary	70,735,039	606,222,882	—	—	676,957,921
Depreciation	—	—	148,344,143	—	148,344,143
TOTAL OPERATING EXPENSES	\$ 1,749,060,938	\$ 1,846,254,490	\$ 148,344,143	\$ 29,041,268	\$ 3,772,700,839

(14) Contingencies and Commitments

UAB has sovereign immunity and is, therefore, in the opinion of UAB counsel, immune to ordinary tort actions including those based on medical malpractice or general injury to patients. Consequently, while UAB is sometimes named as defendant in malpractice actions and other actions for injuries arising in the Hospital, it has consistently been dismissed from those lawsuits on the basis of the sovereign immunity doctrine. That doctrine also protects UAB from vicarious liability arising from the negligence of its employees. To the extent that UAB employees are sued in their individual capacity for actions related to their official duties within the line and scope of their employment, UAB has defended those actions and paid for any resulting costs through its self-insured trust fund. While UAB is not aware of any impending threat to this doctrine, UAB is a named insured under the terms of the PLTF and excess insurance purchased from commercial companies (Note 8). There are some exceptions to the sovereign immunity doctrine, most notably federal court cases arising under the federal constitution or federal statutes.

UAB is engaged in various legal actions in the ordinary course of business. Management does not believe the ultimate outcome of these actions will have a material adverse effect on the financial statements. However, the settlement of legal actions is subject to inherent uncertainties and it is possible that such outcomes could differ materially from management's current expectations.

Amounts received or receivable from grantor agencies are subject to audit and adjustments by such agencies, principally the United States Government. Any disallowed claims, including amounts already collected, may constitute a liability of UAB. The amount, if any, of expenditures that may be disallowed by the grantor cannot be determined at this time, although UAB expects any such amounts to be immaterial.

UAB has contracted for the construction and renovation of several facilities. At September 30, 2020 and 2019, the estimated remaining cost to complete the construction and renovation of these facilities was approximately \$165 million and \$246 million, respectively, which is expected to be financed from private gifts, grants, bond proceeds, and UAB reserves.

(15) Segment Reporting

As discussed in Note 1, UAB's two significant identifiable activities that have bonds outstanding where revenue is pledged in support of the bonds are the University and the Hospital. Condensed financial statement information related to the University and Hospital as of and for the years ended September 30, 2020 and 2019 is as follows:

UNIVERSITY	2020	2019
CONDENSED STATEMENTS OF NET POSITION		
Current assets	\$ 836,713,735	\$ 803,788,221
Capital assets, net	1,168,528,126	1,123,608,474
Other assets	874,816,846	951,213,153
TOTAL ASSETS	\$ 2,880,058,707	\$ 2,878,609,848
DEFERRED OUTFLOW OF RESOURCES	\$ 211,159,055	\$ 203,548,877
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 3,091,217,762	\$ 3,082,158,725
Current liabilities	349,237,084	323,028,646
Long-term debt	601,602,280	624,939,646
Other noncurrent liabilities	991,756,471	1,180,783,793
TOTAL LIABILITIES	\$ 1,942,595,835	\$ 2,128,752,085
DEFERRED INFLOW OF RESOURCES	\$ 319,605,203	\$ 143,674,851
Net investment in capital assets	609,155,955	620,309,247
Restricted nonexpendable	405,387,849	401,505,297
Restricted expendable	305,788,404	330,611,740
Unrestricted	(491,315,484)	(542,694,495)
TOTAL NET POSITION	\$ 829,016,724	\$ 809,731,789
TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION	\$ 3,091,217,762	\$ 3,082,158,725

UNIVERSITY	2020	2019
CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION		
Tuition and fees, net	\$ 244,929,737	\$ 239,912,344
Grant and contract revenue	483,921,581	494,047,342
Sales and services, educational	59,351,275	67,616,490
Other operating revenues	87,197,569	116,635,954
Salaries, wages, and benefits	(877,227,836)	(891,465,112)
Supplies and services	(408,331,442)	(367,622,835)
Depreciation	(76,748,607)	(75,251,119)
Scholarships and fellowships	(35,276,313)	(29,040,392)
OPERATING LOSS	(522,184,036)	(445,167,328)
State appropriations	270,077,351	253,102,906
Investment income	2,940,208	13,591,529
Interest expense	(22,083,632)	(13,088,125)
Gifts	15,640,326	46,152,386
Other nonoperating revenues	61,156,771	40,282,426
LOSS BEFORE OTHER CHANGES IN NET POSITION	(194,453,012)	(105,126,206)
Capital gifts and grants	1,854,223	789,044
Endowment gifts	17,755,898	29,098,263
Intergovernmental transfers	194,127,825	173,063,095
INCREASE IN NET POSITION	19,284,934	97,824,196
Net position, beginning of year	809,731,790	711,907,593
NET POSITION, END OF YEAR	\$ 829,016,724	\$ 809,731,789
CONDENSED STATEMENTS OF CASH FLOWS		
Net cash provided by (used in):		
Operating activities	\$ (428,799,771)	\$ (389,066,206)
Noncapital financing activities	570,845,198	540,437,693
Investing activities	(28,338,182)	(51,845,275)
Capital and related financing activities	(167,695,054)	21,952,161
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(53,987,809)	121,478,373
Cash and cash equivalents, beginning of year	218,944,868	97,466,495
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 164,957,059	\$ 218,944,868

HOSPITAL	2020	2019
CONDENSED STATEMENTS OF NET POSITION		
Current assets	\$ 1,374,342,040	\$ 984,037,176
Capital assets, net	611,158,094	594,578,200
Other assets	621,138,676	662,765,113
TOTAL ASSETS	\$ 2,606,638,810	\$ 2,241,380,489
DEFERRED OUTFLOW OF RESOURCES	\$ 107,671,675	\$ 110,192,665
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 2,714,310,485	\$ 2,351,573,154
Current liabilities	381,660,778	127,767,027
Long-term debt	485,584,419	502,151,049
Other noncurrent liabilities	555,745,556	689,120,222
TOTAL LIABILITIES	\$ 1,422,990,753	\$ 1,319,038,298
DEFERRED INFLOW OF RESOURCES	\$ 202,331,913	\$ 81,140,021
Net investment in capital assets	155,581,621	134,347,019
Restricted nonexpendable	128,099	128,099
Restricted expendable	35,958,408	35,878,430
Unrestricted	897,319,691	781,041,287
TOTAL NET POSITION	\$ 1,088,987,819	\$ 951,394,835
TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION	\$ 2,714,310,485	\$ 2,351,573,154
CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION		
Operating revenues	\$ 2,109,843,405	\$ 2,008,333,371
Operating expenses	(1,800,229,075)	(1,713,161,226)
Depreciation expense	(72,958,684)	(72,137,317)
OPERATING INCOME	236,655,646	223,034,828
Economic relief funds	71,281,071	
State appropriations	36,887,361	34,588,829
Investment income	2,225,634	15,224,317
Interest expense	(18,042,761)	(16,666,917)
Gifts	495,224	111,817
Other nonoperating expenses	(176,882)	(1,706,375)
INCOME BEFORE OTHER CHANGES IN NET POSITION	92,669,647	31,551,671
Capital gifts and grants	—	275
Intergovernmental transfers	(191,732,311)	(153,567,313)
INCREASE IN NET POSITION	137,592,982	101,019,461
Net position, beginning of year	951,394,837	850,375,374
NET POSITION, END OF YEAR	\$ 1,088,987,819	\$ 951,394,835
CONDENSED STATEMENTS OF CASH FLOWS		
Net cash provided by (used in):		
Operating activities	482,366,417	279,439,132
Noncapital financing activities	(87,024,110)	(119,860,364)
Investing activities	(41,132,386)	(18,118,961)
Capital and related financing activities	(108,557,784)	(83,941,304)
NET INCREASE IN CASH AND CASH EQUIVALENTS	245,652,137	57,518,503
Cash and cash equivalents, beginning of year	88,521,798	31,003,295
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 334,173,935	\$ 88,521,798

(16) Health Care Services

Net Patient Service Revenue

The Hospital has agreements with governmental and other third-party payors that provide for reimbursement to the Hospital at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the difference between the Hospital's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

Medicare. Substantially all acute-care services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to the patient classification systems that are based on clinical, diagnostic, and other factors. Additionally, University Hospital is reimbursed for both its direct and indirect medical education costs (as defined), principally based on per-resident prospective payment amounts and certain adjustments to prospective rate-per-discharge operating reimbursement payments. The Hospital generally is reimbursed for certain retroactively settled items at tentative rates, with final settlement determined after submission of annual cost reports by the Hospital and audits by the Medicare fiscal intermediary. The Hospital's cost reports have been audited and settled for all fiscal years through 2012. Revenue from the Medicare program accounted for approximately 21% of the Hospital's net patient service revenue for the years ended September 30, 2020 and 2019.

Section 302 of the Tax Relief and Health Care Act of 2006 authorized a permanent program involving the use of third-party recovery audit contractors (RACs) to identify Medicare overpayments and underpayments made to providers. As of September 30, 2020, the Hospital reported claims in various stages of review based on the requests received by the RACs during the fiscal year. Payment recoveries resulting from RAC reviews are appealable through administrative and judicial processes, and the Hospital intends to pursue the reversal of adverse determinations, where appropriate. The Hospital cannot predict with certainty the impact of the Medicare RAC program on our future results of operations or cash flows.

Blue Cross. Inpatient services rendered to Blue Cross subscribers are paid at a prospectively determined per diem rate. Outpatient services are reimbursed at a prospectively determined rate or under a cost reimbursement methodology. The method of reimbursement is determined by the procedures that are performed. For outpatient services reimbursed under the cost reimbursement methodology, a final settlement is determined after submission of annual cost reports by the

Hospital and audits thereof by Blue Cross. The Hospital's Blue Cross cost reports have been audited and settled for all fiscal years through 2016. Effective December 1, 2016 Blue Cross outpatient services began being reimbursed under the Enhanced Ambulatory Payment Group (EAPG) methodology. This is a prospective payment methodology with no retroactive settlement. Revenue from the Blue Cross program accounted for approximately 34% of the Hospital's net patient service revenue for the years ended September 30, 2020 and 2019.

Medicaid. Inpatient services rendered to Medicaid program beneficiaries are reimbursed at all-inclusive prospectively determined per diem rates. Outpatient services are reimbursed based on an established fee schedule. The Hospital is designated as a Disproportionate Share Hospital (DSH) and receives payments under the Medicaid DSH program. In addition, as a participant in the Alabama Medicaid Plan, the Hospital also receives supplemental payments based on formulas established by the Alabama Medicaid Agency. The net benefit associated with the Hospital's participation in these programs, totaling approximately \$103.1 million and \$65.1 million in 2020 and 2019, respectively, is included in net patient service revenue in the accompanying statement of revenues, expenses and changes in net position. There can be no assurance that the Hospital will continue to qualify for future participation in these programs or that the programs will not ultimately be discontinued or materially modified.

Revenue from the Medicaid program accounted for approximately 20% of the Hospital's net patient service revenue for the year ended September 30, 2020 and 16% for the year ended September 30, 2019.

Other. The Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payments to the Hospital under these agreements includes discounts from established charges and prospectively determined daily and case rates.

The composition of Hospital operating revenue follows:

	2020	2019
Gross Patient Service Revenue	\$ 8,092,812,292	\$ 7,839,365,711
Less Provision for Contractual and Other Adjustments	(6,120,310,515)	(5,969,587,958)
Less Provision for Bad Debts	(187,887,453)	(157,700,738)
Net Patient Service Revenue	\$ 1,784,614,324	\$ 1,712,077,015
Capitation Revenue	82,320,021	73,206,414
Other Operating Revenue	242,899,232	223,035,722
TOTAL HOSPITAL SALES REVENUE	\$ 2,109,833,577	\$ 2,008,319,151

Charity Care

The Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished under its charity care policy, the estimated costs of those services, and supplies and equivalent service statistics.

The estimated cost of charity care provided during the years ended September 30, 2020 and 2019 was approximately \$35.2 million and \$32.3 million, respectively, calculated based on the ratio of total direct and indirect costs to establish charges applied to the charges foregone under the charity care policy.

	2020	2019
Approximate charges foregone, based on established rates	\$ 128,828,588	\$ 123,735,691
Percentage of charity charges to total charges	1.6%	1.6%

Credit Risk

The Hospital grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at September 30, 2020 and 2019 follows:

During 2008, University Hospital entered into an operating agreement with HSF whereby HSF would lease two floors of the Women and Infants Center (“WIC”). HSF reimbursed University Hospital for construction costs of this space as they were incurred on a square-footage basis. Total reimbursements are being amortized as rent revenue on a straight-line basis over a period equal to the 90 year total lease term, commencing on February 22, 2010, the date the building was placed into service. The Hospital had received reimbursements from HSF totaling approximately \$14.7 million in 2020 and 2019, of which approximately \$12.8 million and \$12.9 million respectively, is included in the accompanying statement of net position as unearned revenue-other for the years ended September 30, 2020 and 2019, respectively.

	2020	2019
Other	43%	45%
Blue Cross	35%	35%
Medicare	15%	13%
Medicaid	7%	7%
	100%	100%

Related Parties

The Hospital and the other divisions of UAB provide a variety of support services to each other. The cost of these services is allocated to the end user on bases which vary according to the service being furnished. These services are paid for by transfers of funds which reduce operating expenses of the unit providing the service and are included in the operating costs of the unit receiving the service. Administrative and purchased services provided by UAB and allocated to and reimbursed by the Hospital during the years ended September 30, 2020 and 2019 were approximately \$37.3 million and \$38.7 million, respectively. In addition, during the years ended September 30, 2020 and 2019, the Hospital transferred approximately \$191.7 million and \$153.6 million, respectively, to UAB to support UAB’s academic and medical programs.

The Board and the HSF’s board have entered into an agreement under which UAB and HSF have established a common management group, the UAB Health System (Health System), to provide management for their existing and future health care delivery operations.

In connection with its agreement with the Health System, the Hospital partially funded the operations of the Health System and its corporate office, charging approximately \$14.8 million and \$13.2 million to other operating expense in fiscal year 2020 and 2019, respectively. In addition, the Health System periodically makes payments on behalf of the Hospital for which it is reimbursed. The Hospital had a net payable to the Health System of approximately \$9.8 million and \$6.7 million at September 30, 2020 and 2019, respectively.

As noted in footnote 7, in June 2019, University Hospital borrowed \$77.0 million of UAB Medicine Finance Authority 2019A and 2019B Revenue Bond proceeds from UAB Health System. \$42.5 million of the loan amount was distributed to the Hospital as of September 30, 2020 for capital improvement project spending during the year and the remaining \$34.6 million is held in trust for future projects. The Hospital recorded a note payable for the \$77.0 million loan amount and the undistributed amounts are recorded as Due from affiliate on the statement of net position.

In March 2014, the Hospital assumed operations of the outpatient clinics in The Kirklin Clinic and entered into an agreement with HSF to lease the land and the building known as The Kirklin Clinic. The initial term of the lease, which is cancellable by either party upon proper written notice and without penalty, is five years, with automatic one-year renewals thereafter.

VF's primary purpose is to provide a group medical practice for physicians who are faculty members in the UAB School of Medicine Huntsville program. It is governed by a 17-member board of directors, consisting of three nonvoting members and 14 voting members, of whom seven are affiliated with UAB.

The Hospital received premium revenue (capitation fees) of approximately \$82 million and \$73 million from Triton during the years ended September 30, 2020 and 2019, respectively.

The Hospital purchased \$458 million and \$406 million in management, administrative, and staffing services from the LLC during the years ended September 30, 2020 and 2019, respectively. Payment for contract labor as reported on the Statements of Cash Flows includes amounts paid to employees of the LLC and HSF.

(17) Recently Issued Pronouncements

The GASB issued Statement No. 84, *Fiduciary Activities*, in January 2017. The objective of this Statement is to improve guidance regarding the identification of fiduciary activities for accounting and financial reporting purposes and how those activities should be reported. This statement is effective for reporting periods beginning after December 15, 2019. UAB is evaluating whether there will be any material impact from its adoption of GASB 84.

The GASB issued Statement No. 87, *Leases*, in June 2017. The objective of this Statement is to better meet the information needs of financial statement users by improving accounting and financial reporting for leases by governments. This statement is effective for reporting periods beginning after June 15, 2021. UAB is evaluating whether there will be any material impact from its adoption of GASB 87.

The GASB issued Statement No. 89, *Accounting for Interest Cost Incurred before the End of a Construction Period*, in June 2018. The objectives of this Statement are (1) to enhance the relevance and comparability of information about capital assets and the cost of borrowing for a reporting period and (2) to simplify accounting for interest cost incurred before the end of a construction period. This statement is effective for reporting periods beginning after December 15, 2020. UAB implemented GASB 89 during fiscal year 2020. UAB has determined no material impact from adoption of GASB 89.

The GASB issued Statement No. 90, *Majority Equity Interest - An Amendment of GASB Statements No. 14 and No. 61*, in August 2018. The primary objectives of this Statement are to improve the consistency and comparability of reporting a government's majority equity interest in a legally separate organization and to improve the relevance of financial statement information for certain component units. This statement is effective for reporting periods beginning after December 15, 2019. UAB is evaluating whether there will be any material impact from its adoption of GASB 90.

The GASB issued Statement No. 91, *Conduit Debt Obligations*, in May 2019. The objectives of this Statement are to provide a single method of reporting conduit debt obligations by issuers and eliminate diversity in practice associated with (1) commitments extended by issuers, (2) arrangements associated with conduit debt obligations, and (3) related note disclosures. This statement is effective for reporting periods beginning after December 15, 2021. UAB is evaluating whether there will be any material impact from its adoption of GASB 91.

The GASB issued Statement No. 92, *Omnibus 2020, in January 2020*. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing practice issues that have been identified during implementation and application of certain GASB Statements. The statement is effective for reporting periods beginning after June 15, 2021. UAB is evaluating whether there will be any material impact from its adoption of GASB 92.

The GASB issued Statement No. 93, *Replacement of Interbank Offered Rates*, in March 2020. The objective of this Statement is to address those and other accounting and financial reporting implications that result from the replacement of the IBOR. The requirements of this Statement, except for paragraphs 11b, 13, and 14 are effective for reporting periods beginning after June 15, 2020. The requirement in paragraph 11b is effective for reporting periods ending after December 31, 2021. The requirements in paragraphs 13 and 14 are effective for fiscal years periods beginning after June 15, 2021, and all reporting periods thereafter. UAB is evaluating whether there will be any material impact from its adoption of GASB 93.

The GASB issued Statement No. 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements*, in March 2020. The objective of this Statement is to improve financial reporting by addressing issues related to public-private partnership arrangements. This Statement also provides guidance for accounting and financial reporting for availability payment arrangements. The statement is effective for reporting periods beginning after June 15, 2022. UAB is evaluating whether there will be any material impact from its adoption of GASB 94.

The GASB issued Statement No. 95, *Postponement of the Effective Dates of Certain Authoritative Guidance*, in May 2020. The objective of this Statement is to provide temporary relief to governments and other stakeholders in light of the COVID-19 pandemic. That objective is accomplished by postponing the effective dates of certain provisions in Statements 83 - 93. The effective dates disclosed above have been adjusted to reflect this deferral. UAB is evaluating whether it will postpone implementation of certain of the applicable GASB Statements.

The GASB issued Statement No. 96, *Subscription-Based Information Technology Arrangements*, in May 2020. The objective of this Statement is to provide guidance on the accounting and financial reporting for subscription-based information technology arrangements for government end users. The statement is effective for reporting periods beginning after June 15, 2022. UAB is evaluating whether there will be any material impact from its adoption of GASB 96.

The GASB issued Statement No. 97, *Certain Component Unit Criteria, and Accounting and Financial Reporting for Internal Revenue Code Section 457 Deferred Compensation Plans* - an amendment of GASB Statements No. 14 and No. 84, and a supersession of GASB Statement No. 32, in June 2020. The primary objectives of this Statement are to (1) increase consistency and comparability related to the reporting of fiduciary component units in circumstances in which a potential component unit does not have a governing board and the primary government performs the duties that a governing board typically would perform; (2) mitigate costs associated with the reporting of certain defined contribution pension plans, defined contribution other postemployment benefit (OPEB) plans, and employee benefit plans other than pension plans or OPEB plans (other employee benefit plans) as fiduciary component units in fiduciary fund financial statements; and (3) enhance the relevance, consistency, and comparability of the accounting and financial reporting for Internal Revenue Code (IRC) Section 457 deferred compensation plans (Section 457 plans) that meet the definition of a pension plan and for benefits provided through those plans. The requirements in (1) paragraph 4 of this Statement as it applies to defined contribution pension plans, defined contribution OPEB plans, and other employee benefit plans and (2) paragraph 5 of this Statement are effective immediately. All other requirements of this Statement are effective for reporting periods beginning after June 15, 2021. UAB is evaluating whether there will be any material impact from its adoption of GASB 97.

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information relates to UAB's participation in the Teachers' Retirement System of Alabama.

Schedule of UAB's Proportionate Share of the Net Pension Liability Teachers' Retirement Plan of Alabama

	2020	2019	2018	2017	2016	2015
Employer's proportion of the net pension liability	11.260686 %	11.750518 %	11.814264 %	11.863961 %	11.916376 %	12.188512 %
Employer's proportionate share of the collective net pension liability	\$1,245,083,000	\$1,168,305,000	\$ 1,161,162,000	\$1,284,396,000	\$1,247,128,000	\$1,107,275,000
Employer's covered payroll during the measurement period	\$ 940,203,000	\$ 916,059,000	\$ 901,338,000	\$ 876,899,000	\$ 864,300,000	\$ 880,666,000
Employer's proportionate share of the collective net pension liability as a percentage of its covered payroll	132.43 %	127.54 %	128.83 %	146.47 %	144.29 %	125.73 %
Plan fiduciary net position as a percentage of the total collective pension liability	69.85 %	72.29 %	71.50 %	67.93 %	67.51 %	71.01 %

Schedule of UAB's Contributions Teachers' Retirement Plan of Alabama

	2020	2019	2018	2017	2016	2015
Contractually required contribution	\$ 98,485,000	\$ 94,900,000	\$ 91,228,000	\$ 88,660,000	\$ 86,334,000	\$ 84,999,000
Contributions in relation to the contractually required contribution	\$ 98,485,000	\$ 94,900,000	\$ 91,228,000	\$ 88,660,000	\$ 86,334,000	\$ 84,999,000
Contribution deficiency (excess)	—	—	—	—	—	—
Employer's covered payroll	\$ 946,084,905	\$ 940,203,000	\$ 916,059,000	\$ 901,338,000	\$ 876,899,000	\$ 864,300,000
Contributions as a percentage of covered payroll	10.41%	10.09%	9.96%	9.84%	9.85%	9.83%

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to a pension plan are based.

Measurement period:

For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018

For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

For fiscal year 2017, the measurement period is October 1, 2015 – September 30, 2016

For fiscal year 2016, the measurement period is October 1, 2014 – September 30, 2015

For fiscal year 2015, the measurement period is October 1, 2013 – September 30, 2014

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information related to UAB's participation in the Alabama Retired Education Employees' Health Care Trust (PEEHIP).

Schedule of UAB's Proportionate Share of the Net OPEB Liability Alabama Retired Education Employees' Health Care Trust (PEEHIP)

	2020	2019	2018
Employers' proportion of the net OPEB liability	7.028808 %	8.029386 %	8.670675 %
Employer's proportionate share of the net OPEB liability	\$ 265,180,609	\$ 659,913,266	\$ 644,008,211
Employer's covered payroll during the measurement period	\$ 911,573,992	\$ 922,919,000	\$ 908,353,000
Employer's covered payroll OPEB liability (asset) as a percentage of its covered payroll	29.09 %	71.50 %	70.90 %
Plan fiduciary net position as a percentage of the total OPEB liability	28.14 %	14.81 %	15.37 %

Schedule of UAB's Contributions to the Alabama Retired Education Employees' Health Care Trust (PEEHIP)

	2020	2019	2018
Contractually required contribution	\$ 20,775,402	\$ 19,976,210	\$ 19,713,541
Contributions in relation to the contractually required contribution	\$ 20,775,402	\$ 19,976,210	\$ 19,713,541
Contribution deficiency (excess)	—	—	—
Employer's covered payroll	\$ 951,987,983	\$ 911,573,992	\$ 922,919,000
Contributions as a percentage of covered payroll	2.18 %	2.19 %	2.14 %

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

Measurement period:

For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018

For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information is related to the UAB Health Care Plan.

Schedule of Change in UAB Health Care Plan's Total OPEB Liability

	2020	2019	2018
Total OPEB Liability	\$ 17,698,575	\$ 20,320,823	\$ 26,032,496
Service cost*	169,614	168,312	6,230,996
Interest on TOL and cash flows	708,983	691,351	690,596
Changes in benefit terms	—	—	(6,710,449)
Difference between expected and actual experience	(6,173,296)	(787,087)	—
Changes of assumptions or other inputs	(4,662,781)	(767,436)	(961,631)
Benefit payments	(1,489,763)	(1,927,388)	(4,961,185)
Net changes in Total OPEB Liability	(11,447,243)	(2,622,248)	(5,711,673)
Total OPEB Liability - Beginning	\$ 17,698,575	\$ 20,320,823	\$ 26,032,496
Total OPEB Liability - Ending	\$ 6,251,332	\$ 17,698,575	\$ 20,320,823
Covered payroll	\$ 922,919,000	\$ 922,919,000	\$ 908,353,000
Total OPEB Liability as a percentage of covered-employee payroll	1.92 %	1.92 %	2.24 %

*The service cost include interest for the year.

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

Measurement period:

For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018

For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

The University of Alabama at Birmingham Administration

As of September 30, 2020



Ray L Watts, M.D.
President

Pamela Benoit
Senior Vice President for Academic Affairs
and Provost

G. Allen Bolton, Jr.
Senior Vice President for Finance and
Administration

Tom Brannan
Vice President for Advancement

Christopher S. Brown Vice President for
Research

Curtis A. Carver, Jr.
Vice President for Information Technology
and Chief Information Officer

Paulette Patterson Dilworth
Vice President for Diversity, Equity and
Inclusion

Will Ferniany CEO,
UAB Health System

John R. Jones
Vice President for Student Affairs

Selwyn M. Vickers, M.D.
Senior Vice President for Medicine and
Dean, School of Medicine

Shannon Blanton
Dean, UAB Honors College

Andrew J. Butler
Dean, School of Health Professions

Michelle Robinson, Interim Dean, School of
Education

Paul C. Erwin
Dean, School of Public Health

Doreen C. Harper
Dean, School of Nursing

Jeffery Holmes
Dean, School of Engineering

Eric P. Jack
Dean, Collat School of Business

Lori L. McMahon
Dean, Graduate School

Kasia Gonnerman
Dean, UAB Libraries

Kelly K. Nichols, O.D.
Dean, School of Optometry

Russell Taichman, D.M.D., DMSc.
Dean, School of Dentistry

Kecia M. Thomas
Dean, College of Arts and Sciences



The Board of Trustees of The University of Alabama

As of September 30, 2020

The Honorable Kay Ivey Governor of Alabama
President ex officio



W. Stancil Stranes, President pro tempore
Sixth Congressional District

Trustees Emeriti



Paul W. Bryant, Jr.

Mike Brock
Second Congressional District

Angus R. Cooper II

Karen P. Brooks
Seventh Congressional District

Joseph C. Espy III

John H. England, Jr.
Seventh Congressional District

Joseph L. Fine

Ronald W. Gray
Fifth Congressional District

Sandra Hullett

Barbara Humphrey
Seventh Congressional District

Andria Scott Hurst

Vanessa Leonard
Sixth Congressional District

John D. Johns

W. Davis Malone III
Second Congressional District

Peter L. Lowe

Evelyn VanSant Mauldin
Fourth Congressional District

John J. McMahon, Jr.

Harris V. Morrissette
First Congressional District

John T. Oliver, Jr.

Scott M. Phelps
Fourth Congressional District

Joe H. Ritch

William Britt Sexton
Fifth Congressional District

Finis E. St. John IV

Marietta M. Urquhart
First Congressional District

Cleophus Thomas, Jr

Kenneth L. Vandervoort, M.D.
Third Congressional District

John Russell Thomas

James W. Wilson III
Third Congressional District

